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The mammalian target of rapamycin (mTOR) plays a key role in tumour cell cycle
control, proliferation and survival, and has been implicated in resistance to endocrine
therapy in breast cancer. RAD001 (everolimus) is a novel macrolide that inhibits
mTOR and its downstream substrates in vitro. This study explores the use of
RAD001 at a dose of 5mg daily in women with early breast cancer.
31 postmenopausal women were given RAD001 for 14 days prior to primary surgical
intervention for early breast cancer. RAD001 was well tolerated in most patients, 5
did not complete treatment due to drug adverse effects.
Tumour samples before (pre) and after (post) 14 days treatment were assessed for
changes in proliferation and markers of the mTOR pathway. Significant reductions in
proliferation (Ki67) and oestrogen receptor (ER) expression were seen, and the
downstream effects of the mTOR pathway inhibited (p-S6 (ser235/236 and ser
240/244) and nuclear expression of p-Akt). Gene expression profiling from these
tumour samples has confirmed these findings, demonstrating reduction in expression
of proliferative genes and oestrogen dependence genes with RAD001 treatment.
The mTOR protein exists in two distinct complexes, raptor and rictor, and it has
previously been thought that mTOR inhibitors such as RAD001 only have effects
upon raptor. The implication of this if correct would be upregulation of Akt (Protein
Kinase B), which has been shown to be present in more aggressive and resistant
tumour types. The cell line study described herein has demonstrated no upregulation
in p-Akt expression with RAD001 treatment, and in one cell line inhibition ofp-Akt
was sustained with prolonged cell treatment.
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To further assess the role ofAkt in resistance to endocrine treatment, tumour samples
with known endocrine resistance or sensitivity were assessed for p-Akt expression
before and after treatment. The results suggest an increase in nuclear expression of p-
Akt in endocrine resistant tumours.
The mTOR inhibitor RAD001 is therefore effective at reducing proliferation of early
breast cancer, inhibiting mTOR in both raptor and rictor complexes, and may be of
particular use in highly proliferative or resistant tumours that overexpress p-Akt.
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Normal Structure and Function ofthe Breast
Discussion of the normal structure and function of the breast is necessary in order to
understand the pharmacology of the medical treatment of breast cancer.
The breasts exist in both sexes but are rudimentary in the male throughout life,
comprising small ducts without alveoli, supported by fibrous tissue and fat. The male
breast is still prone to the same major diseases that affect the female breast, and 240
men were diagnosed with breast cancer in the UK in 2000.' The studies carried out
as part of this thesis recruited only women, and for this reason, reference to breast
cancer in this text applies to female breast cancer unless otherwise specified.
Anatomy of the breast
In the female, each of the two breasts lies within the superficial fascia overlying the
second to sixth ribs, extending superolaterally toward the axilla to form the axillary
tail.2'3 The deep fascia separates the breast from the underlying pectoralis major,
serratus anterior and, at the lower medial edge, the rectus sheath. The dissection of
the breast from the deep fascia during mastectomy is facilitated by a zone of loose
areolar tissue, the retromammary space. The breast consists of glandular tissue in 15-
20 lobules, each ofwhich is drained by lactiferous ducts to the nipple. This glandular
tissue is embedded in fat, which accounts for the smooth shape and variation in size
of the breasts between individuals. Fibrous septa known as the suspensory ligaments
(ofCooper) run from the subcutaneous fascia to the nipple separating the lobules. If
infiltrated by malignancy, these ligaments can become contracted resulting in
tethering and retraction of the skin.
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The nipple commonly lies at the level of the 4 intercostal space, and is a pink or
light brown eminence that projects from just below the centre of the anterior of the
breast containing numerous circumferential and longitudinal arrangements of
unstriped muscle fibres. These muscle arrangements result in erection and
contraction of the nipple. The base of the nipple is encircled by a coloured area of
skin called the areola, underneath which the lactiferous ducts draining the breast
lobes form dilatations known as lactiferous sinuses, which act as reservoirs for milk
during pregnancy and lactation. At the base of the nipple these ducts perforate it at
small orifices at the tip.
After the menopause, the mammary gland atrophies as most of the cellular elements
of the alveoli and ducts degenerate, although the breast size remains variable due to
amount of fat.
The blood supply of the breast comes from two primary sources: the axillary artery,
via lateral thoracic and acromiothoracic branches, and from the internal thoracic
artery via perforating branches. The lateral perforating branches of the intercostal
arteries provide additional supply.
Venous drainage is via an anastomotic circle, the circulus venosus around the base of
the nipple, which branches drain blood to the circumference of the breast, and thence
into the axillary and internal thoracic veins.
The sensory nerve supply to the breast is from T4-6, from the anterior and lateral
cutaneous branches. These nerves convey sympathetic fibres to the breast, but its
secretory fibres are under hormonal control as discussed below.
The lymphatic drainage of the breast is ofmuch interest in oncological surgery, and
is a topic of debate with the development and increased use of techniques to identify
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the 'sentinel' node. This will be discussed in more detail under the section on the
surgical management of breast cancer.
Physiology of the breast
The action of drugs to combat cancer can only fully be comprehended with
knowledge of the normal function of the organ concerned and its related physiology,
and an understanding of the change that is undergone by the cancer process.
In the non-pregnant female the breasts have a rudimentary duct system as described
above. Each lobule contains sac-like epithelial-lined alveoli from which milk is
synthesised and then secreted into the alveolar lumen. Milk then drains via the ducts
to the surface of the nipple. The process of duct development during pregnancy takes
place due to high oestrogen concentrations in pregnancy, and high levels of
progesterone stimulate the alveolar-lobular formation. From the anterior pituitary
prolactin is secreted in response to high oestrogen contributing to mammary gland
development in pregnancy. Until birth, the stimulatory effect of prolactin is blocked
by progesterone and oestrogen, which dramatically decrease after parturition
resulting in prolactin stimulation of lactation. In conjunction with oxytocin from the
hypothalamus, milk ejection is stimulated by prolactin. Release of both these




Breast cancer is the most common cancer in the UK, although it is a rare disease in
men. More than 100 new cases of breast cancer are diagnosed each day in the UK.1
In Scotland in 2006, 4079 people were diagnosed with breast cancer, an increase in
incidence of 9.6% from ten years previous.4 In England and Wales between 1971 and
2002, the incidence rate for breast cancer (after adjustment for age) increased by
around 70 per cent - with a steep increase in the period following the introduction of
the national programme of mammographic screening ofwomen aged 50-64 in 1988.5
Although diagnosis and treatment have improved significantly over the last thirty
years with a corresponding fall in mortality, breast cancer remains the third most
common cancer death in the Scotland after cancers of the lung and large bowel, with
around 1000 deaths per year.4
Risk Factors
The incidence of breast cancer diagnosis increases with age in women.4 Hormone
dependent factors are likely to be involved in this increase, and lifetime exposure to
endogenous sex hormones affects the risk of breast cancer, dependent on many
variables such as age at menarche, age at first pregnancy, number of pregnancies and
age at menopause.6 Use of exogenous hormones such as hormone replacement
therapy after the menopause are associated with increased breast cancer risk with
prolonged use, as well as current or recent use of combined preparations or
progesterone only oral contraceptives.7"9 Obesity in postmenopausal years, tall
stature and increased alcohol intake, as well as increased intake of saturated fat are
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associated with increased risk.10'11 High mammographic density is also associated
with higher rates of breast cancer.7
For some patients there is an increased risk of breast and other cancers due to family
history or specific genetic mutations, in particular those associated with BRCA1 or
BRCA2. From a study amongst Ashkenazi Jews, who have specific inherited
mutations of BRCA1 or BRCA2, the estimated increased risk of developing breast
cancer is 56%, ovarian cancer 16% and prostate cancer 16%.12 These mutations have
been implicated in association with other malignancies such as non-melanoma skin
cancers (BRCA1), thyroid (BRCA1), leukaemia (BRCA1 and BRCA2), colorectal,
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pancreatic, gallbladder and bile duct, stomach and malignant melanoma (BRCA2). '
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The options for prevention of breast cancer in these women include chemoprevention
or prophylactic surgery in the form of bilateral oophorectomy or bilateral
mastectomy. In patients with a strong family history who are known to be at high or
moderate risk, a retrospective study has shown a risk reduction of greater than 90%
with bilateral prophylactic mastectomy after 14 years.15 For patients who have
known BRCA1 or BRCA2 mutation, the risk reduction of bilateral prophylactic
mastectomy has been reported as being between 85-89.5% at 13.4 years.16
Diagnosis
The main referral routes through which patients are diagnosed with breast cancer in
the UK are through symptomatic clinics or through the National Breast Screening
Programme. Patients present symptomatically most commonly with a lump in the
breast, with skin changes or distortion, nipple changes or discharge, or an axillary
lump. A triple assessment approach is used, incorporating clinical, radiological and
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cytological or histological examination, thereby increasing the accuracy of diagnosis.
1719 In many centres in the UK, core biopsy is performed to confirm clinical and
radiological suspicion ofmalignancy and may be combined with fine needle
aspiration cytology, which can be reported at the one stop clinic. Histological
correlation between core biopsy and excision specimens have been assessed in a
number of studies and found to have comparable results for ER, PR, p53 and
proliferation (MIB-1). 20-22
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Management Options in Breast Cancer
The National Cancer Plan published by the UK government in 2000 stressed the
importance ofmultidisciplinary team (MDT) working in the management of cancer
patients, stating that patients treated by specialist teams are more likely to survive by
improvement of co-ordination and continuity of care for patients. The Plan advised
that all patients with cancer should be formally reviewed by a specialist team. The
National Institute for Clinical Excellence (NICE) published a report recommending
meetings of the core team on a regular basis (usually weekly) to discuss each patient
with confirmed breast cancer both after initial diagnosis and after surgery to plan and
monitor treatment.24 Decisions about future treatment should also be discussed at
these meetings, taking account of clinical practice guidelines and protocols agreed by
the team. These recommendations should form the backbone of the way in which
breast cancer care is delivered, and management decisions discussed fully by the
MDT and with the patient and her family. With increasing methods of obtaining
information available to patients, it can be bewildering for patients recently
diagnosed to understand the array of potential options for treatment.
The clinical management of the newly diagnosed patient with breast cancer can be
subdivided into local and systemic approaches. The management of patients with
advanced disease will not be discussed as it is outwith the scope of this thesis, which
addresses drug development within the setting of early breast cancer.
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Local management of breast and axilla
Surgery
In patients with large operable or locally advanced breast cancer where it is felt that
surgery is either not technically feasible, would require mastectomy or where the
patient is considered unfit for anaesthetic and extensive surgery, neoadjuvant
treatment has emerged as a preferred choice of treatment. This will be discussed
below with the options for systemic treatment.
Radical mastectomy remained the surgical treatment of choice for breast cancer from
when first it was described by Halsted in 1898 until the 1970s.25 Following results
from randomised, controlled studies which were commenced to determine the
potential benefits of less extensive surgery for early breast cancer, less extensive
surgery is now recommended. One of the first trials to publish comparative results
was the NSABP-06, for which there are now 20-year follow-up data available, these
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data being consistent with the five year data originally published. Patients with
tumours <4cm which were either node positive or negative were randomised to three
groups to receive either lumpectomy alone or lumpectomy followed by radiotherapy
or total mastectomy each combined with axillary dissection (modified radical
mastectomy). Results for 1851 randomised patients showed no difference in overall
survival or disease-free survival or distant disease-free survival between the three
groups. There was, however, a statistically significantly greater number of local
recurrences in the group of patients that had lumpectomy alone (39.2%) compared to
those who had lumpectomy plus radiotherapy (14.3%; p<0.001).
The Milan trials of quadrantectomy and radiotherapy versus Halsted mastectomy
have reported results similar to those ofNSABP-06. 27 Twenty-year follow-up data
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published for 701 patients with Tl, NO, MO breast cancer randomised to one of two
arms: quadrantectomy, axillary dissection and radiotherapy or radical mastectomy
have shown no difference between the two arms for distant metastases, breast cancer
death, overall survival or contralateral breast cancer. There was a higher number of
local recurrences in the quadrantectomy arm (8.8% versus 2.3%; p<0.001). An
EORTC study of 868 patients randomised to either breast-conserving surgery with
radiotherapy or mastectomy showed no difference at ten years in overall survival or
distant metastases-free survival, but there was a significantly lower local recurrence
rate in the mastectomy group (12.2%) compared with breast-conservation and
radiotherapy (19.7%; p=0.0097). 28 The conclusions from these studies were that
breast-conserving surgery is appropriate when followed by radiotherapy for patients
with small tumours, provided that the margins of the resection are free of tumour and
an acceptable cosmetic result can be achieved.
As part of the traditional approach to the surgical management of breast cancer,
axillary surgery has been performed as part of standard treatment for all patients both
for diagnostic and therapeutic purposes. 25 Axillary dissection or removal of all the
axillary lymph nodes is associated with morbidity in terms of arm and shoulder
function, pain, lymphoedema and numbness. The effectiveness of 'sentinel node
mapping' in melanoma has led to randomised trials of this technique in early breast
cancer.30 A trial from Milan randomised 516 female patients with <2cm tumours and
clinically negative axillary lymph nodes to either sentinel lymph node biopsy
(SLNB) followed by axillary dissection or to SLNB with no further surgery if the
3 ]sentinel node was negative on frozen section or to axillary dissection if positive.
Results showed an overall accuracy of the sentinel-node technique of 96.9%, with
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sensitivity of 91.2% and specificity of 100%. It was not stated in this paper what was
the mean number of sentinel nodes removed per patient. A comparative side effect
analysis for a subgroup of patients was favourable for patients who had only SLNB
in terms of length of hospital stay, pain, numbness, arm mobility and swelling. In the
intention to treat population, there was no difference in breast cancer related events
or overall survival at a median 46 months of follow-up. A more detailed study of
quality of life outcomes with SLNB and axillary dissection has been published by the
Axillary Lymphatic Mapping Against Nodal Axillary Clearance (ALMANAC)
trialists.32 This was a multicentre randomised trial of 954 male and female patients
<80 years with early stage breast cancer who were clinically node negative and
proceeding to either breast-conserving surgery or mastectomy, and were randomised
to either SLNB or standard axillary treatment. In contrast to the Milan study, patients
with any tumour size were entered, and patients who were found to have one or more
positive sentinel lymph nodes were subsequently offered either delayed axillary
dissection or radiotherapy to the axilla. Outcomes relating to quality of life (QoL)
and side effects were assessed in both groups at 1, 3, 6 and 12 months. In the SLNB
group there was significantly less moderate/severe lymphoedema, less sensory
deficit, better arm functioning and better QoL scores at all time points. There was
significantly less arm swelling at each but the 12 month timepoint and better
shoulder function at 1 month. The duration of surgery in both groups was the same,
with a shorter hospital stay in the SLNB group, possibly related to less axillary drain
usage, and there was a trend to fewer infections in the SLNB group. Local recurrence
and survival data are awaited from this and other ongoing studies, but early data
33 34
suggest no increase in axillary recurrence with sentinel node biopsy alone. ' The
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use of sentinel lymph node biopsy has been established as a minimally invasive
staging procedure for the axilla, and a national training programme has been started
in the UK for this procedure.
Radiotherapy
As discussed above, there have been a number of studies showing that radiotherapy
should be used in conjunction with breast-conserving surgery for it to be equivalent
in long term local disease control and survival to mastectomy. This was confirmed in
the most recent meta-analysis by the Early Breast Cancer Trialists' Collaborative
Group (EBCTCG) of radiotherapy in early breast cancer published in 2005, which
analysed local recurrence and 15-year survival on 42,000 women in 78 randomised
trials.35 For patients receiving radiotherapy after breast-conserving surgery, there
was a highly significantly lower rate of local recurrence (7%) compared to those who
did not receive radiotherapy (26%) at 5 years. In those allocated radiotherapy there
was a significant reduction in breast cancer mortality (absolute reduction 5.4%). For
patients who underwent mastectomy and axillary clearance who were node negative
there was a low risk of local recurrence (6%) without radiotherapy to chest wall,
axilla, supraclavicular fossa and internal mammary chain. The local recurrence risk
was significantly lower when radiotherapy was given after mastectomy even to the
node negative group, but with an absolute five-year gain of only 4%, and with no
difference in mortality between the two groups. For patients with node-positive
disease, however, there was a significant and clinically important reduction in local
recurrence from 23% without radiotherapy to 6% with radiotherapy (absolute 5-year
gain 17%). In node-positive disease there was also an improvement in breast cancer
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mortality with radiotherapy (54.7% versus 60.1% without; absolute reduction 5.4%;
p=0.0002).
Radiotherapy is not without its risks. In the above meta-analysis, it was found that
there was an excess incidence of cancers in the contralateral breast in those patients
who received radiotherapy (p=0.002) and an excess incidence of lung cancers
(p=0.0007), as well as an increase in mortality from heart disease (p=0.0001) and
lung cancer (p=0.0004).
Current practice is in keeping with the above findings: patients who undergo breast-
conserving surgery are recommended to have radiotherapy, as well as patients who
have undergone mastectomy and axillary surgery and are shown to be node-positive.
Systemic non-hormonal therapy
It is outwith the scope of this thesis to explore in any depth the use of chemotherapy
in the management of early breast cancer. Chemotherapy has, however, a key role in
improving overall survival, as emphasised in the results of the most recent Early
Breast Cancer Trialists' Collaborative Group meta-analysis of the effects of
-3 z:
chemotherapy and hormone therapy in early breast cancer. These data show that
although single-agent regimens significantly reduce recurrence rates,
polychemotherapy regimens, most commonly anthracycline based, result in an even
better reduction in recurrence rates, and improved breast cancer specific and overall
survival rates at 15 years. The reduction in mortality benefits of polychemotherapy
compared with no chemotherapy were three times greater for women age <50 years
(15-year gain 10%) compared with women aged 50-69 years (15-year gain 3%). The
greatest reduction in mortality was seen in younger patients who were node positive
(15-year gain 14.6%), or had oestrogen receptor (ER) poor tumours (15-year gain
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13.2%). From trials directly comparing anthracycline-based regimens versus CMF-
based regimens, usually given for about 6 months, there was a significant advantage
for anthracyclines for recurrence (ratio 0.89; p=0.001) and for breast cancer mortality
(ratio 0.84; p<0.00001). The absolute difference between the two regimens for
probability of recurrence, breast-cancer mortality and overall mortality was 3% at 5
years and 4% at 10 years, irrespective of age of the patient. There was no significant
increase in mortality, heart disease or haemopoietic neoplasms in groups who
received anthracyclines.
Current recommendations in the UK are for anthracycline combinations to be
prescribed in favour of non-anthracycline regimens in the adjuvant setting, with
epirubicin also recommended due to its lower risk of cardiotoxicity.37
Five large trials have been performed to assess the role of taxanes (docetaxel and
paclitaxel) in the adjuvant setting.38 42 Three studies have been in node positive
disease with taxanes given either concurrently or following chemotherapy. The
CALGB 9344 study randomised 3121 node-positive women who had completed
surgical management to 4 courses ofAC (doxorubicin at three doses 60, 75, 90
mg/m2 plus cyclophosphamide) followed by 4 cycles of paclitaxel or nothing.38 At a
median follow-up of 69 months there was no significant difference in disease-free
survival (DFS) or overall survival (OS) for different doses of doxorubicin, but there
was a significant benefit favouring the addition of paclitaxel for DFS (HR 0.83;
95%CI 0.73, 0.94; p=0.0023) and OS (HR 0.82; 95%CI 0.71, 0.95; p=0.0064). This
equals an improvement of 5% in disease-free and 3% in overall survival at 5 years
with paclitaxel. 92% of the patients who started paclitaxel completed all four cycles.
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In a similar study design, the NSABP B-28 trial randomised 3060 patients who had
undergone initial surgical management for node-positive breast cancer to 4 cycles of
doxorubicin and cyclophosphamide alone or followed by 4 cycles of paclitaxel. 39
After a median follow-up of 64 months there was a significant improvement in DFS
(HR 0.83; 95%CI 0.73, 0.95; p=0.008) but no significant difference in OS (HR 0.94;
95%CI 0.78, 1.12; p=0.46). No difference in DFS, relapse-free survival (RFS) or OS
was seen between ER positive (ER+) and ER negative (ER-) tumours. In both of the
above studies patients received adjuvant tamoxifen. Baseline characteristics were
similar for both studies, although the NSABP B-28 had a higher proportion (70%) of
patients with less than 4 nodes positive than in the CALGB (46%), which could in
part account for lack of OS benefit for taxanes in NSABP B-28, although in the
French study disussed below both node negative and positive disease had a benefit
with a taxane.
The BCIRG 001 trial randomised 1491 women with node-positive tumours who had
undergone primary surgery to with 6 cycles of docetaxel plus doxorubicin plus
cyclophosphamide (TAC) or to 6 cycles of fluorouracil plus doxorubicin plus
cyclophosphamide (FAC). 40 At a median follow-up of 55 months there was a
significant improvement in DFS (HR 0.72; 95%CI 0.59, 0.88; p= 0.001) in favour of
the TAC regimen. A significant improvement in OS was also found for TAC
compared with FAC (HR 0.70; 95%CI 0.53, 0.91; p=0.008). In planned subgroup
analyses, there was a benefit for TAC regardless of lymph node status, ER status,
menopausal status or HER-2 status.
In a French study of 1999 women with node negative and node positive disease,
randomisation was to six cycles of FEC (5FU/ epirubicin/ cyclophosphamide) or to
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FEC three cycles followed by docetaxel for 3 cycles. 41 Patients received concurrent
tamoxifen. At a median follow-up of 60 months, there was a significant improvement
in DFS in patients who received docetaxel (HR 0.83; p=0.012) and a significant
improvement in OS (HR 0.77; p=0.014).
In the largest of the primary adjuvant taxane studies, the UK based TACT trial
(Taxanes as Adjuvant ChemoTherapy), 4162 patients with node positive or high risk
node negative operable early breast cancer were randomised to 4 cycles of 5-FU plus
epirubicin plus cyclophosphamide (FEC) followed by docetaxel or 8 cycles of FEC
or 4 cycles of epirubicin followed by 4 cycles of CMF, with the primary endpoint
disease-free survival. 42 Results at median follow-up 62 months for ITT population
did not show a DFS (HR 0.95; 95%CI 0.85, 1.08; p=0.44) or OS (HR 0.99; 95%CI
0.86, 1.14; p=0.91) benefit for taxanes. There were significantly greater numbers of
acute grade 3 or 4 adverse events reported in the taxane arm of the study, and nearly
20% of the patients did not complete the scheduled four cycles of docetaxel in the
experimental group.
Given the preceding results from taxane studies this lack of benefit in the TACT trial
was surprising. A meta-analysis of adjuvant taxanes in early breast cancer has shown
an absolute 5-year risk reduction of 5% for DFS and 3% for OS with taxanes, with no
difference between agent used, or whether taxane given sequentially or in
combination. 43
Current UK guidelines are that docetaxel, but not paclitaxel should be offered as part
of adjuvant chemotherapy regimen in node-positive early breast cancer. 44
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Hormonal treatment ofbreast cancer
Ovarian ablation
Historically, the earliest description of successful hormonal manipulation in the
treatment of breast cancer was by Beatson in 1896. 45 He described the effective use
of oophorectomy in 2 premenopausal women with locally advanced breast cancer to
reduce tumour bulk, after observing during the time ofwriting up his MD thesis a
similar practice carried out in sheep in order to continue milk production. He
proposed that there was evidence of the ovaries and testicle having control in the
human body over local proliferation of epithelium, challenging the understanding at
that time of "cancer-bodies" as a parasitic entity. This discovery served as the basis
for the use of ovarian ablation until randomised trials began in 1948. The combined
analysis of these early trials conducted by the Early Breast Cancer Trialists'
Collaborative Group (EBCTCG) confirmed that ovarian ablation is associated with
improvement in recurrence-free and overall survival in premenopausal women. 46
The method of choice can be tailored to the needs of the woman in terms of whether
temporary or permanent ablation is required, and whether surgical or medical
treatment is preferred. Methods include potentially reversible use of luteinising-
hormone releasing hormone (LH-RH) agonists such as goserelin, or permanent
methods such as surgical oophorectomy or ovarian ablation by radiotherapy.
Oestrogen antagonists
The most commonly used oestrogen antagonist in therapeutic use is tamoxifen.
Tamoxifen functions through its ability to compete with oestradiol at an allosteric
site on the oestrogen receptor (ER) with reduction of nuclear expression of the ER. 47
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Tamoxifen is a classical example of a partial agonist with tissue specificity for
inducing either agonist or antagonist responses. In the clinical context, this results in
antagonism in breast tissue and thus reduction in the incidence of primary breast
cancer development in high risk women and a reduction in contralateral breast
cancer, but agonist effects in bone, leading to maintenance of bone density and
agonist effects on the endometrium, causing an increase in incidence of endometrial
cancer in women who take this drug. A number of other drugs have been
developed in this class known as selective oestrogen receptor modulators (SERMs),
and are under investigation for adjuvant and preventative therapeutic use. 49 51
Tamoxifen is currently licensed for use as a first line agent in early and advanced
breast cancer in pre-, peri- and post-menopausal women, and for chemoprevention in
women at high risk of breast cancer. The use of tamoxifen in the neoadjuvant setting
is discussed below. For early breast cancer current recommendations are five years of
tamoxifen, which has been shown to lower recurrence rates and breast cancer
mortality compared to a shorter 1 -2 year period of treatment in patients who have
ER-positive disease,36 although this benefit in survival is not apparent until after five
years treatment is completed. In randomised studies patients who had ER-positive
disease and received 5 years tamoxifen had a significantly lower recurrence rate
(33.2% versus 45%; p<0.00001) compared to control groups at 15 years, and a lower
mortality rate (25.6% versus 34.8%; p<0.00001) compared with control groups. The
relative reduction in recurrence was even greater for patients under 40 years or with
node positive disease.36 The use of tamoxifen for longer than 5 years is not currently
advised, as prolonged treatment in one study actually decreased disease-free survival
ST
(tamoxifen 78% versus 82%; p=0.03), with no improvement in overall survival.
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The large multicentre trial ATLAS (Adjuvant Tamoxifen- Longer Against Shorter)
and the national aTTom (adjuvant tamoxifen-offer more?) trials are currently
ongoing to address the issue of prolonged tamoxifen treatment by randomising
patients to 5 years or ten years tamoxifen. The most recent data from these trials
suggest that earlier results indicating prolonged tamoxifen is detrimental are wrong
and show an approximate 12% reduction in events with 10 rather than 5 years of
treatment.54'55
A newer generation ofpure oestrogen antagonists have been developed which by
their nature do not have any of the oestrogen agonist effects of a drug such as
tamoxifen. Fulvestrant is one example of such drugs, and this agent has been shown
in premenopausal and postmenopausal women to be as effective in reducing
proliferation and to have similar anti-oestrogenic properties as tamoxifen,56 and has
a clinical benefit rate of 35% in postmenopausal patients who have progressed on
aromatase inhibitors.57 This drug is currently available only as an intramuscular
injection, which is well tolerated by patients, and serves as an alternative in patients
where there may be compliance issues.56
Aromatase inhibitors
Over three quarters of breast cancers are dependent on oestrogen for growth, and
virtually all breast cancers that respond to endocrine treatment express significant
levels of oestrogen receptor (ER) alpha. As will be discussed, despite high levels of
ER, some cancers do not respond and others develop resistance to treatments that
block ER such as tamoxifen. A class of drugs called the aromatase inhibitors have
been developed that inhibit oestrogen production. In the premenopausal woman, the
majority of oestrogen is produced in the ovaries by negative feedback loops
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involving the anterior pituitary. In the postmenopausal woman, however, oestrogen
biosynthesis occurs mainly in tissues such as subcutaneous fat, skin, liver, muscle
and breast cancer cells. From the starting point of cholesterol, there are a series of
conversions through progestogens and corticoids to androgens to oestrogens. The
final step is the conversion of androgens to oestrogens catalysed by the aromatase
enzyme, the target for aromatase inhibitors.58 The aromatase inhibitors can be sub¬
classed on the basis of their structure as steroidal (exemestane and formestane) or
non-steroidal (letrozole, anastrozole and aminoglutethimide).
The three most commonly used aromatase inhibitors in current clinical practice are
letrozole, anastrozole and exemestane, all three having had a licence for use in
metastatic breast cancer for some time. More recently letrozole and anastrozole have
been licensed as first-line adjuvant therapy for early breast cancer, and letrozole is
licensed for use in the extended adjuvant setting. Anastrozole and exemestane also
are licensed for use after 2-3 years tamoxifen (switching). The evidence base for
these therapeutic applications is discussed below.
Adjuvant and extended adjuvant aromatase inhibitors
The ATAC (Anastrozole or Tamoxifen Alone or in Combination) trial randomised
9366 postmenopausal women with invasive breast cancer (ER positive or unknown)
to 5 years of adjuvant anastrozole, tamoxifen or a combination of the two.59
Anastrozole achieved a significant disease free survival benefit at 100 months with a
hazard ratio (HR) of 0.85 (95%CI 0.76, 0.94; p=0.003) in the ER+ group compared
with tamoxifen or the combination, but no difference in OS (HR 0.97; 95%CI 0.86,
1.11; p=0.7). There was a reduction in contralateral breast cancer in the anastrozole
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treated group compared with tamoxifen or the combination (HR 0.60; 95%CI 0.42,
0.85; p=0.004).
The BIG 1-98 study directly compared letrozole with tamoxifen as primary adjuvant
therapy in 8010 women with early breast cancer randomised to one of four study
arms: tamoxifen for 5 years, letrozole for 5 years, tamoxifen for 2 years followed by
letrozole for 3 years, or letrozole for 2 years followed by tamoxifen for 3 years. After
a median overall follow up period of 25.8 months patients receiving immediate
treatment with letrozole rather than tamoxifen had an improved disease free survival
(HR0.81; 95%CI 0.70, 0.93; p=0.003), a better breast cancer relapse rate (absolute
benefit 3.4% at 5 years, p=0.0002) and a significant improvement in time to
development ofmetastases (HR=0.73), but no difference in overall survival. 60 At a
median 40.4 months the disease-free survival benefit of letrozole over tamoxifen was
sustained for the 4922 patients in the two monotherapy arms. 61
In both the ATAC and BIG 1-98 studies there were more fractures, less
thromboembolic events and less endometrial cancer in women receiving anastrozole
or letrozole. There was a trend toward increased cardiac events (4.1% v 3.8%,
p=0.61) in the letrozole group, with significantly more grade 3-5 cardiac events
(2.1% v 1.1%; p<0.001).
A number of studies assessing optimum effects of switching between tamoxifen and
aromatase inhibitors are ongoing, but three have reported results. In a combined
report from the ABCSG8/ARN095 study, results have shown that a switch to
anastrozole after 2 years of tamoxifen therapy improves event free survival compared
to continuing on tamoxifen (HR 0.60; 95%CI 0.44, 0.81) at a median of 28 months
follow-up. 62 There was no difference in overall survival between those who
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continued on tamoxifen and those that switched to anastrozole. Patients switching to
anastrozole had significantly more fractures (2% versus 1%; p=0.015), and less
thrombotic events (p=0.034), although the numbers of these events were small. In the
Italian Tamoxifen Anastrozole trial (ITA), 448 women were randomised to continue
tamoxifen after 2-3 years or switch to anastrozole. 63 After a median follow-up of 64
months in the intention to treat population there was a significant benefit in terms of
event-free survival (HR 0.57; 95%CI 0.38, 0.89; p=0.005) and recurrence-free
survival (HR 0.56; 95%CI 0.35, 0.89; p=0.01) in favour of those who switched to
anastrozole, but no difference in overall survival (HR 0.56; 95%CI 0.28, 1.15;
p=0.1). A meta-analysis of these trials concluded that there was an overall survival
advantage to switching to anastrozole (OS HR 0.71; 95%CI 0.52,0.98; p=0.04)
although the study groups differed in their entry criteria and also on both baseline
data and design and only the two smaller trials contributed to this significant
difference. 64 The study populations differed with those patients randomised in the
ITA study being 90% node positive with many of these women having also received
chemotherapy, whereas the ABCSG/ARNO study included mainly grade 1 and 2
tumours and no patients received chemotherapy. No difference in overall survival
was seen in the ABCSG8 trial which was a true sequencing trial with 2579 patients
randomised prior to starting tamoxifen in contrast to the other two trials which were
switching trials.
Exemestane has been examined in the adjuvant setting with sequential use of
exemestane therapy after 2-3 years of tamoxifen to complete 5 years of therapy, and
results at 3 years showed a significant improvement of switching over 5 years
tamoxifen alone with a reduction in events (HR 0.68; 95%CI 0.56, 0.82; p<0.001)
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and an absolute disease free survival benefit of 4.7%. 65 These benefits in disease-
free survival for switching over tamoxifen were sustained at 58 months follow-up. 66
The potential increased cardiovascular risk associated with aromatase inhibitor use
was highlighted in this study with a small but non-significant excess ofmyocardial
infarcts in the exemestane group.
In addition to use in the adjuvant setting, the role of using an aromatase inhibitor
after 5 years of tamoxifen has been investigated in the MA. 17 trial. This study
randomised 5187 postmenopausal women who had completed 5 years tamoxifen
within the previous three months to receive either letrozole or placebo for five years.
Results from this study at a median follow-up of 30 months showed a significant
disease-free survival benefit with letrozole (HR 0.58; 95%CI 0.45, 0.76; p=0.00004)
and also a distant disease-free survival benefit (HR 0.60; 95%CI 0.43, 0.84;
p=0.002). No difference in overall survival was found for the whole intention-to-treat
population (ITT), but for patients with node-positive disease a significant
improvement in overall survival was evident (HR 0.61, 95%CI 0.38, 0.98, p=0.04).67'
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Letrozole treatment did not result in a higher risk of hypercholesterolemia,
cardiovascular events or clinical fractures, but there was a trend towards more
patients having newly diagnosed osteoporosis with letrozole (p=0.07). Toxic effects
were primarily of grade 1 or 2, and 4.5% ofwomen in the letrozole group
discontinued because of toxic effects, which overall was not significantly different
from the 3.6% ofwomen in the placebo group who withdrew for similar reasons
(p=0.11).
An analysis of the benefit of prolonged treatment with letrozole compared with
placebo over time compared hazard ratios at 12 month intervals to 48 months median
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treatment, and found a significant improvement in disease-free survival that
increased over time (HR 0.59 at 6 months to HR 0.19 at 48 months, p<0.0001) and a
significant improvement in distant disease-free survival over time (HR 0.51 at 6
months to HR 0.21 at 48 months, p=0.0013), irrespective of nodal status. 69 No
significant difference in overall survival was found. These results would indicate that
prolonged treatment with letrozole (up to 4 years) improves disease-free and distant
disease-free survival compared with shorter periods of treatment.
In a sub-group analysis of ER and PR status within the ITT population of the MA. 17
trial, significant benefit for disease-free survival was found for letrozole in tumours
that were ER+/PR+ (HR 0.49; 95%CI 0.36, 0.67) and ER-/PR+ (HR 0.56; 95% CI
0.15, 2.12), but not for those tumours that were ER+/PR- (HR 1.21; 95% CI 0.63,
2.34), with similar findings for distant disease-free survival. 70 For overall survival
there was a 42% improvement in survival for patients on letrozole compared with
placebo in the ER+/PR+ subgroup (HR 0.58; 95% CI 0.37, 0.90). The subgroup of
ER+/PR- and ER-/PR+ patients on letrozole did not appear to benefit for overall
survival when compared with the placebo group. While this subgroup analysis
contained small numbers ofER+/PR- tumours (n= 636) compared to the whole group
which may weaken the analysis, it has furthered discussion of the role of PR in
determining response to aromatase inhibitors. A retrospective analysis from the
ATAC trial showed that tumours with ER+/PR- status had a greater relative benefit
with anastrozole for disease-free survival (HR 0.43; 95%CI 0.31, 0.61) than tumours
that were ER+/PR+ (HR 0.84; 95%CI 0.69, 1.02). 71 However, results of central
analysis of the study tumours for ER and PR did not shown any benefit ofER+/PR-
tumours over ER+/PR+ for disease-free survival.72 Similar to the MA. 17 analysis,
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the numbers in the subgroups that were ER+/PR- were smaller than the ER+/PR+
group (n= 1372 vs n=5709), and analysis was retrospective. A central review ofER
and PR status was performed for patients in the BIG 1 -98 trial of letrozole versus
tamoxifen in the adjuvant setting resulting in a significant disease-free survival
benefit for ER+/PR+ tumours treated with letrozole (HR 0.67; 95%CI 0.51, 0.88),
and a disease-free survival for ER+/PR- with letrozole (HR 0.88; 95%CI 0.55, 1.41).
This did not amount to a significant difference in disease-free survival between the
two subgroups of ER+/PR+ and ER+/PR- (p=0.32).73 The biological differences
between these two subsets of tumours and the potential mechanisms underlying the
different clinical responses to tamoxifen and aromatase inhibitors will be discussed
later.
Following the results of these randomised studies, national recommendations have
been revised. In September 2005, the Scottish Medicines Consortium (SMC) advised
that anastrozole had been accepted for restricted use in women with early invasive
breast cancer that is hormone sensitive, and in 2006 was granted restricted use for
switching after 2-3 years of tamoxifen.74'75 Restricted use of adjuvant letrozole was
advised in May 2006, while the SMC stated that another aromatase inhibitor
[anastrozole] was available for the same indication at a lower cost.76 In March 2005
the SMC advised that letrozole was accepted for use for treatment of invasive early
breast cancer in postmenopausal women who have already received standard
tamoxifen therapy, and that treatment should continue for three years. 77 The
National Institute of Clinical Excellence has set out preliminary recommendations
that the aromatase inhibitors anastrozole, exemestane and letrozole, within their
licensed indications, are recommended as options for the adjuvant treatment of early
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oestrogen-receptor-positive invasive breast cancer in post-menopausal women, and
that the choice of treatment strategy (that is, primary adjuvant treatment with an
aromatase inhibitor, switching from tamoxifen to an aromatase inhibitor or use of an
aromatase inhibitor after completion of 5 years of tamoxifen treatment) should be
made after discussion between the responsible clinician and the patient about the
risks and benefits of the options available. Consideration of the strategy to be
adopted should include whether the patient has received tamoxifen as part of their
treatment so far, the side-effect profiles of the individual drugs and, in particular, the
assessed risk of recurrence.
Aromatase inhibitors and neoadjuvant use
Until recently neoadjuvant therapy of breast cancers consisted predominately of
cytotoxic chemotherapy. 79-82 Studies comparing neoadjuvant versus adjuvant use of
chemotherapy regimens have shown that while disease-free survival, progression-
free survival and overall survival are not changed by the timing of treatment, there is
an improvement in all of the above outcomes in patients who have had a good
clinical response to treatment in the neoadjuvant setting.83-85 These results highlight
one of the key benefits of using neoadjuvant treatment as a way of predicting
response and therefore potentially a survival benefit.
Endocrine treatment is now emerging as an attractive alternative in postmenopausal
women with large operable or locally advanced hormone receptor positive breast
cancers, many ofwhom cannot tolerate the toxicities of chemotherapy. A small
study from Russia reported results of 121 postmenopausal women with T2-4 ER
and/or PR positive breast cancer who were randomised to receive either neoadjuvant
doxorubicin and paclitaxel chemotherapy (n=62) or neoadjuvant endocrine treatment
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with anastrozole (n=30) or exemestane (n=29) for 3 months prior to surgery.
Clinical and mammographic objective response rates were similar for endocrine
therapy and chemotherapy, and there was a trend for increasing rates of breast-
conserving surgery in favour of endocrine therapy (p=0.054) with no significant
differences in local recurrence rates at 34 months. Grade III/IV toxicity for alopecia,
neutropaenia, cardiotoxicity and neuropathy were experienced by significant
numbers ofwomen in the chemotherapy group. Neoadjuvant endocrine therapy was
better tolerated; the most common adverse events reported were hot flushes, fatigue,
vaginal bleeding and arthralgia. These data confirm that endocrine therapy is a safe
alternative to chemotherapy in postmenopausal women with ER+ cancers, with
similar response rates but less toxicity. There is some evidence to suggest that
neoadjuvant chemotherapy is less effective in ER+ breast cancer than in ER- breast
cancer. A retrospective study of 1,731 patients who had primary chemotherapy
showed a significantly lower rate of pathologic complete response to chemotherapy
in patients with hormone receptor-positive tumours compared with those with
hormone receptor-negative tumours (8% versus 24%; p< .0001). 87 These data are
consistent with the observation that patients with hormone receptor-positive disease
are less chemosensitive and respond better to endocrine therapy.
Early studies of neoadjuvant hormonal therapy used tamoxifen but did not select
patients on the basis ofER or PR to identify those most likely to respond. Most
studies with tamoxifen involved elderly patients and compared surgery with or
without post-operative tamoxifen to the use of tamoxifen alone, and thus were not
designed to assess tamoxifen in the true neoadjuvant setting. These studies do,
however, show the effect of tamoxifen as a primary treatment. There have been three
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large randomised trials of tamoxifen alone versus surgery alone. While one trial
88found no difference between the two treatments at six years, a study from
Nottingham found a significant increase in local progression in the group who
89
received tamoxifen alone at a median follow-up of 145 months. This was
confirmed in a multi-centre European study that reported a shorter time to
progression, a worse disease-free survival and worse loco-regional control in women
who received tamoxifen alone.90 A recent meta-analysis of the randomised studies of
surgery versus primary endocrine therapy for operable breast cancer in elderly
women found no difference in overall survival. 91
Several randomised trials have compared tamoxifen alone with surgery followed by
tamoxifen 92-96 and in all but one of these studies 96 there was a significant increase in
local events in the tamoxifen alone group. In one study there was a significantly
higher mortality in patients treated with tamoxifen alone, but this increase in
QT
mortality was only apparent after three years follow-up. The authors of these
studies concluded that long-term hormonal treatment without surgery should be
reserved only for patients whose life expectancy is very limited. A meta-analysis of
the above studies found a non-significant trend in favour of surgery with tamoxifen
over tamoxifen alone for overall survival (HR 0.86, p=0.06), and a significant
improvement in local disease control with surgery and tamoxifen compared with
tamoxifen alone (HR 0.28, p<0.00001).91
Initial studies performed in Edinburgh suggested there may be benefits to using
aromatase inhibitors rather than tamoxifen as neoadjuvant therapy in postmenopausal
women with ER+ cancers. 97-99 These results led to a series of randomised studies.
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The P024 trial compared 4 months of neoadjuvant letrozole with tamoxifen in 337
postmenopausal women with large breast cancers that required mastectomy or were
locally advanced and inoperable and were ER or PR positive. 100 The primary
endpoint of P024 was the percentage of patients in each treatment arm with objective
responses (complete or partial response) determined by clinical palpation of the
breast cancer. Secondary endpoints were overall objective response rate (ORR)
determined by mammogram and ultrasound at 4 months, and the percentage of
patients in each treatment arm who became eligible for breast-conserving surgery.
World Health Organization response criteria based on bidimensional measurements
of area were applied. The results demonstrated that letrozole achieved a significantly
higher clinical response rate by palpation than tamoxifen (55% versus 36%; p<
0.001) in the intention to treat population. The superiority of letrozole was observed
irrespective of baseline tumour size (T2 vs >T2). Letrozole was significantly more
effective than tamoxifen irrespective of the assessment method, although response
rates assessed by ultrasound and mammography were lower than those assessed by
clinical examination. Median time to response was 66 days in the letrozole group and
70 days in the tamoxifen group. The higher response rates assessed by clinical
examination were reflected by significantly more letrozole-treated patients than
tamoxifen-treated patients being suitable for and undergoing breast-conserving
surgery after treatment (45% vs 35%; p=0.022). Even in patients with locally
advanced breast cancer, significantly more patients from the letrozole arm than from
the tamoxifen arm were eligible for breast-conserving surgery. At the end of
therapy, 135 (88%) patients in the letrozole arm underwent some type of surgery,
compared to 139 (82%) patients in the tamoxifen arm.
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The only other factor besides treatment that influenced the likelihood of patients
being suitable for breast-conserving surgery was tumour size at presentation, with
patients with T2 tumours being more likely to be candidates for breast-conserving
surgery than larger tumours (p=0.0001). In this randomised study, letrozole was at
least as well tolerated as tamoxifen.
In the P024 study, tumour responses to letrozole versus tamoxifen were also
evaluated according to biopsy-confirmed ER and/or PR status. 101 Both letrozole and
tamoxifen achieved significantly more responses in patients with ER+ tumours than
those with ER- tumours. Differences in response rates between these two agents were
most marked for tumours that were both ER+ and/or PR+ and also positive for the
markers HER-1 and/or HER-2 (response rate to letrozole 88% versus 21% for
tamoxifen; p=0.0004). There was also some evidence of a direct correlation between
the degree of ER expression and the incidence and extent of tumour response. In the
P024 randomised trial, clinical responses were related to the level of ER expression
as determined by immunohistochemistry (IHC) using the semi-quantitative Allred
scoring system (0-8). There were no tamoxifen-induced responses at ER levels
below a score of 6, in contrast to letrozole-induced responses of>30% at a score of
3.
Two large multicentre, double blind, double-dummy, randomised trials have been
published, both comparing efficacy of preoperative use of anastrozole and tamoxifen
for postmenopausal women with hormone receptor positive tumours.
The IMPACT study (/Mmediate Preoperative zlrimidex, Tamoxifen or Combined
with Tamoxifen) recruited 330 patients from UK and Germany, of which 292 were
analysable for response, who were randomised to receive anastrozole or tamoxifen or
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both in combination for 3 months prior to surgery. Patients had pre-treatment
surgical assessment for mastectomy or breast-conserving surgery. The primary
endpoint was objective clinical response measured by callipers. As a secondary
endpoint, ultrasound response was measured. This study found no difference in
objective response between the three treatments as measured by callipers and
ultrasound, except for those patients who had HER-2+ tumours, where anastrozole
had a numerically higher clinical response rate than tamoxifen (p=0.09) and the
combination arm. It was also found that anastrozole enabled significantly more
breast-conserving surgery in patients initially thought to require mastectomy than
tamoxifen or combination (anastrozole 46% versus tamoxifen 22%; p=0.03).
The PROACT fPReCperative vfrimidex Compared with Tamoxifen) trial, performed
in a number of centres in Europe and USA, recruited postmenopausal women with
similar criteria to the IMPACT trial, but also included patients who were inoperable,
and those on concurrent chemotherapy. 103 Patients were randomised to receive either
lmg anastrozole (n=202) or 20 mg tamoxifen (n=201), both with placebo, for 3
months. The primary endpoint was objective tumour response measured by
ultrasound scan. Calliper measurement was included as a secondary endpoint,
alongside surgical assessment at baseline and 3 months. No significant difference in
objective response rate (ORR) was seen between treatment arms in all patients,
although a trend was noted in favour of anastrozole in those patients who had
hormonal therapy alone. There was, however, a significantly higher ORR in favour
of anastrozole in those patients initially assessed as requiring mastectomy (36.6% vs
24.2% on ultrasound, p=0.03; and 48.6% vs 35.8% with callipers, p=0.04). This also
translated into a significant surgical improvement for those initially requiring
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mastectomy with 43% of those treated by anastrozole having breast-conserving
surgery versus 30% with tamoxifen (p=0.04), and greater numbers of those with
initially inoperable tumours having a surgical procedure performed with anastrozole
compared with patients randomised to tamoxifen. No significant adverse events were
noted.
A combined analysis of these two studies has been presented but not published, with
a total combined population of 535 patients, and an analysis performed of ORR and
improvement in surgery. 104 There was a trend in favour of anastrozole in ORR as
measured by callipers and ultrasound in the whole group, but this was not
statistically significant. There was however, a significant improvement in ORR in
favour of anastrozole in the subgroup of patients who were thought to require
mastectomy or to have tumours that were inoperable at initial diagnosis; response
rate as measured by callipers being 47% vs 35%, (p=0.026) and on ultrasound 36%
vs 26%, (p=0.048). For the purposes of the analysis feasible surgery was defined as
the surgery required at 12 weeks and actual surgery as surgery that was actually
performed at 12 weeks. There was a significant reduction in the extent of feasible
(anastrozole 47% versus tamoxifen 35%, p=0.021) and actual surgery (anastrozole
43% versus tamoxifen 31%, p=0.019) in those patients whose tumours were thought
to require a mastectomy or were inoperable at initial assessment.
Promising results were shown in an initial study of exemestane in Edinburgh, in
which women with large operable or locally advanced primary breast cancer were
qo
treated with exemestane for 12 weeks prior to surgery. Twelve patients were
treated, ofwhom 10 had >50% reduction in tumour size, and 2 had stable disease
defined as <50% reduction or <25% increase in size. No patients had an increase in
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tumour size >25%. Ten patients initially required mastectomy, but only two required
mastectomy after neoadjuvant exemestane (breast-conservation rate 80%).
In the "German Neoadjuvant Aromasin® Initiative" (GENARI) trial 27 post¬
menopausal women with hormone receptor positive T2-4 tumours were treated with
16 weeks exemestane. Of 27 patients, 10 had a partial response and 17 had stable
disease, and 14 patients underwent breast-conserving surgery. 105
In a French study 42 postmenopausal women with ER positive operable breast
cancer were given 4-5 months of exemestane prior to surgery. 106 Clinical response
as measured on ultrasound confirmed clinical objective response in 73.3%, with a
pathological partial response rate of 16.7%. Breast conserving surgery was achieved
in 57.1%.
A Japanese study has reported results of four months neoadjuvant exemestane in
ER+ and/or PR+ large breast cancers. 107 A pathological response was observed in 13
(43%) of 30 patients who underwent surgery at 4 months, and a clinical response was
seen in 27 (66%) of 41 evaluable patients. Breast conserving surgery was performed
in 27 (90%) of 30 patients who underwent surgery at 4 months.
In another trial of neoadjuvant exemestane 55 women (age >65) with ER+ tumours
>3cm not suitable for breast conservation were given treatment for 6 months, after
which time 51% had partial response, 47% had stable disease and 2% had
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progressive disease on mammography, with a breast conservation rate of 55.8%.
In the only reported randomised study of neoadjuvant exemestane, 151 women with
hormone receptor positive breast cancer to be treated with either exemestane (E) or
tamoxifen (T) for 3 months pre-operatively. 109 Clinical objective response rate
assessed by palpation was the primary endpoint. Secondary endpoints were response
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measured on mammogram and ultrasound, and number of patients undergoing
breast-conserving surgery. Clinical objective response on palpation was superior in
the exemestane group (76.3%) compared to tamoxifen (40.0%; p=0.05). There was
no significant difference in objective response on ultrasound (E 60.5% vs T 37.3%;
p=0.092) or on mammogram (E 64.0% vs T 37.3%; p=0.082). Exemestane treatment
resulted in a higher rate of breast-conserving surgery than tamoxifen (36.8% versus
20.0%; p=0.05). Exemestane had a similar reported adverse events rate to
tamoxifen.
Neoadjuvant hormone therapy is thus effective at downstaging tumours, particularly
large tumours initially thought to be inoperable or requiring mastectomy.
Randomised trials have shown that the newer aromatase inhibitors letrozole,
anastrozole and exemestane increase the numbers ofwomen who are suitable for
breast-conservation compared with tamoxifen, and that letrozole is superior to
tamoxifen in terms of clinical response.
A recent meta-analysis of aromatase inhibitors versus tamoxifen for neoadjuvant
treatment included the P024, IMPACT, PROACT and the Semiglazov exemestane
trials and pooled results from these four trials. 110 Combined results showed superior
rates for aromatase inhibitors compared with tamoxifen for clinical objective
response rate (ORR) (RR; 1.29; 95% CI 1.14, 1.47; p< 0.001), ultrasound ORR (RR
1.29; 95% CI 1.10, 1.51; p=0.002) and breast-conserving surgery rate (RR 1.36; 95%
CI 1.16, 1.59; p< 0.001).
When compared to neoadjuvant chemotherapy, aromatase inhibitors have similar
objective response rates and rates of local recurrence after downstaging and breast
conserving treatment, but are better tolerated due to their lower toxicity. Aromatase
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inhibitors are now the neoadjuvant hormonal agents of choice in appropriately
selected postmenopausal women with hormone sensitive breast cancers. Patients
who are most likely to gain benefit from neoadjuvant therapy include: women with
locally advanced breast cancer whose disease is not suitable for an initial surgical
approach but following response may become operable either by mastectomy or
breast conserving surgery; patients with single unifocal cancers of a size relative to
the breast size that would require mastectomy, but that with response to neoadjuvant
therapy would be suitable for breast conserving surgery; patients with large unifocal
cancers that could be treated by breast conserving surgery but where breast
conserving surgery would remove a significant volume of the breast and would be
unlikely to produce a satisfactory cosmetic outcome. 1'1
There are certain tumour types that have been shown to respond slowly or in which
response is difficult to assess such as invasive lobular carcinomas (ILC) and
mucinous carcinomas, and these cancer types may therefore be less suitable for this
treatment. In one study of neoadjuvant chemotherapy invasive lobular carcinomas
were found to have lower rates ofpathological complete response and lower rates of
breast conserving surgery than invasive ductal carcinomas, although this did not
112translate into poorer overall survival at a median 68 months follow-up.
Randomised studies of neoadjuvant endocrine therapy have treated patients for 3-4
months, based upon previous experience with neoadjuvant chemotherapy. These
studies have not addressed the issue of the optimum duration of treatment. One
prospective study published recently from Edinburgh included 184 women with large
operable or locally advanced ER+ breast cancers who were treated with neoadjuvant
113letrozole. Tumour samples from this study were utilised for the study outlined
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later on within this thesis. One hundred and twenty seven patients (69.8%) had a
complete or partial response by 3 months and only four patients had disease
progression (>25% increase in tumour volume). Of the 119 patients who had surgery
at 3 months, 99 had breast conserving surgery and 19 had mastectomy. The 19
undergoing mastectomy included 15 patients who had locally advanced breast cancer
not initially considered suitable for surgery but whose tumours became operable
following 3 months of letrozole. Sixty-three patients continued on letrozole beyond
3 months. The mean reduction in clinical volume in the first 3 months in these 63
patients was 46.7%, with a median of 52%. There was a sustained response with
continued treatment with further reductions in volume between 3 and 6 months
(mean 46.6%, median 50%), between 6 and 12 months (mean 47.8%, median 37%)
and 12-24 months (mean 35.8%, median 33%). Prolonged treatment with
neoadjuvant letrozole treatment resulted in an increase in the number of patients who
were converted from requiring a mastectomy or who were inoperable at diagnosis to
be later suitable for breast conserving surgery from 81 of 134 (60%) at 3 months with
96 (72%) eventually being treated with breast conservation. At a median follow-up in
this group of 3 years, the median time to treatment failure in women had not yet been
reached with 70% of those on prolonged letrozole treatment having their disease
controlled on letrozole alone. These data show that in selected patients prolonged
treatment with letrozole can result in sustained response with tumour shrinkage.
There are no randomised studies of the use of aromatase inhibitors as neoadjuvant
endocrine therapy only versus neoadjuvant endocrine therapy followed by surgery,
88 90but studies for tamoxifen showed poorer locoregional control without surgery. " '
114 The authors of this study opined that surgery should be offered to patients after a
42
satisfactory response to neoadjuvant letrozole has been achieved. In patients who are
not suitable for or who refuse surgery, neoadjuvant letrozole given for prolonged
periods appears safe and appears to provide this group ofwomen with long-term
disease control.
Resistance to therapy and predicting response
Results from long term studies with tamoxifen have shown that while some patients
will have their disease well controlled by hormone therapy alone, many patients will
develop resistance. Results from neoadjuvant studies with letrozole have shown
similar findings, with some tumours being resistant from the start, others developing
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resistance over time. In the neoadjuvant setting, the option is open for excision of
a tumour that has ceased to respond to therapy. The therapeutic dilemma in the
adjuvant setting is that the tumour has been excised and there is no predictive marker
to say which cancers will respond and which are resistant or will develop resistance
to endocrine treatment until a clinically evident recurrence is apparent. Clearly
having a predictive marker for patients who are likely to respond and those who are
likely to be resistant would be of great therapeutic benefit.
One marker that has been identified in neoadjuvant trials as a potential marker of
response to treatment is proliferation as assessed by Ki67 (MIB-1).
In the P024 study there was a significantly greater reduction in proliferation with
letrozole, with a reduction in geometric mean Ki67 of 87% with letrozole compared
with 75% for tamoxifen (p = 0.0009). '15 Results from analysis of tumours samples
from the BIG 1 -98 trial of letrozole versus tamoxifen have shown a significantly
poorer DFS for those patients with tumours with high Ki67 at baseline (HR 1.4;
95%CI 1.1, 1.9; p=0.02), with a better DFS for highly proliferative tumours treated
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with letrozole than with tamoxifen (HR [Let:Tam] 0.53; 95%CI 0.39, 0.72; p=0.09).
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As part of the IMPACT trial, immunohistochemical analysis was assessed after 2
weeks of treatment and at surgery (12 weeks after commencement of hormonal
treatment). 117 Initial results revealed that there was a significantly greater reduction
in Ki67 in the anastrozole group than tamoxifen or combination groups at 2 weeks
(p=0.004) and 12 weeks (p<0.001) but found no significant relationship between
Ki67 changes and clinical response. Analysis at a median 37 months follow-up have
confirmed a statistically significant correlation between Ki67 after 2 weeks treatment
and relapse-free survival (HR 1.96; 95%CI 1.23, 3.07; p=0.004). Ki67 at baseline
was not significantly correlated to outcome on multivariate analysis, nor was the
change in Ki67 (rather than absolute value for Ki67 at 2 weeks). The implication of
these findings is that there is a predictive value in the treatment-determined Ki67 at 2
weeks, which could potentially be used as a prognostic tool for predicting response
to neoadjuvant therapy.
Further data are reported from the Edinburgh neoadjuvant letrozole series mentioned
previously for 63 patients who had tumour biopsies taken at 0, 2 and 12 weeks (2
week biopsies taken between 10-14 days of starting treatment) for Ki67, and for
whom clinical and pathological response data were collected. 118 A clinical response
was seen in 76.2%, and a pathological response in 75.8%, with some disconcordance
between the two outcomes. While there was no difference in pre-treatment Ki67
counts for responders and non-responders, there was a significantly higher Ki67 at 2
weeks in those that had no pathological response compared to those that had a
pathological response (9.35% versus 4.02% respectively, p=0.024), and the same was
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seen at 3 months (8.11% versus 3.47%, p=0.009). A significant reduction in Ki67
was seen in responders (both clinical and pathological) between 2 weeks and 12
weeks, but not for non-responders.
A change in Ki67 of 40% between different paired biopsies was taken as being
meaningful by the authors, and significantly more pathological responders (42 of 47)
had a reduction of >40% compared with pathological non-responders (9 of 15,
p=0.034). No difference was seen between clinical responders and non-responders.
Different patterns of changes in Ki67 over the treatment period were detected. The
largest cohort of tumours (n=47) showed substantial decreases at 10-14 days that
were maintained or fell further at 3 months, but there was a cohort of five patients in
which a decrease at 10-14 days was followed by a substantial rise in score at 3
months. There is therefore evidence for the predictive value of Ki67 at baseline and
at 2 weeks for treatment response with aromatase inhibitors.
The development of resistance to endocrine therapy is a major clinical problem
occurring either de novo or acquired during treatment. ER positivity is the strongest
predictor of response to treatment but the development of resistance indicates the
influence of other factors, as this resistance can occur without loss of ER expression
in tamoxifen resistance. 119'120 In the case of tamoxifen this may be because of the
partial agonist effects to stimulate non-genomic activity of ER in cells with high
EGFR and HER-2. 121 An intrinsic mechanism of tamoxifen resistance has also been
identified in 8% of Caucasian women carrying inactive alleles of cytochrome
P450 2D6 (CYP2D6) resulting in failure to convert tamoxifen to its active
122
metabolite, endoxifen, and consequently less responsiveness to tamoxifen.
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Figure 1 shows the normal mechanism of ER signalling. There are a number of
co-activators in the oestrogen bound cell, as opposed to co-repressors present when
not in oestrogen bound state, thus modulation ofER is likely to be a balance of co-
activation and co-repressor activity. The co-activator complexes (histone
acetyltransferase (HAT) complexes) stimulate ER activity following ligand
stimulation through direct interaction with AF2. Drugs such as tamoxifen and
raloxifene inhibit AF2 activation (active in breast epithelium) and thus ER activity,
but do not prevent activation of AF1 (active in other tissues such as the uterus). Pure
anti-oestrogens such as faslodex inhibit both AF1 and AF2 and are thus anti-
oestrogenic in all tissues. In the case of aromatase inhibitors the oestrogen
availability for binding is reduced, shutting off genomic and non-genomic signalling,




In the normal cell, oestrogen binds to ER resulting in a conformation change by
binding as a dimer to oestrogen response elements (EREs) in the gene
promoters at 2 distinct ER activation domains AF1 (regulated by
phosphorylation) and AF2 (regulated by oestrogen binding), which in turn
activate transcription of oestrogen regulated genes. (AF- activation domains,
CoA- co-activators, DBD- DNA-binding domain, LBD- ligand-binding domain).
Courtesy of Dr LA Martin, Institute of Cancer Research, Breakthrough Breast
Cancer Centre, London.
A number ofmolecular mechanisms have been proposed to be involved in endocrine
resistance. These include ER mutations resulting in increased sensitivity to ligand
recruitment, ligand independent activation of ER (through growth factor signalling
pathways), increased expression of co-activator proteins mediating ER activity and
non-genomic effects of ER, such as direct interaction with signal transduction
pathways, also known as post-translational modification. 123-125 Figure 2
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ER activity classically is thought to require ligand binding but growth factors can
stimulate ER in the absence of a ligand, such as epidermal growth factor (EGF),
Protein Kinase A, steroid receptor co-activator (Src), HER-2 and PI3K/ Akt. Of
particular significance in this thesis is the phosphorylation by Akt that occurs at ser
1 96
167 resulting in ligand-independent activation of ER. A number of therapeutic
agents are available or are under development as antagonists to these growth factors,
such as HER-2 antagonist herceptin (discussed later), gefitinib and erlotinib (EGFR
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Figure 2
Post translational modifications of the oestrogen receptor-signalling pathway,
demonstrating growth factor pathways that have been implicated as activating
ER in the absence of oestrogen. Courtesy of Dr LA Martin, Institute of Cancer
Research, Breakthrough Breast Cancer Centre, London.
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As well as the structural and functional changes to the ER in endocrine resistance, it
has been recognised that there is an influence of PR in response to treatment. As
mentioned previously, the ATAC and BIG 1-98 studies both showed a better
response to aromatase inhibitors over tamoxifen in ER+/PR- tumours, indicating
resistance to SERMs in ER+/PR- tumours and less resistance to oestrogen
withdrawal.71'73
It had previously been thought that the PR was dependent upon ER and that absence
of PR reflected a non functional ER and thus resistance to hormone therapy.
However the results from the ATAC trial suggest that there is a response to
oestrogen withdrawal in ER+/PR- tumours indicating simple loss of ER function via
low levels of oestrogen or ER is not the whole explanation. Indeed, there is a
suggestion that the benefit seen for anastrozole over tamoxifen in the ATAC trial was
127
largely due to reduced efficacy in the ER+/PR- tumours. In a study of tamoxifen
treated tumours both ER and PR were independent predictors of overall survival,
128with a greater response to tamoxifen in ER+/PR+ compared to ER+/ PR- tumours.
There is good evidence to date that there are significant biological differences
between ER+/PR- tumours to account for these different levels of responsiveness to
endocrine therapy. ER+/PR- tumours have higher levels ofHER-2 positivity and
EGFR signalling than ER+/PR+ tumours, and loss of PTEN associated with
upregulation ofmTOR/Akt/PI3K pathway results in loss of PR, implicating other
regulatory mechanisms. These proposed mehcanisms include loss of PR due to
hypermethylation and repression of the PR promoter, or genetic loss at the PR gene
locus in up to 40% of breast cancers. 127 Also implicated are growth factor mediated
downregulation of PR independent of ER, as IGF-1, EGF and heregulin have been
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shown to lower PR levels in cell lines, and/or growth factor influenced translational
modification of ER resulting in alteration of oestrogen-regulated genes, ofwhich PR
may be an example.
All of this emerging evidence of the significance of PR in endocrine resistance and
the biological differences between PR+ and PR- cancers is suggestive of inherent
resistance ofER+/PR- tumours to tamoxifen, and that aromatase inhibitors should be




Receptor tyrosine kinases and growth factor receptors regulate numerous functions in
normal cells and have a crucial role in oncogenesis. Epidermal growth factor (EGF)
was one of the first to be identified in 1962, with identification of the EGF receptor
in 1978 in epidermoid carcinoma cells. The development of cloning techniques has
allowed characterisation of the molecular mechanisms by which EGFR and other
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tyrosine kinase receptors function.
The targeted therapy that has been most investigated to date is that against HER-
2/neu receptors. Amplification of the HER-2/neu oncogene is present in 20-25% of
breast tumours, and is associated with reduced overall survival and shorter time to
relapse in node-positive patients. I30'131 When amplified the gene produces high
expression of JTER-2 cell surface receptors. Trastuzumab is a monoclonal antibody
that was developed to recognise HER-2 cell surface receptors, and has been shown to
be active against HER-2 positive disease in both metastatic and early breast cancer.
Early studies of efficacy and safety in metastatic breast cancer yielded objective
response rates of between 23-35% in those with over-expression of HER-2. 132'133
Several large clinical trials of trastuzumab in early breast cancer have reported
results. The HERA study included 5081 women with histologically confirmed HER-
2 amplified (IHC 3+ or FISH amplification positive) node-positive breast cancer or
node-negative tumours >lcm who had received primary treatment including adjuvant
chemotherapy and were randomised to observation or to one year of trastuzumab or
two years of trastuzumab. 134 Interim results after one year showed that patients in
the one-year trastuzumab arm had a significant improvement in disease-free survival
(HR 0.54, p<0.0001) and distant disease-free recurrence (HR 0.49, p<0.0001) and a
trend towards better overall survival (HR 0.76, p=0.26) compared with the
observation group. At 2 year follow-up an overall survival benefit was shown for
trastuzumab over placebo. 135 The most recent data from the HERA trial presented at
St Gallen 2009 at a median 4 year follow-up showed significantly better disease-free
survival (HR 0.76; 95%CI 0.66, 0.87; p<0.0001), but not overall survival (HR 0.85;
95%CI 0.70, 1.04; p=0.1087) with trastuzumab. 136 These latest results are for the
intention-to-treat (ITT) population, and this is thought to be influenced by the large
number of patients who crossed over to the trastuzumab arm of the trial after the one
year data were presented (885 patients of original 1689 in observation group crossed
to trastuzumab arm).
Two studies that randomised patients either to receive trastuzumab concurrently with
chemotherapy or chemotherapy alone reported a combined analysis. The NSABP
trial B-31 randomised 2043 women to doxorubicin and cyclophosphamide followed
by paclitaxel or the same chemotherapy with one year of trastuzumab commencing
on the same day as paclitaxel. The NCCTG trial N9831 randomised 1633 women to
the same arms as above but had a third study arm not included in the combined
analysis in which patients were randomised to doxorubicin and cyclophosphamide
followed by paclitaxel and then commencing trastuzumab after completion of
paclitaxel therapy. In the combined analysis of 3351 patients (control arm n=1679,
trastuzumab n=1672) there was a significantly longer disease-free survival (HR 0.48,
p<0.0001), distant disease-free survival (HR 0.47, p<0.0001) and improved overall
137survival (HR 0.67, p=0.015) after a median follow-up of 2 years. At median
follow-up of 3 years, there continued to be benefit for trastuzumab for DFS (HR
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0.49; 95%CI 0.41, 0.58; p<0.0001) and OS (HR 0.63; 95%CI 0.49, 0.81; p=0.0004).
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In the BCIRG 006 study 3222 women with node positive or high risk node negative
HER-2 positive tumours were randomised to receive either doxorubicin and
cyclophosphamide followed by docetaxel (AC —*-T) or doxorubicin and
cyclophosphamide followed by docetaxel and trastuzumab (AC -*~TH) or
docetaxel, carboplatin and trastuzumab (TCH). 139 Interim results at 36 months
median follow-up showed an absolute disease free survival (DFS) benefit of AC—^
TH over AC-*-T of 6% (HR 0.61; 95%CI 0.48, 0.76; p<0.0001) and an overall
survival benefit ofAC -*-TH over AC -*-T (HR 0.59; 95%CI 0.42, 0.85;
p=0.004). The combination of TCH also had overall survival (HR 0.66; 95%CI 0.47,
0.93; p=0.017) and disease free survival benefit (HR 0.67; 95%CI 0.54, 0.83;
p=0.0003) over AC—►T.
In the FinHer study 1010 women with axillary-node-positive or high-risk node-
negative cancer to receive three cycles of docetaxel or vinorelbine, followed by (in
both groups) three cycles of fluorouracil, epirubicin, and cyclophosphamide. 140 The
232 women whose tumours had an amplified HER-2 gene were further randomised
to receive or not to receive nine weekly trastuzumab infusions. In this study,
trastuzumab was administered before other cardiotoxic therapies and concomitantly
with potentially synergistic chemotherapy for only nine weeks to test the hypothesis
that such a schedule would limit cardiotoxicity and maintain efficacy. In those
patients who were HER-2 positive there was a significant improvement in
recurrence-free survival (HR 0.42, p=0.01) and a trend for better overall survival
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(HR 0.41, p=0.07) after a median of three years follow-up. Numbers in this study
were smaller than the other published studies of adjuvant trastuzumab.
The most significant adverse event emerging from trastuzumab studies has been
cardiotoxicity, primarily congestive cardiac failure, with an incidence of 1.4% in
132 133
women receiving trastuzumab as a single agent. ' In patients with metastatic
disease receiving trastuzumab concomitantly with paclitaxel or anthracyclines higher
incidences of cardiac dysfunction have been reported (13% and 27% respectively).
139'141 From study results available it appears the risk of cardiac dysfunction varies
with the type and timing of chemotherapy, in that concomitant use of trastuzumab
with non-anthracyclines is low-risk, use of sequential anthracycline then trastuzumab
is higher risk, and concomitant trastuzumab and taxane after anthracyclines is
associated with a risk of severe congestive heart failure. 142
These promising results with targeted therapy against HER-2 have sparked renewed
enthusiasm for discovery of and development of therapies to combat specific
molecular targets in oncogenesis.
Ofparticular relevance to this thesis is the potential use of agents that target specific
molecular pathways for combination treatments. More specifically, there is a
reasonable body of scientific evidence to suggest that these agents may be useful in
endocrine resistant tumours, either endocrine-nai've or those that have become
resistant over time. 143-145 One such potentially important target, the mammalian
target of rapamycin (mTOR) will be discussed in this thesis.
Oestrogen deprived MCF7 cells have increased mTOR and Akt activity, which has
led to the hypothesis that both proteins are an essential part of adaptation of breast
cancer cells to low oestrogen levels. 146 It has previously been shown that patients
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treated with tamoxifen were more likely to relapse if they had high expression of p-
Akt, and that such patients have a decreased overall survival. 147 A study in breast
cancer cell lines with aberrant Akt activity has shown that by inhibiting mTOR
tamoxifen response can be restored. 148 Furthermore it has been shown in breast and
ovarian cell lines that by combining tamoxifen and RAD001 there is an additive
antitumoural effect, 149 also seen with the combination of letrozole and RAD001 in
breast cancer cell lines. 143
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The mTORpathway
The mTOR pathway: background
The mammalian target of rapamycin (mTOR) is a 289kDa serine/threonine protein
kinase that belongs to the phosphatidylinsotide-30H kinase related kinase (PIKK)
family. The PIKKs are a subfamily of kinases related to phosphoinositide 3-kinase
(PI3K) by a similarity on the catalytic domains. The first members of the PIKK
family to be molecularly cloned from studies in budding yeast cells were TORI and
TOR2, identified as the target of the drug rapamycin when bound with FK506
binding protein-12 (FKBP-12). The mammalian orthologue of TOR (mTOR) was
isolated shortly thereafter by several groups of investigators, thus it is also known as
FKBP-12 and rapamycin-associated target (FRAP), rapamycin and FKBP-12 target-1
(RAFT1), rapamycin target-1 (RAPT1) or sirolimus effector protein (SEP). 150154
mTOR exists in two distinct complexes within the mammalian cell, one containing
mTOR, G-protein beta-subunit-like (G(3L) and raptor (regulatory associated protein
ofmTOR), and the other containing mTOR, GPL and rictor (rapamycin-insensitive
companion ofmTOR). 155-158 Figure 3 The roles of these components will be
discussed later, as most of what is understood about these complexes is as a direct
result of drug studies with rapamycin. The mTOR protein consists of up to 20
tandemly repeated motifs at the amino-terminus called HEAT motifs, which are
thought to form interfaces for protein-protein interactions. I59'160 At the carboxyl
terminus there is a mutated FRAP-ataxia-telangiectasia (FAT) domain, a
transformation/ transcription domain, a FKBP-12-rapamycin binding (FRB) domain,
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a catalytic kinase domain (similar to those found in the PI3K family), a probable







mTOR exists in two distinct complexes within the mammalian cell, one
containing mTOR, GpL and raptor (mTORCl) and the other containing
mTOR, GpL and rictor (mTORC2).
Downstream of mTOR
P70S6 kinase (S6KI) and elF4E binding proteins (4E-BPs, also known as
translational repressor protein PHAS-1) are the two best characterised downstream
effector molecules of mTOR. 161 Figure 4 It has become apparent that these actions
of mTOR are through the mTORl complex with raptor. The actions ofmTOR2
complex with rictor will be discussed separately.
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Figure 4
Actions of mTOR in complex with raptor (mTORCl) on S6 kinase 1 and 4E-
BP1, thus promoting progression of the cell cycle from G1 to S phase (see text
below).
S6K1 is a serine-threonine kinase, activation ofwhich by mTOR enhances the
translation ofmRNA that bears a 5 "-terminal oligopyrimidine tract (TOP). '"9 S6K1
requires phosphorylation at two sites for its full activation: at Thr389 in its C-
terminal hydrophobic motif and phosphorylation of its T loop. mTORCl mediates
phosphorylation ofThr389. 161 Activated S6K1 phosphorylates the 40S ribosomal
protein S6 to actively translate mRNAs with TOP, including ribosomal proteins,
elongation factors and insulin growth factor-Il and is thought to regulate cell size. 160
162164 S6K1 has been shown to phosphorylate mTORCl at ser 2448, l65'166 with ser
2481 the main site of phosphorylation ofmTORC2. 167 Studies comparing normal
breast, benign and malignant breast tumours have shown immunohistochemical
overexpression of S6K1 and S6K2 in breast cancer, 168 and in a study of 452
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premenopausal breast cancer patients, p70S6 kinase overexpression was
independently predictive for poor locoregional disease control (HR 2.5, p=0.006) and
disease-free survival (HR 1.8, p=0.025) at median 10.8 year follow-up. 169
The second signalling pathway promoted by mTOR involves phosphorylation of 4E-
BP1 and inactivation of 4E-BP1 suppressor proteins. The phosphorylation of 4E-BP1
results in a dissociation from eIF4E, facilitating the subsequent formation of the
eIF4F complex consisting of eIF4E, eIF4G, eIF4A and eIF3, thereby enhancing cap-
dependent protein translation. 159'170'171 The eIF4F complex is necessary for the
recruitment and positioning of ribosomes at mRNA sites, as eukaryotic ribosomes do
not have the ability to locate and bind to the 5' end ofmRNA, but need translation
initiation factors to guide them. This is a crucial step toward activating translation of
mRNAs with specific regulatory elements in the 5'-untranslated terminal region
(5'UTR), especially c-myc, cyclin D1, vascular endothelial growth factor (VEGF)
and ornithine decarboxylase. 162'172
Other proteins that have been shown to be directly affected by mTOR include PP2A
and STAT3. PP2A is a serine /threonine phosphatase that is involved in a variety of
cellular functions such as cellular metabolism, DNA replication, transcription,
translation, cell proliferation and cell transformation. mTOR controls the binding of
catalytic subunits and regulatory proteins within PP2A, thereby negatively regulating
the function of these subunits, and affecting the translation by eukaryotic elongation
factor 2 (eEF2). I62'173 STAT3 is a transcriptional activator that is directly
173
phosphorylated by mTORCl resulting in regulation of transcription factors.
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Upstream ofmTOR
The phosphoinositide 3-kinase (PI3K) family is deregulated in oncogenesis resulting
in disruption to a cascade of signals that normally regulate basic cellular properties
such as proliferation, survival and angiogenesis. 174 There are multiple mechanisms
for this deregulation, including mutation or silencing of the PTEN tumour suppressor
gene which, in the normal cell, acts to inhibit the activation of the PI3K-Akt cascade.
Figure 5 Without this suppressor mechanism, the hyperactivation of Akt, also known
as protein kinase B (PKB), is associated with resistance to apoptosis, increased cell
growth, cell proliferation and cellular energy metabolism. 175 All of the above
enzymes are implicated in the regulation of the mTOR pathway, primarily through
the interaction of Akt and mTOR. This interaction is complex and not well
understood due to continued new developments in the discovery of how Akt is
influenced by rictor-mTOR and raptor-mTOR in apparent antagonism.
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Figure 5
The interaction of mTOR as mTORCl and niTORC2 with PI3K/ Akt pathway
(see above text).
A study of RNA interference (RNAi) in Drosophila cells with knockdown of aspects
of the mTOR pathway was performed to determine the role of mTOR upon Akt
signalling. 176 What was found is described in Figure 6. In the normal Drosophila
cell, Akt stimulated mTOR which stimulated S6kinase with a resulting negative
feedback loop to control Akt activation. Direct inhibition of S6kinase resulted in
upregulation of Akt, as did inhibition of mTOR raptor. If, however, mTOR was
inhibited, there was little change in the activation of Akt, or a slight decrease in
activation, indicating that mTOR is involved in activation of Akt.
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(a) (b) (c) (d)
Figure 6
Findings from Sarbassov et al, Science 2005, 176 in Drosophila with direct
inhibition of different parts of the mTOR pathway, (a) normal pathway with no
inhibitors: Akt stimulates mTOR activation which activates S6 kinase with a
negative feedback loop to maintain similar levels of Akt. (b) when S6 kinase is
directly inhibited, there is loss of the negative feedback loop and upregulation of
Akt. (c) if mTOR raptor complex is inhibited, there is subsequent reduction in
p-S6 kinase and thus loss of negative feedback with upregulation ofAkt. (d) If
both complexes of mTOR are inhibited, however, there is downregulation of
S6kinase but with no reduction in Akt, suggesting an action of mTOR that is






mTOR as a therapeutic target in cancer
The majority of what is understood about the mTOR molecule is due to the discovery
of rapamycin in the 1970s. After isolation from a strain of Streptomyces
hygroscopicus in the soil of Easter Island (Rapa Nui), it was discovered that as well
as being a potent fungicide, rapamycin's antiproliferative properties extended beyond
fungi to have high potency as both an immunosuppressant and antineoplastic agent
against mammalian cells. More specific details on how rapamycin achieved these
effects remained elusive for 20 years until several groups of investigators identified
the mTOR protein kinase in 1994. Since then derivatives of rapamycin have been
developed, namely cell cycle inhibitor-779 (CCI-779, Wyeth-Ayerst, MA), AP23573
(Ariad Pharmaceuticals, Cambridge, MA) and RAD001 (Novartis Pharmaceuticals,
Basel, Switzerland). All three drugs are currently undergoing clinical development as
potential anticancer agents, but the focus of this thesis will be on RAD001
(everolimus, Certican®) and its effects in early breast cancer.
RAD001 in cancer studies
RAD001 is currently being assessed as an agent in a number of cancers. Studies in
prostate cancer have shown that particularly in PTEN-deficient cell lines, RAD001
amplifies the autophagic pathway of cell death and is thus capable of radiosensitising
these tumours. 177
In ovarian cancer, a study has been performed in Tag-DR26 mice which develop
ovarian tumours with strong immunoreactivity for Tag, phospho-Akt, phospho-
mTOR, and phospho-p70S6K in early and advanced lesions. 178 These mice when
treated with RAD001 from 5 weeks of age to 20 weeks of age at 5mg/kg nearly all
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developed ovarian tumours but RAD001 treatment significantly delayed tumour
onset and progression (median time for ovaries to reach a volume of 50 mm was 90
days in the placebo group compared with >122 days in RAD001-treated mice;
median tumour burden measured at time of euthanasia was 429.2 mm in controls
versus 26.2 mm in RAD001-treated mice). RAD001 treatment resulted in a
significant reduction in the number of mice with advanced disease and inhibited
ascites formation and peritoneal dissemination.
In a cell line study of human pancreatic neuroendocrine tumour (NET), BON cells,
known to have constitutive Akt/mTOR phosphorylation, were treated with RAD001
at different concentrations for 72 hours. 179 Lost expression of the PI3K antagonist
PTEN occurs in 54% of poorly differentiated neuroendocrine carcinomas and 76% of
all NETs display constitutive Akt phosphorylation. Results from this study showed
inhibition ofproliferation by 50% and induction of apoptosis with RAD001
treatment.
One clinical study has been reported of RAD001 in patients with advanced
1 RO
haematological malignancies. Patients with histologically confirmed advanced,
relapsed, or refractory acute myeloid leukaemia (AML) or myelodysplastic
syndrome (MDS), chronic lymphocytic leukaemia (CLL), T-cell leukaemia,
myelofibrosis, or mantle cell lymphoma (MCL) were treated with RAD001 5mg
(first three patients) or 10 mg orally once daily (one cycle lasting 28 days). Toxicity
data were available for 27 patients and included grade 1 or 2 hyperlipidemia (44%),
elevation of transaminases and/or alkaline phosphatase (41%), anorexia (37%),
mouth ulcers (37%), diarrhoea (29%), hyperglycaemia (26%), and hypomagnesaemia
(22%). One patient with refractory anaemia with ringed sideroblasts developed a
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biopsy-proven grade 3 cutaneous leucocytoclastic vasculitis (LCV) after 120 days of
therapy, which was believed to be related to RAD001. Thirty-eight infectious
episodes were noted in 21 (78%) patients at some time during the therapy. Fourteen
(37%) of the 38 infectious episodes that occurred in 9 patients required
hospitalisation and in some patients this was prolonged. One objective response was
sustained of 26 evaluable for response. Although no patients with CLL patients
achieved a complete or partial response, three patients had a 27% to 34% reduction
in lymphadenopathy, documented radiologically, after two to three cycles of therapy.
The most promising results to date with RAD001 are in advanced renal cell cancer.
181 Two hundred seventy-two patients with metastatic renal cell carcinoma with
progressive disease were randomised (2:1) to RAD001 or placebo, with progression-
free survival (PFS) the primary outcome. There were 191 PFS events (47% of 410
pts) reported by central review: 37% on RAD001 compared with 65% receiving
placebo. As a consequence of these interim analysis results, the Independent Data
Monitoring Committee stopped the study to allow remaining patients on placebo to
receive RAD001. Most common adverse events (AEs; all grades/ grade 3^1) were
mouth ulcers (RAD001 36/ 4%, placebo 7/ 0%), anaemia (RAD001 28/ 7%, placebo
15/ 5%), and fatigue (RAD001 28/ 2%, placebo 20/ 4%). 10% of pts had AEs leading
to discontinuation with RAD001 versus 4% with placebo. 68 deaths were observed,
and study follow-up is ongoing to assess the secondary endpoint of overall survival.
Studies with other mTOR inhibitors are at a similar stage in development as
oncological agents as RAD001, but lack the advantage of RAD001, it being licensed
for a different purpose, namely that of multi-drug immunosuppression for transplant.
Valuable insights into the function, safety and tolerability of RAD001 are thus
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already available. CCI-779 (Wyeth Pharmaceuticals) has been shown in pre-clinical
breast cancer cell lines to inhibit cell growth, particularly in PTEN wildtype cell
lines, and those with elevated baseline Akt and mTOR signalling. 182 A delay in
tumour growth with treatment with CCI-779 has also been seen in human pancreatic
1 8^
neuroendocrine tumours (PNET) and malignant glioma xenografts. CCI-779 has
been trialled as a single agent in 109 patients with locally advanced or metastatic
breast cancer who had failed to respond to anthracycline or taxane based regimens.
1 84
Clinical benefit was seen in 36 patients (37%), including patients with liver
metastases. Median duration of response was 5.4 months. Interestingly, no response
was seen in the 33 HER-2-neu negative patients.
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Pharmacology of RAD001
RAD001 is a novel macrolide that is similar to rapamycin but bears a hydroxyl-ethyl
chain giving it increased polarity for oral formulation. RAD001 has a licence for use
in multi-drug immunosuppression after transplantation, and is thus well investigated
in terms of its pharmacology and toxicity in the transplant population. The
pharmacological discussion herein will focus upon the oncological studies that have
taken place, but evidence from the transplant setting will be drawn upon where
appropriate.
RAD001 is formulated as 5mg tablets, and is metabolised mainly by CYP3A4 in the
liver. Co-administration of other compounds that are known inhibitors or inducers of
CYP3A should be avoided, which includes grapefruit, certain anticonvulsants and
antibiotics. Appendix 1 Taken orally, RAD001 is rapidly absorbed with peak levels
after an hour and an elimination half-live of 30 hours.
The mechanism by which RAD001 inhibits mTOR is similar to the action of
rapamycin, which has high affinity for the immunophilin FKBP-12 and when bound
together interact with mTOR. It is thought that the main interaction with mTOR is
within mTOR complex 1 (in association with raptor), but there is evidence to suggest
that with prolonged treatment mTOR complex 2 (in association with rictor) is also
inhibited.
RAD001 has a licence for use in solid organ transplantation as part of multi-drug
immunosuppression, and as a result has more toxicity data available than would be
normal for a drug undergoing phase II testing. None of these studies have been
published and details of results are owned by Novartis Pharma AG.
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In healthy subjects and stable renal transplant patients undergoing single dosing up to
4mg there were few side effects, headache being most notable. A small reduction in
platelet and neutrophil counts was seen but this was transient. Two multiple dose
studies were carried out with placebo control of doses up to lOmg/day in 63 stable
renal transplant patients who were also taking cyclosporin, which was expected to
increase the exposure to RADOO1. The dose limiting toxicity in transplantation was
established as being thrombocytopenia (<100 xl09/L) at lOmg/day. Longer term
studies up to 24 months were carried out in 1404 kidney transplant patients, and a
consistent increase in blood lipid levels and reduction in platelet and leucocyte
counts occurred with longer durations of treatment.
In phase 1 oncology studies to date, the most frequent adverse events reported have
been stomatitis, diarrhoea, mouth ulceration, gastroenteritis and
hypercholesterolaemia.
In a phase 1 oncology study to identify an optimal dosage of RADOO 1 given weekly,
20-30 mg / weekly was tolerated satisfactorily and resulted in downregulation of
p70S6kinase in peripheral blood mononuclear cells which were used as a marker of
pharmacodynamic effects. This was in patients with advanced cancers (none were
breast). Daily dosing of up to lOmg in the transplant setting resulted in no increase in
adverse events and with a half-life of 30 hours, daily dosing of 5mg, a cumulative
dose of 35mg per week was chosen as the initial phase 2 dose for this study.
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Aims
Within this thesis the candidate has attempted to answer the questions defined below
through a number ofmodalities. While these aims run throughout the thesis, each
method of investigation has a separate section with individual aims specified at the
beginning of each section. It is important to stress at the outset the common thread of
these methods and the ultimate unifying aims of this thesis.
These aims are:
• To assess the safety and tolerability of RAD001 in postmenopausal women
with early breast cancer
• To assess the effects of 5mg RAD001 upon tumour proliferation
• To investigate potential biological markers within the mTOR pathway as
predictive for response to RAD001
• To clarify the role of any biological marker identified above in breast cancer
cell lines treated with RAD001
• To assess the role of any biological marker identified above in the resistance
and sensitivity of breast cancer to endocrine agents, and thus the potential for




The principal aim of the clinical study was to investigate the safety and tolerability of
RAD001 at a dose of 5mg in postmenopausal women with early breast cancer in the
pre-operative setting. The collection of breast cancer biopsies from each patient was
a prerequisite for entry into the RAD001 study, in order to meet the primary aims of
the biological study.
Patients andmethods
The clinical study was a pre-operative 2 week study of patients with operable early
breast cancer. The initial target accrual was 30 patients, with 25 evaluable patients
with adequate tissue samples at diagnosis and at surgery who had also completed the
course of treatment with RAD001 and had surgery within 14-16 days of starting
RAD001. If after 30 patients less than 25 were evaluable, more patients would be
recruited until 25 evaluable patients were obtained. The non-evaluable patients
would be replaced with 25 evaluable patients at the final analysis. The patients were
all postmenopausal females, identified at the staging meeting at the Edinburgh Breast
Unit. Inclusion and exclusion criteria are shown below.
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Inclusion Criteria
• Postmenopausal women defined as >12 months since last menses. In patients
whose last menses was <12 months before start of treatment, follicle-
stimulating hormone (FSH) and luteinizing hormone (LH) levels must be in
postmenopausal range: FSH >35IU/L and LH >40 IU/L
• Fresh tissue available from core biopsies taken at diagnosis.
• No evidence of metastatic disease
• Operable breast cancer
• Written informed consent obtained from all subjects
• Performance status <2 (ECOG/WHO scale)
• Life expectancy >4 months.
• At least 2 weeks since last major surgery. A shorter interval was permissible if
the patient had recovered with no continuing complications.





> Creatinine <1.5 x upper limit of normal (ULN) for the testing
laboratory, or creatinine clearance >60mL/min
> Adequate liver function as defined by bilirubin <1.5 of upper limit of
normal (ULN), albumin >30g/l, serum ALT <2.5 x ULN and Alkaline
Phosphatase <2.5 x ULN.
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Exclusion Criteria
• Prior therapy for breast cancer
• Inflammatory breast cancer
• Concurrent medical or psychiatric problems unrelated to breast cancer, which
would significantly limit full compliance with the study or expose the patient to
extreme risk or decreased life expectancy.
• Treatment with another investigational drug within 30 days or five half-lives
(whichever is longer) prior to entry into the study.
• Presently receiving or expected to require concurrent chemotherapy,
immunotherapy, radiotherapy, chronic corticosteroid therapy or other hormonal
therapy for breast cancer.
• Presently receiving warfarin anticoagulant therapy.
• Current treatment with high dose oral corticosteroid therapy.
• Patients being treated with drugs recognized as being strong inhibitors of the
isoenzyme CYP3A within the last 7 days. Appendix 1
Patients were identified as eligible for the study at the staging meeting at which the
initial management plan was discussed by the multidisciplinary team (MDT). The
date of surgery was allocated at the MDT meeting, and if the date of surgery was
within 14 days of the MDT meeting, the patient was considered ineligible for the
study, ensuring that no patient had surgery delayed as a result of entering the study.
The named consultant saw the patient that day and discussed the proposed
management plan with the patient and family, and introduced the potential for
entering the RAD001 study. Interested patients then discussed the study with the
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research fellow or research nurse and were given a patient information sheet
(Appendix 2), and the patient was allowed at least 24 hours to decide upon entry. If
the patient did not wish to re-attend for randomisation on another day but wanted to
enter the study on the day of discussion, the study documentation was completed and
the drug dispensed with the patient aware that she should further consider the study
and withdraw from the study before or after commencing study medication if she so
decided. Once the patient had decided upon entry into the study, a consent form was
signed (Appendix 3). Safety bloods were taken on the day of randomisation in
addition to the routine bloods taken within the previous 10 days for screening. Also
performed were assessments of general health including pulse, blood pressure,
physical examination, electrocardiogram (ECG) if not already performed, height and
weight. World Health Organisation performance scale was assessed for each patient.
Patients were dispensed 14 days of RAD001 5mg once daily, and advised to contact
the research team in the event of any questions or side effects. A patient diary was
completed each day by the patient to allow assessment on Day 13 (pre-operative
admission day) of compliance with medication and monitoring of side effects
experienced by patients if not notified to the research team during the study period.
Appendix 4 Patients were strongly advised to contact the study team in the event of
any side effect that was unexpected in its nature or severity. A study information
sheet was sent to the patients' registered general practitioner in case of contact by the
patient regarding the study. Appendix 5
At the end of the study period, patients were admitted on the day prior to surgery
(study Day 13) or the morning of surgery (study Day 14), and were seen by a
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member of the research team for assessment of side effects, compliance and repeat of
safety bloods.
Safety data was collected at time of consent to enter the trial (Day 0) and on Day 13
when the patient was admitted to the ward for surgery the next day. For the few
patients who were admitted on the morning of surgery, blood samples were taken on
admission on Day 14. On both visits blood pressure, pulse, temperature, weight and
height (latter only on Day 0) were recorded.
Blood samples were taken on Day 0 and Day 13/14 for full blood count, renal
function, liver function and cholesterol. It was apparent to the researchers that in the
first three patients there had been a drop in neutrophil counts after 14 days treatment
with RAD001. In the next nine patients, full blood count samples were taken at Day
7 to determine any significant reduction in neutrophil counts prior to admission to
surgery. Interpretation of the neutrophil counts in these patients and data made
available from Novartis Pharmaceuticals regarding the nadir of Day 14 neutrophils
led to the cessation of the Day 7 blood tests in the remainder of the study patients as
it was clear there was no predictive value therein.
Statistical Analysis
The number of patients required for this study was 30 evaluable patients to power an
80% detection of reduction in Ki67 in 50% of patients. Analysis of variance
(ANOVA) was performed to determine the significance of changes between pre and
post treatment scores for all measurements. In the cases of data that were highly
skew, log transformation was performed. In order to examine the linear relationship
between the blood results and Ki67 counts, Pearson's Correlation (r) was used.
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Ethical Approval
Ethical approval for this study was sought and obtained through the UK national
application system (COREC). Approval was met through the Northern and Yorkshire
MREC for the clinical and biological studies. Appendix 6 Further application was
made and approved by the Lothian MREC for retrospective use of tissue collected
from patients who had been treated with endocrine agents. These patients had
consented for the tissue to be collected and further ethical approval was obtained to
utilise this tissue for the purposes of the analysis of endocrine resistant and sensitive
breast tumour samples.
Approval was sought and obtained from the Lothian Hospital Research and
Development department, and the Medicine and Health Regulatory Authority




Recruitment for this study commenced in March 2005 and was completed in
February 2006, during which time 91 patients were screened. Of those screened, 48
were excluded from the study for the following reasons: planned treatment with
neoadjuvant letrozole (n=18), peri-menopausal (n=8), ongoing medical problems
(n=8), operation date too early (n=7), medications in exclusion criteria (n=2), out of
UK during study period (n=2). Forty-three patients were approached by the research
team to discuss the study, of which 11 declined to enter. Four gave no reason, 4 did
not wish to take medication prior to surgery, 2 did not want any extra visits to
hospital or any extra intervention and one felt she was too old to participate. 32
patients were recruited to this study. One patient did not take any study medication
due to a flu-like illness prior to commencing RAD001 and was thus excluded and
returned all study medication. Patient 32 was recruited to reach the total of 25
evaluable patients required at the outset of the study who had completed the full 14
days of the trial medication.
Six patients withdrew from the study prior to completing 14 days of RAD001 5mg,
in all but one case due to side effects, discussed in full below. One patient completed
11 days of medication prior to reaching the expiry date of the drug batch. While this
had been anticipated, it was hoped that more trial drug would be available in time for
the patient to complete 14 days but this was unfortunately not the case. Biopsy
samples from all patients who withdrew early from the study were analysed for the
same outcomes as those samples from patients who had completed 14 days.
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Patient baseline characteristics
All patients were postmenopausal women with newly diagnosed early breast cancer.
The mean age was 67.5 years (range 51-89), and all had a WHO performance scale
of 0-2. Eleven patients had been on hormone replacement therapy in the past, and six
had had a hysterectomy. Only four patients had no past medical history, and five
were on no medication at the time of entry into the study. For the other patients, past
medical history and concomitant medication are shown in Tables 1 and 2. Patients
were staged pre-operatively as Tl-2, NO, MO, with the exception of 3 patients who
had palpable nodes at diagnosis, and were staged as T2 N1 MO. All patients
proceeded to surgery after the 14 day study period. Eight patients had a mastectomy
and axillary clearance and 23 had wide local excision of tumour with either axillary
clearance (n=8) or sentinel node biopsy (n=15). Three patients required further
surgery for complete excision of tumour, although initial excision samples were used
for the purposes of this study.
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Pt No Age Hysterectomy HRT PMH
1 79 No No CABG, IHD
2 73 No No Cholecystectomy, NIDDM
3 76 No No Hypertension, NIDDM
4 59 No Yes None
5 79 No No Thyroid adenoma
6 89 No No Cholecystectomy, Hypertension, Macular degeneration,
Osteoporosis
7 70 No No Hypertension, RTA- knee fusion
8 54 No Yes Angina - coronary stent, CVA, OA spine
9 76 No No Rheumatoid arthritis
10 51 No Yes Dental abscess, Depression
11 67 No No Hypothyroid
12 78 No No CVA, Hypertension, Hypercholesterolaemia
13 52 Yes Yes Irritable bowel, OA
14 64 No Yes Appendicectomy, Basal Cell Care, Ovarian cyst, TB lung
15 55 No Yes Bunionectomy
16 65 Yes Yes Bells palsy, Hypercholesterolaemia, Hypertension, Shoulder
fusion, Tuberculosis
17 57 No No None
18 68 No No Hypercholesterolaemia, Hypertension
19 74 No No Hypertension, Osteoarthritis
20 62 No No Meningitis
21 77 No Yes COPD, Hypertension
22 67 Yes Yes None
23 52 No No None
24 74 Yes No Hypercholesterolaemia, Hypertension
25 60 No Yes Aortic stenosis, Hypercholesterolaemia, Hypothyroid, Lap chole,
OA (knee), Sterilisation
26 75 No No Anaemia, Anal fissure, GORD, NIDDM (diet), Scarlet fever
28 76 No No Hypercholesterolaemia, Hypertension, IDDM
29 77 Yes No Arthritis, Cervical spondylosis, Hypertension, NIDDM
30 59 No No Endometrial polyps, Joint pain (knee)
31 53 Yes Yes Depression, Eczema, Goitre, Hypertension, OA, Psoriatic
arthropathy, Spondylosis
32 75 No No Asthma, Hypercholesterolaemia, Hypertension, IHD, Migraines
Table 1
Age, past and current medical history at time of entry into RAD001 clinical
study (coronary artery bypass graft (CABG), ischaemic heart disease (IHD),
non-insulin dependent diabetes mellitus (NIDDM), road traffic accident (RTA),
cerebrovascular accident (CVA), osteoarthritis (OA), tuberculosis (TB),
chornic obstructive airways disease (COPD), gastro-oesophageal reflux disease
(GORD)).
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Pt No Age Concurrent Medications
1 79 Amlodipine, Aspirin, Atenolol, GTN, ISMN, Lactulose, Nicorandil, Simvastatin
2 73 Bendrofluazide, Lisinopril, Metformin, Nifedipine, Simvastatin
3 76 Amlodipine, Aspirin, Lisinopril, Metformin, Simvastatin, Ventolin
4 59 Omeprazole
5 79 Nitrazepam
6 89 Adcal, Bendrofluazide, Celluvisc eye drops, Fosamax, Paracetamol
7 70 Atenolol, Dihydrocodeine
8 54 Atenolol, Atorvastatin, Chlordiazepoxide, Frusemide, GTN, Methocarbamol,
Omeprazole, Paracetamol
9 76 Sulfasalazine
10 51 Amoxicillin, Paroxetine
11 67 Amitriptyline, Thyroxine
12 78 Allopurinol, Atenolol, Frusemide, Simvastatin
13 52 Celebrex, Codydramol, Mebeverine
14 64 None
15 55 None
16 65 Bendrofluazide, Nifedipine, Simvastatin
17 57 None
18 68 Atenolol, Bendrofluazide, Lipitor, Lisinopril
19 74 Aspirin, Atenolol, Bendrofluazide, Celecoxib
20 62 None
21 77 Amitriptyline, Aspirin, Bendrofluazide, CoQIO, Propanolol
22 67 Co-codamol, Zimovane
23 52 None
24 74 Aspirin, Co-tenidone, Enalapril, Nifedipine, Simvastatin
25 60 Atenolol, Atorvastatin, Bendrofluazide, Thyroxine
26 75 Amlodipine, Atenolol, Bendrofluazide, Cocodamol, Ferrous sulphate, Ranitidine
28 76 Aspirin, Frusemide, Insulin, Lisinopril, Simvastatin
29 77 Atorvastatin, Bendrofluazide, Cocodamol, Enalapril, Gliclazide
30 59 Echinacea, Ibuprofen, Glucosamine
31 53 Ibuprofen, Paracetamol, Propanolol, Venlafaxine
32 75 Antihistamine, Aspirin, GTN, Simvastatin
Table 2
Age and concurrent medications for patients participating in the RAD001
clinical study.
(GTN: glyceryl trinitrate, ISMN: isosorbide mononitrate)
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Tumour characteristics
Of the 31 tumours from which biopsies were analysed for RAD001 outcomes, 27
were invasive ductal carcinoma of no special type (IDCNST), although two of these
displayed mixed mucinous features. Of the others, one was lobular, one was tubular,
one was papillary and one was neuroendocrine. The latter two were initially thought
to be IDCNST on diagnostic core biopsy. One tumour was thought to be tubular or
cribriform on core biopsy but was IDCNST on excision pathology. The mean size of
tumour was 23.9mm (range 11-41mm). On the excision specimen following 14 days
of therapy, three of the tumours were grade 1,16 were grade 2 and 12 were grade 3.
Tumour grades from core biopsy and excision specimens as scored by the consultant
pathologist correlated in 24 cases; in 5 cases the tumour was upgraded to grade 2
from 1, in two cases from grade 2 to 3, and in one case the tumour was downgraded
from grade 3 to 2. Eleven patients had evidence of lymphovascular invasion (LVI).
On pathological assessment of the axilla, 13 patients had at least one positive node,
including 5 patients who had more than 4 positive nodes on histology. The mean
number of nodes removed at axillary surgery was 12 (range 4-25). The Nottingham
Prognostic Index was calculated for each patient using the formula NPI= size (cm) x
0.2 + stage (lymph node stage 1-3) + grade (1-3). 185 Seven patients had a score in
the good prognosis category (NPI <3.4), 16 were in the intermediate prognosis group
(NPI 3.4-5.4) and 8 were in the poor prognostic category (NPI>5.4). Pathology












1 17 NST 2 Y 0 5 3.34
2 26 NST 2 N 0 6 3.34
3 24 NST 2 Y 20 20 5.48
4 30 Lobular 2 N 4 18 5.6
5 30 NST 3 N 1 16 5.6
6 25 NST 2 N 0 6 3.5
7 41 NST 3 N 0 17 4.82
8 36 NST/MUC 3 Y 1 15 5.72
9 22 NST 2 Y 1 20 4.44
10 17 NST 2 Y 2 22 4.34
11 21 NST 2 N 0 17 3.42
12 30 NST/MUC 2 N 0 9 3.6
13 16 Tubular 1 N 0 9 2.32
14 13 NST 3 Y 2 9 5.26
15 27 NST 3 Y 0 13 4.54
16 14 NST 3 N 0 4 4.28
17 35 NST 3 Y 15 21 6.7
18 29 NST 2 N 0 4 3.58
19 35 NST 3 N 0 18 4.7
20 35 NST 2 Y 10 15 5.7
21 18 NST 3 N 0 18 4.36
22 11 Neuroendocrine 3 N 0 5 4.22
23 27 NST 3 N 7 12 6.54
24 35 Papillary 2 N 0 14 3.5
25 15 NST 2 N 0 4 3.3
26 22 NST 2 N 1 5 4.44
28 14 NST 2 N 0 6 3.28
29 20 NST 2 Y 8 25 5.4
30 18 NST 1 N 0 5 2.36
31 23 NST 3 Y 1 19 5.46
32 16 NST 1 N 0 5 2.32
Table 3
Pathology of tumours for each patient participating in RAD001 clinical study
indicating size; type (invasive ductal no special type (NST), mucinous (MUC));
grade; lymphovascular invasion (LVI) present yes (Y) or no (N); number of
positive nodes of total excised; Nottingham Prognostic Index (NPI).
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Results for proliferation before and after treatment with RAD001 will be presented
later, but correlations with the above tumour characteristics will be discussed here
(Spearmans rank correlation (r)). There was a significant correlation between pre-
treatment proliferation (Ki67%) and tumour grade for both core biopsy (r=0.59;
95%CI 0.29, 0.78; p=0.0013) and excision specimens (r=0.61; 95%CI 0.32, 0.79;
p=0.0009)). No correlations were found between pre-treatment Ki67 and either
tumour size, type, presence of LVI, node positivity, NPI, or HER-2 positivity. There
was a trend toward highly proliferative tumours having lower ER pre-treatment, but
this did not reach significance (r=0.35; 95%CI 0.01, 0.63; p=0.0554).
Tumours that were of higher grade had a significantly greater reduction in
proliferation after RAD001 treatment (r=0.41; 95%CI 0.07, 0.67; p=0.024). Figure 7
Tumour size, type, presence of LVI, node positivity, NPI, and HER-2 positivity were
not found to correlate with the change in proliferation with treatment. There was a
trend toward tumours lower in ER having a greater change in Ki67 with RAD001
treatment (r=0.35; 95%CI 0.01, 0.62; p=0.0588).
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Figure 7
Tumour core biopsy grade correlated significantly with the change in Ki67 after
RAD001 treatment, with high grade tumours having a greater reduction with
treatment (r=0.41; 95%CI 0.07, 0.67; p=0.024).
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Tolerability
Twelve of 31 patients reported no symptoms while taking RAD001 5mg for the two
week treatment period. All adverse events reported are shown in Table 4. Each
symptom reported during the two weeks, either reported by direct contact with the
research team, or on submission of the diary at the end of the study period, is shown
in the table. As can be seen, all adverse events were grade 1 or 2 on the NCIC-CTC
scale. As stated above, five patients withdrew during the two week treatment period
due to adverse events, ofwhich two patients had more than one symptom that
contributed to their withdrawal. Median duration of treatment in those that withdrew
was 9.5 days (range 4-13 days). Four patients had mouth ulcers which were of
sufficient impact with pain on swallowing or chewing to result in the patient
withdrawing from the study, although one patient continued her medication until
planned admission to hospital for surgery on Day 13. One patient who withdrew due
to mouth ulcers had mouth ulcers prior to commencing treatment. Another patient
who withdrew with mouth ulcers also experienced nausea and fatigue, and felt these
symptoms contributed equally to her decision to withdraw from the study. A further
four patients had mouth ulcers but did not feel these to be a significant problem as
the ulcers were few in number or lasted for less than 2 days. The mouth ulcers
reported appeared from study Day 3 to Day 12. Patients were advised to use
antiseptic mouthwashes or throat lozenges, and a number of patients tried home
remedies such as salt mouthwashes. The other patient who withdrew from the study
experienced tiredness, nausea and anorexia for the first three days of the study period
and withdrew on Day 4.
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Two patients reported rashes; one was a small area ofmacular rash over the dorsum
of her right hand during study Day 12-14, with no itch or scaling; the other patient
had two acneiform spots over her anterior chest wall on study Day 7 that resolved
spontaneously, as well as a flushing redness and heat on the left side of her neck on
Day 11 that resolved spontaneously.
Two patients developed infections during the study period. One patient had a dental
abscess requiring treatment with ciprofloxacin, and the other had a urinary tract
infection and was treated with trimethoprim. A further patient experienced urinary















Mouth ulcers 8 (25.8) 4 (12.9) 1-2
Fatigue 6 (19.4) 2 (6.5) 1
Nausea 3 (9.7) 2 (6.5) 1-2
Rash 2 (6.5) 0 1
Dry mouth 2 (6.5) 0 I
Infection 2 (6.5) 0
Headache 2 (6.5) 0 1
Indigestion 1 (3.2) 0 1
Light-headed/
dizziness
1 (3.2) 0 1
Itch 1 (3.2) 0 1
Easy bruising 1 (3.2) 0 1
Joint pains 1 (3.2) 0 1
Table 4
All toxicities reported in two week study period while taking RAD001 showing
numbers (%) of patients reporting specific symptoms, and numbers (%)
withdrawing from the study because of the specific symptoms. Some patients
experienced and reported more than one symptom.
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Safety
Safety assessments of general health were performed before and on Day 13/14 of
treatment. Body mass index was calculated for each patient with a mean BMI of 27
both pre and post treatment (range pre-treatment 20-52). There was no significant
difference in systolic blood pressure pre- and post-treatment (mean pre 137 versus
mean post 136mmHg, p=0.71). There was a significant rise in pulse rate on the Day
13/14 measurements (71 b/m Day 0 versus 78 b/m Day 13/14, p=0.019). This
difference may be accounted for by the level of anxiety experienced by patients on
the second measurement due to admission to hospital. Similarly, a fall in peripheral
temperature from 36.7 C to 36.5 C (p=0.0053) can be accounted for by the change of
location from a warm clinic room to the relative cool of the admissions bay. There
was no change in the Performance Status score for any patient during the treatment
period ofRAD001. All patients had a Performance Score of either 0 or 1.
Pre- and post-treatment mean values for the intention to treat (ITT) population for the






Haemoglobin (g/dL) 13.7 13.6 0.7098
White blood cells (xlOy/L) 7.9 5.8 <0.0001
Neutrophils (mmJ) 5.01 2.95 <0.0001
Platelets (xlOy/L) 290* 208* <0.001
Creatinine (pmol/L) 71.5* 73.9* =0.3104
Sodium (mmol/L) 142* 142* =0.8396
Potassium (mmol/L) 4.3 4.0 =0.0001
Albumin (mg/L) 42.8 42.5 =0.5599
Calcium (corrected) (mmol/L) 2.39 2.33 =0.0005
Bilirubin (pmol/L) 6.9* 5.6* =0.0029
Alkaline phosphatase (mmol/L) 80.1* 86.0* =0.0311
Alanine amino-transferase (U/L) 31.0* 34.8* =0.0253
Cholesterol (mmol/L) 5.3 6.0 =0.0001
Triglycerides (mmol/L) 1.51* 1.81* =0.0186
HDL (mmol/L) 1.64 1.66 =0.6885
LDL (mmol/L) 2.85 3.26 <0.0001
Glucose (random) (mmol/L) 5.6* 6.2* =0.0542
Table 5
Pre-and post-treatment mean values for safety bloods taken in all patients
participating in RAD001 clinical study.
*denotes non-normal distribution of data where logarithmic transformation was back-
transformed therefore means shown are geometric.
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Haematology
There was no significant difference in haemoglobin levels with RAD001 treatment.
Figure 8 There was a significant fall in white blood cell count (WBC) (mean fall
2.11 x109/L, 95% CI 1.59 to 2.62, p<0.0001). Figure 9 The change in WBC highly
correlated with the pre-treatment WBC (r=0.71, p<0.0001), in that those with high
WBC had the greatest fall with RAD001 treatment. There was no evidence to
suggest a relationship between pre-treatment WBC and Ki67 pre-treatment or change
in Ki67 (Ki67 results to follow), nor did the change in WBC correlate with the Ki67
pre-treatment or change in Ki67 with treatment.
There was a significant reduction in the neutrophil differential of the WBC (mean
fall 2.06mm3, 95% CI 1.55 to 2.57, p<0.0001). Figure 10 The fall in neutrophils
correlated to the pre-treatment neutrophil count (r=0.78, pO.OOOl). There was no
relationship between either pre-treatment neutrophils or change in neutrophils and
pre-treatment Ki67 or change in Ki67 with treatment.
There was a significant fall in platelet count with RAD001 treatment (geometric
mean fall 1.39 xl09/L, 95% CI 1.26 to 1.53, p<0.001), such that the post-treatment
count was 71% that of pre-treatment. Figure 11 The change in platelets correlated
with the pre-treatment platelet counts (r=0.45, p=0.015), in that those with high
platelets pre-treatment had the greatest fall with RAD001 treatment. There was no
relationship between either pre-treatment or change in platelet count and Ki67 pre-
treatment or change in Ki67.
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Figure 8
Individual values for haemoglobin pre- and post-treatment with RAD001











Results for white blood cell counts (WBC) before and after treatment with
RAD001 demonstrating a significant fall with RAD001 treatment (p<0.0001)



















Individual values for neutrophil differential counts pre- and post-treatment





Results for platelet (Pit) counts pre- and post-treatment with RAD001
demonstrating a significant fall with RAD001 treatment (p<0.0001) (min, 25th
percentile, median, 75th percentile and max values shown as box plot)
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Biochemistry
There was no significant change in renal function as measured by creatinine. Figure
12 There was no significant change in sodium (Figure 13) with RAD001 treatment
but there was a significant fall in potassium (mean fall 0.3mmol/L, 95% CI 0.17 to
4.78, p=0.0001). Figure 14 It is possible that this may be due to varying hydration
status such as the fasting status of patients admitted on the same day for theatre.
There was no difference in serum albumin levels with RAD001 treatment (Figure
15) but there was a significant reduction in corrected calcium levels with RAD001
(mean fall 0.07 mmol/L, 95% CI 0.03 to 0.10, p=0.0005). Figure 16
Liver function tests were all affected by RAD001 treatment, but with no consistent
trend to suggest hepatotoxicity, as there was a significant reduction in bilirubin
(geometric mean fall 1.23 mmol/L, 95% CI 1.08 to 1.41, p=0.0029) (Figure 17), but
a rise in liver transaminase (ALT) (geometric mean rise 0.89 U/L, 95% CI 0.81 to
0.98, p=0.0253) (Figure 18) and alkaline phosphatase (geometric rise 0.93 mmol/L,
95% CI 0.87 to 0.99, p=0.0311) (Figure 19). There was no evidence to suggest any
relationship between change in bilirubin with Ki67 pre-treatment or change in Ki67.
There was a rise in random total cholesterol (mean increase 0.73 mmol/L, 95% CI
-0.99 to 5.75, p=0.0001) (Figure 20) and random triglycerides (mean rise 0.08
mmol/L, 95% CI 0.73 to 0.97, p=0.0186). Figure 21 Pre-treatment cholesterol was
not associated with Ki67 pre-treatment or change in Ki67. There was, however, an
association between Ki67 pre-treatment and the change in cholesterol (r=0.576,
p=0.0017), in that those with high Ki67 pre-treatment had the greatest rise in
cholesterol with RAD001 treatment. For the analysis of the two main lipoproteins
(high density lipoprotein (HDL) and low density lipoprotein (LDL)) there was no
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change in HDL (Figure 22) but a significant increase in LDL (mean increase 0.41
mmol/L, 95% CI -0.56 to 5.68, p<0.0001) with RAD001 treatment. Figure 23
There was a trend towards a rise in random serum glucose (mean increase 0.90














Day 0 Day 13/14
Figure 12
Individual values for creatinine (Crt) pre-and post-treatment showing no









Individual values for sodium (Na) pre- and post-treatment with RAD001










Values for potassium (K) pre- and post-treatment with RAD001 demonstrating
a fall with RAD001 treatment (p=0.0001) (min, 25th percentile, median, 75th









Individual values for serum albumin pre- and post-treatment showing no












Values for corrected calcium pre- and post-treatment demonstrating a
significant fall with RAD001 treatment (p=0.0005) (min, 25th percentile, median,














Individual values for serum bilirubin (Bil) pre- and post-treatment with
RAD001 demonstrating a significant fall with treatment (p=0.0029) (min, 25th









Results for alanine amino-transferase (ALT) pre- and post-treatment
demonstrating a significant rise with RAD001 treatment (p=0.0253) (min, 25th
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Day 0 Day 13/14
Figure 19
Results for alkaline phosphatase (Alk Phos) pre- and post-treatment
demonstrating a significant rise with RAD001 (p=0.0311) (min, 25th percentile,











Results for random serum cholesterol pre- and post-treatment demonstrating a
significant rise in cholesterol with RAD001 (p=0.0001) (min, 25th percentile,
median, 75th percentile and max values shown as box plot)
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Trig Trig
Day 0 Day 13/14
Figure 21
Results for serum triglycerides (Trig) pre- and post-treatment demonstrating a
rise after treatment with RAD001 (p=0.0186) (min, 25th percentile, median, 75th








Individual values for high density lipoprotein (HDL) pre- and post-treatment






Day 0 Day 13/14
Figure 23
Results for low density lipoprotein (LDL) pre- and post-treatment
demonstrating a significant rise with RAD001 (p<0.0001) (min, 25th percentile,





Day 0 Day 13/14
Figure 24
Individual values for random glucose pre- and post-treatment with RAD001,
showing a trend toward a rise with RAD001 treatment (p=0.0542)
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Peri- and post-operative complications
Data were collected on any complications occurring before, during or up to six
weeks after surgery.
Eight patients had either wound infection or infected seroma during the study period.
Three of these patients developed a suspected wound infection on the first post¬
operative day, all but one of which resolved with one course of antibiotics. None of
the patients who developed immediate post-operative wound infection had a
reduction in neutrophil count prior to surgery. One patient who developed an
multiple resistant staphylococcus aureus (MRSA) wound infection had more than
one course of antibiotics. This particular patient's husband was an inpatient in
another hospital, and was known to be a MRSA carrier. Three further patients
developed wound infections within four weeks of stopping RAD001 (4 weeks post¬
operatively). One patient had a re-excision prior to developing wound infection. Two
of these patients had reduced neutrophils at the time of surgery, despite one of them
having stopped the drug on Day 10 of the drug treatment. Two patients who had
seromas drained in the post-operative period developed local infection 4-6 weeks
after surgery.
Bleeding problems occurred in 4 patients of the total study group. Three patients had
haematomas that required return to theatre for evacuation and haemostasis, two of
whom had stopped the drug on Day 9 and Day 11. The other patient had reduced
platelets (110 x 109 /L), but an obvious single bleeding point was seen on return to
theatre. One patient had bleeding into her drain post-operatively despite normal
platelets and coagulation factors pre-operatively. This patient required iron
replacement for anaemia post-operatively.
108
During the study period it was local policy to give patients unfractionated low
molecular weight heparin prior to surgery, but due to an increase in bleeding
problems experienced outwith this study, this was changed and a different form of
1 86
prophylaxis introduced.
The numbers of patients experiencing post-operative problems with bleeding or
infection were greater than would have been expected within a normal population of
patients undergoing breast surgery within the Edinburgh Breast Unit at that time. All
the patients who bled had large tumours and underwent extensive mobilisation of
breast tissue to close the breast defect. All apparent post-operative infections settled
with antibiotics. Those who developed late infections were related to seromas. There
was no correlation between reduction in white cells or neutrophils and infections, nor
with reduction in platelets and bleeding problems.
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Discussion
As can be seen from the high recruitment uptake of patients into the clinical study,
the option of entering into a pre-operative study is an attractive one for patients. One
reason for this may be the active participation and ability to take some form of
potential treatment while awaiting surgery. Obviously in regions where there is only
a short waiting time for surgery this benefit is diminished. The clear benefits of the
design of this study for the investigator are the direct comparison of the same tumour
before and after treatment, and the short study period, thereby not suffering the
disadvantage of adjuvant studies where a long follow-up period is required in order
to determine any treatment benefit. The challenge in the pre-operative setting is to
find a biological marker that predicts for response in the long term. As previously
discussed, there is increasing evidence for the role of Ki67 as a predictor of clinical
response. 117'118 A further discussion of these markers will take place after
presentation of the results of the immunohistochemical studies carried out as part of
this thesis.
From the above data, it can be concluded that RAD001 at a dose of 5mg is tolerable
to patients with the exception of the most commonly reported symptom ofmouth
ulcers. Of the eight patients who experienced this side effect, four withdrew from the
study with Grade I or II (mild or moderate) level symptom, defined as patients
having pain on swallowing but being able to tolerate an adequate oral intake of liquid
and solid. One of these patients had mouth ulcers at the time of entry into the study
and withdrew on day 9 of treatment. Four other patients experienced mouth ulcers
but remained in the study as they felt that their symptoms were not interfering with
their quality of life. In general, those who withdrew had more mouth ulcers and they
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were present for a longer period of time than those who remained in the study. The
mouth ulcers resolved within 2 days in all patients after stopping RAD001. It is
reasonable to expect that the level of tolerability of a drug in the early stage of
treatment in a pre-operative setting will be different than that in an adjuvant or
advanced study due to different levels of expectation and previous experience of
patients. It is therefore encouraging that RAD001 was well tolerated in this pre¬
operative study.
The safety data are also reassuring from a group of patients who were typical of the
medical fitness ofwomen who experience breast cancer. It has become apparent
from data now available from further studies carried out by Novartis Pharmaceuticals
that the reduction in neutrophils found at 14 days in our study is the nadir and that
this normalises with continued treatment. Significantly, there was no obvious
increase in infective complications in the patients participating in this study, and in
particular among those who had reduction in neutrophils counts. Reported rates of
infective complications after breast surgery vary in the literature from 2% in
retrospective studies to 18% in prospective studies with infective complications as
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primary outcome. " All those who had reduced neutrophils in this study had the
expected response to surgery with a raise in neutrophil counts post-operatively.
Similarly, although there were more bleeding complications than might be expected
these did not occur in those who had a reduction in platelets. As mentioned above
this RAD001 study period coincided with a local change in policy for deep vein
thrombosis prophylaxis, with the resulting increase in bleeding complications, 186 and
this may compound the results seen with RAD001.
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One other published study has reported safety and tolerability data from a clinical
study of RAD001 in cancer. 180 In that study patients with histologically confirmed
advanced, relapsed, or refractory acute myeloid leukaemia or myelodysplastic
syndrome, chronic lymphocytic leukemia, T-cell leukemia, myelofibrosis, or mantle
cell lymphoma were treated with 5mg (first three patients) or 10 mg orally once daily
for 28 days. From 27 patients for whom toxicity data was available, the following
were reported as grade 1 or 2 toxicity: hyperlipidaemia (n=12, 44%), elevation of
transaminases and/or alkaline phosphatase (n=l 1, 41%), anorexia (n=10, 37%),
mouth ulcers (n=10, 37%), diarrhoea (n=8, 29%), hyperglycaemia (n=7, 26%), and
hypomagnesaemia (n=6, 22%). One patient with refractory anaemia with ringed
sideroblasts developed a biopsy-proven grade 3 cutaneous leukocytoclastic vasculitis
(LCV) after 120 days of therapy, which was believed to be related to RAD001.
Thirty-eight infectious episodes were noted in 21 (78%) patients at some time during
the therapy. Fourteen (37%) of the 38 infectious episodes that occurred in 9 patients
required either hospitalisation or prolongation of hospital stay. The frequency of
infectious episodes did not seem to be increased in the study patients, in keeping with
the results of the above results from this study of RAD001 in early cancer. The
findings of hyperlipidaemia and elevation of liver transaminase and alkaline
phosphatase with 14 days ofRAD001 would correlate with these findings in the
metastatic setting. One study in renal transplant patients treated with rapamycin
found a trend towards correlation between higher triglyceride levels and lower levels
of Akt phosphorylation, not found in this current study ofRAD001. 190
Two patients in this study were taking metformin for diabetes mellitus control.
Metformin has been shown in cell line studies to activate AMPK in the presence of
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TSC2, leading to phosphorylation of TSC1/2 complex, with a resulting reduction in
mTOR signalling and dephosphorylation of S6 and 4E-BP1. 191 It is therefore unclear
what effect concomitant treatment with metformin will have on tumours in
combination with an mTOR inhibitor. There were not sufficient numbers of patients
on metformin in this study to allow analysis of the effects of this drug on RAD001
efficacy. One of the patients on metformin developed mouth ulcers and stopped
RAD001 after 10 days, while the other patient completed 14 days treatment with no
side effects. In the study considered above in advanced haematological malignancy
grade 3 hyperglycaemia occurred in six patients requiring insulin therapy, ofwhich
five had a history of diabetes mellitus and grade 2 hyperglycaemia was noted at
baseline in four patients. 180 The hyperglycaemia resolved to baseline or better with
cessation ofRAD001. It has previously been shown that in patients with renal
transplant rapamycin therapy was associated with impaired glucose tolerance and
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development of new-onset diabetes mellitus, and that chronic exposure to
rapamycin inhibits basal and insulin-stimulated activation of Akt, and leads to an
increase in total insulin receptor substrate (IRS-1 and IRS-2) proteins, similar to the
pattern seen in naturally occurring type 2 diabetes mellitus. 190 There was a trend
towards a rise in serum glucose during our study of two week pre-operative treatment
with RAD001, but this did not reach significance. Random glucose levels can be
classified as normal <5.6mol/L, impaired glucose levels 5.6-11.1 mmol/L, diagnostic
of diabetes >11.1mmol/L. 193'194 One patient who had known diabetes mellitus had
high levels both before at the start and finish of treatment with RAD001. Eight
patients had normal random glucose before treatment but had glucose > 5.6 mmol/L
after RAD001. Four patients had glucose >5.6 mmol/L before treatment but these
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levels were normal after RAD001. In four patients both pre and post-treatment
glucose levels were over 5.6 mmol/L. There was no dominant pattern seen in the
results, probably because the samples were taken two weeks apart at different times
of the day, and with differing fasting status of the patients. Further investigation of
fasting blood glucose levels in patients with RAD001 would clarify any adverse
effect, as it has been demonstrated that hyperglycaemia preoperatively is associated
with increased cardiovascular mortality with surgery. 195
The other mTOR inhibitor that has been trialled in the clinical setting in breast
cancer is CCI-779 (Wyeth Pharmaceuticals). Tolerability from a study of two
different doses of CCI-779 in patients with locally advanced or metastatic breast
cancer revealed that all patients (n=106) had a drug-related treatment-emergent
adverse event (TEAE) at some point in the treatment period (median 11 weeks
treatment). 184 The most common of these was mouth ulcers (70%), with no
difference between the two treatment groups dosing of 75mg or 250mg by weekly
intravenous infusion. Similar rates of mouth ulcers have been reported with CCI-779
in advanced renal cancer and mantle cell lymphoma. I96'197 The very high rate of
mouth ulcers reported in these studies compared to our findings in the pre-operative
setting may be due to the patient population included in these metastatic studies as
these patients have been heavily pre-treated. However, the reported rate ofmouth
ulcers from the RAD001 study in metastatic haematological malignancies was 37%,
and so there may be differences between CCI-779 and RAD001 safety and
tolerability, possibly due to the methods of administration being oral for RAD001




Collection of biopsy samples
All patients entering this study had diagnostic core biopsies taken at time of
presentation with a symptomatic breast lump. The tissue was processed in
accordance with local pathology department policy. The surgical excision specimen
was processed by the pathology laboratory and once all diagnostic procedures
completed, the tumour blocks were retrieved and sectioned for study purposes.
All patients entering this study had fresh tissue stored at the time of diagnostic core
biopsy. This was in line with current policy in the Edinburgh Breast Unit approved
by the local Ethics Committee. Patients who attended the symptomatic breast clinic
with a clinically malignant palpable lump were approached by a member of the
research team to discuss taking of additional core biopsies for research purposes. The
uptake for this was high as most patients had up to 10 core biopsies taken for
diagnostic purposes and the addition of a further 3-4 core biopsies for research
caused no additional distress due to the infiltration of local anaesthetic and the
additional time taken. The tissue samples were stored immediately in a liquid
nitrogen canister within 2-3 minutes, and transferred to full storage in liquid nitrogen
at the end of the clinic. For the purposes of this study during surgery core biopsies
were taken for liquid nitrogen storage after the lump (in the case ofwide local
excision) or breast (in the case ofmastectomy) had been removed from the patient.
The diagnostic tissue was processed in accordance with local policy.
115
Analysis of biopsy samples
Immunohistochemical analysis was used to assess the effects of RAD001 on the
paired samples from the patients. Staining was performed on all samples collected
including those from patients who did not complete 14 days of treatment. Pre- and
post-treatment sections were stained within the same staining run and anonymised
prior to scoring.
Proliferation
Immunohistochemistry for Ki67 (MIB-1, diluted 1:50; Dako, Cambridge, UK) was
performed as follows:
epitope retrieval was performed in citrate buffer pH6.0 in a microwave for 6 minutes,
slides were then treated with 3% hydrogen peroxide (H2O2) for 5 minutes to block
endogenous peroxidase before washing and incubating with primary antibody as
above at room temperature (RT) for 30 minutes before incubation with secondary
antibody for 30 minutes (RT) (Dako EnVision+, K5007), then visualised with DAB
chromogen for 10 minutes (RT) and counterstained with haematoxylin.
Hormone receptors
Immunohistochemistry for oestrogen receptor (ER, NCL-L-ER-6F11/2 diluted 1:25;
Novocastra Laboratories, UK) and progesterone receptor (PR, PR636 diluted 1 TOO;
Dako) were performed as follows:
for both ER and PR epitope retrieval was performed in citrate buffer pH6.0 in a
microwave for 6 minutes, slides were then treated with 3% H202 for 5 minutes to
block endogenous peroxidase before washing and incubating with primary antibody
as above (RT) for 1 hour for ER and 30 minutes for PR before incubation with
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secondary antibody for 30 minutes (RT) (Dako EnVision+, K5007), then visualised
with DAB chromogen and counterstained with haematoxylin.
mTOR pathway effects
In order to determine that RAD001 was downregulating mTOR, phospho-mTOR
staining was carried out as described below. To show that the downregulation of
mTOR resulted in reduction in activity of downstream effects, phospho-S6 staining
was performed for ser 235/236 and ser 240/244 using a protocol worked up by
Michael Stumm, Novartis as described below.
Immunohistochemistry for phospho-mTOR (serine 2448) and phospho-S6 (serine
235/236 and 240/244) were performed as follows:
for both phospho-S6 and phospho-mTOR epitope retrieval was performed in citrate
buffer pH6.0 at 96°C for 10 and 20 minutes respectively, slides were treated with 3%
H2O2 for 10 minutes and 30 minutes respectively to block endogenous peroxidase and
with casein (p-mTOR) or 10% normal goat serum (p-S6) before washing and
incubating overnight at 4°C with the appropriate primary antibody (p-mTOR2448,
49F9, diluted 1:50; p-S6235/236 clone 2211, diluted 1:400; p-S6240/244 2215,
diluted 1:100, all Cell Signaling Technology) before incubation with secondary
antibody (Dako EnVision+, K5007) for 30 minutes at RT, visualized with DAB
chromogen for 10 minutes at RT and counterstained with haematoxylin.
Immunohistochemical staining for phospho-Akt (serine 473) was performed as
described below to determine the levels of expression and changes in expression with
treatment with RAD001.
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Epitope retrieval was performed in TRIS/ EDTA buffer pEI9.0 at 97°C for 20
minutes, slides were then treated with 3% H2O2 for 5 minutes before washing and
incubating with primary antibody (p-Akt s473, clone 14-5, diluted 1:6; Dako,
Denmark) for 30 minutes (RT) followed by incubation with secondary antibody and
DAB and counterstaining as described above.
Several attempts were made to optimise immunohistochemical staining for phospho-
PTEN (ser 380) by the candidate and members of the laboratory group of John
Bartlett. No optimum method was reached and it was not possible to obtain
satisfactory results for this within the time and financial restraints of this study.
HER-2
HER-2 assessment was performed routinely on the excision specimens of patients
with poor prognostic scores at the Pathology Laboratory. Testing for HER-2 was
performed by the same laboratory staff on those patients who did not routinely have
this done for research purposes. Immunohistochemical testing was performed and
scored by a pathologist. All samples scored as 2+ for HER-2 status by
immunohistochemistry were tested by fluorescent in situ hybridisation (FISH).
Overexpression of HER-2 was defined as tumours staining 3+ or 2+ and FISH
positive, while all patients with tumours scored as 0 or 1+ were considered not to
overexpress HER-2.
Apoptosis
Apoptosis was measured by assessment of active caspase-3 by the method described
as follows:
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Epitope retrieval was performed in TRIS/ EDTA buffer pH8.0 at 97°C, slides were
then treated with 3% H2O2 for 10 minutes before washing and incubation in serum-
free block (DAKO) for 1 hour. Primary antibody detecting cleaved caspase-3
(Abeam ab 2302, UK) was applied overnight at 4°C followed by incubation with
secondary antibody (EnVision, DAKO) and DAB and counterstaining.198
Scoring and intra-observer and inter-observer correlations
All sections were checked by a pathologist and appropriate areas of cancer for
scoring were ascertained. All samples except Ki67 and apoptosis were scored blind
using the histoscore method 199 performed by two scorers, one of whom was the
candidate. Ki67 was counted using a previously described and validated method of
scoring the percentage of stained cells as a proportion of the total cancer cells. 200 A
semi-automated method of calculating apoptosis using Ariol (Applied Imaging) was
employed where sections were scanned at high resolution (20x) using Ariol and
tumour areas were manually identified. Tumour cells were scored using a previously
validated algorithm.201 Inter-observer error was assessed for Ki67 count and for
histoscores. Figures 25 and 26 A significant correlation for both pre-treatment
(r=0.753, p<0.0001) and post-treatment samples (r=0.889, p<0.0001) was achieved.
The first count by the candidate had correlated significantly with the scores reported
by the second scorer, and the mean of the two scores was used for results analysis.
One patient's (pt 16) score was considerably different on first and second assessment
by the candidate and that closest to the score of the second scorer was used in the
results analysis.
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Intra-observer error for the candidate was assessed for Ki67 counts and for histoscore
on p-S6 (ser 235/236) by double scoring of both pre and post treatment samples with
a four week interval between scores by the candidate.
The intra-observer correlations for histoscores for p-S6 (ser 240/244), and for Ki67
were highly significant. Figures 27 and 28
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Figure 25
Inter-observer correlation for Ki67 (%) counts for pre and post treatment
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Figure 26
Inter-observer correlation for histoscore for p-S6 (ser 240/244) for pre and post
treatment tumour samples (r=0.9485 (95% CI 0.9157-0.9688, p<0.0001)).
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Ki67 Score A (%)
Figure 27
Intra-observer correlation for Ki67 (%) for pre and post treatment counts
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Figure 28
Intra-observer correlation for p-S6 (ser 235/236) histoscores for pre and post-
treatment (r=0.8573 (95%CI 0.7730 to 0.9118, p<0.0001)).
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Statistical Analysis
Results were analysed on an intention to treat (ITT) basis, after initial ANOVA
showed no difference between those completing 14 days and those who took
RAD001 for less than 14 days for change in proliferation as measured by Ki67, this
being the primary outcome; neither was there any difference between those
completing the full course or stopping early for the other markers of the mTOR
pathway assessed.
ANOVA was also employed to determine differences between those that had a
marked reduction in Ki67, "responders" (R), and those who did not, "non-
responders" (NR). Estimations of "responders" and "non-responders" were based
upon dual observer analysis of Ki67 staining; the 95% confidence interval for the
mean difference in Ki67 counts between two observers was taken as the minimum
difference which could be regarded as a change in Ki67 status between pre- and post-
treatment samples. 202 Due to the non-normal distribution of the data, Ki67 scores
were log transformed prior to analysis. The change between pre and post treatment
scores for each patient was calculated as the difference in the logged scores.
In order to examine the linear relationship between the immunohistochemical and
blood results with the Ki67 scores, Pearson's Correlation (r) was used. ANOVA was
used to examine the change between pre and post treatment scores for all the
measurements for each patient.
For the purpose of sub-group analysis data were split about the median value to
differentiate between those with high and low scores for each variable.
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Results ofbiological study
The results discussed below are for the intention-to-treat population of 31 patients
who received up to 14 days RAD001 treatment. There was no difference between
those who completed 14 days and those who had less than 14 days treatment for any
of the outcomes discussed below. Using the 95% CI of the absolute value for change
in Ki67%, 18 tumours were classified as "responders" and 13 as "non-responders".
Proliferation
Proliferation as measured by Ki67 was the primary outcome of the biological
RAD001 study (staining before and after treatment shown in Figure 29). There was
a significant reduction in proliferation as assessed by Ki67 (absolute median fall
8.5%, p=0.019). Figures 30 and 31; Table 6 Using log transformed data, the post-
treatment levels ofKi67 were 26% of those before treatment (95% CI 5, 56%).
Those that had a high proliferation at diagnosis had the greatest absolute decrease in
Ki67 (based on log transformed data r=0.36, p=0.046) with RAD001 treatment.
The relationships between pre-treatment Ki67 and the change in Ki67 with treatment
with the markers of the mTOR pathway examined will be discussed below with the
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Figure 30
Individual values for Ki67 before and after treatment with RAD001 (p=0.019).
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Figure 31
Proliferation (Ki67%) before and after RAD001 shown as box plot indicating
min, 25th percentile, median, 75th percentile and maximum. There was a












1 14 15.64464054 22.37932062 6.73468
2 10 20.07644202 13.43729499 -6.63915
3 14 9.49 10.89715232 1.402831
4 14 5.481474736 1.075595461 -4.40588
5 14 9.823652319 2.223224354 -7.60043
6 14 21.52219033 15.58552629 -5.93666
7 14 43.28024569 32.2784848 -11.0018
8 14 33.57424721 20.74116394 -12.8331
9 14 4.396040326 2.662083981 -1.73396
10 14 1.27 4.382147737 3.107816
11 14 15.39655555 5.668893311 -9.72766
12 14 22.8634227 6.522736121 -16.3407
13 9 4.23 1.208029547 -3.02269
14 14 22.59140438 3.982225303 -18.6092
15 14 21.21863803 7.365469905 -13.8532
16 14 25.72022868 16.0953047 -9.62492
17 14 3.59 47.20248447 43.60966
18 13 18.14672924 4.800763944 -13.346
19 14 44.9045913 24.52508402 -20.3795
20 14 10.33850024 3.576862616 -6.76164
21 14 42.8795435 16.59442075 -26.2851
22 14 17.40172389 9.906312325 -7.49541
23 14 23.04 17.74421659 -5.29804
24 14 13.14334833 0.593160477 -12.5502
25 11 8.674283646 5.274745273 -3.39954
26 4 12.20 6.229246176 -5.96992
28 14 10.97713215 11.45599451 0.478862
29 14 16.88578809 8.370806833 -8.51498
30 14 6.573965217 5.219653324 -1.35431
31 14 18.7829559 8.961546814 -9.82141
32 7 7.86 8.151975205 0.288313
Table 6
Individual numeric values for Ki67% before and after treatment with RAD001
(classified as responders (highlighted) and non-responders)
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Oestrogen and Progesterone receptors
There was a significant reduction in ER scores with RAD001 treatment over 14 days
(mean fall 40.5, 95%CI 16.9, 64.2, p=0.001). Table 7 Data were split about the
median (240) into high and low ER groups, demonstrating that those with lower ER
pre-treatment (n=12) had a significantly greater fall in ER (mean fall 77.5, 95%CI
43.26, 111.74) compared with those with high ER pre-treatment (n=19; mean fall
17.21, 95%CI -10.00, 44.42, p=0.009). Figure 32 This implies that tumours with
high ER were more likely to preserve ER after treatment that than those with lower
ER, who lost ER with treatment. There was however no correlation between Ki67
pre-treatment and ER scores before or after treatment, nor between ER score and
change in Ki67 with treatment. There was no difference in pre-treatment ER or
change in ER score with RAD001 between those that responded to treatment (as
assessed by Ki67) and those that did not respond.
There was no significant change in PR with treatment, and no correlation between
PR and Ki67 for either pre-treatment values or change in value with treatment. Table
8 There was, however, a significantly different change in PR score with treatment
between those that were classified on the basis of Ki67 change to have responded
and those that did not respond, in that responders had an increase in PR after 14 days
RAD001 (mean increase 14 (95%CI -1.5, 30.3) and non-responders had a decrease in





ER pre-treatment ER post-treatment
1 14 285 270
2 10 170 15
3 14 285 270
4 14 200 160
5 14 260 190
6 14 285 260
7 14 160 15
8 14 170 10
9 14 295 280
10 14 210 165
11 14 240 240
12 14 255 260
13 9 210 180
14 14 210 210
15 14 155 10
16 14 240 180
17 14 230 15
18 13 300 300
19 14 160 90
20 14 297 230
21 14 240 240
22 14 240 300
23 14 285 285
24 14 285 300
25 11 270 210
26 4 275 240
28 14 240 240
29 14 225 240
30 14 180 240
31 14 240 225
32 7 240 210
Table 7
Individual numeric values for ER histoscores before and after treatment with
RAD001 (classified as responders (highlighted) and non-responders by Ki67).
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Figure 32
Individual values for ER score before and after treatment with RAD001,
demonstrating a significant reduction in ER with RAD001 treatment (p=0.001).
Those with high pre-treatment ER (above median 240, dashed line shown)
showed no significant change in ER, but those with initially lower ER score (less





PR pre-treatment PR post-treatment
1 14 70 70
2 10 0 0
3 14 18 15
4 14 0 2
5 14 0 0
6 14 250 220
7 14 0 3
8 14 18 0
9 14 155 150
10 14 140 130
11 14 90 120
12 14 180 255
13 9 0 0
14 14 140 210
15 14 0 0
16 14 140 160
17 14 6 2
18 13 3 3
19 14 1 5
20 14 200 190
21 14 100 30
22 14 120 145
23 14 5 3
24 14 180 200
25 11 170 90
26 4 150 180
28 14 230 170
29 14 70 150
30 14 240 270
31 14 140 140
32 7 260 240
Table 8
Individual numeric values for PR histoscores before and after treatment with










Results for PR scores before and after RAD001 shown as box plot indicating
min, 25th percentile, median, 75th percentile and maximum. In those that did not
show a response to RAD001 (defined by change in Ki67%) (non-responders)
there is a small reduction in median PR with treatment and those that
responded to RAD001 (responders) there was a small increase in PR with
treatment. The difference between the two groups was significant (p=0.025).
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HER-2
HER-2 scoring was performed by a trained pathologist, and scored as 0, 1, 2 or 3 on
immunohistochemistry. Fluorescent in-situ hybridisation (FISH) testing was
performed on those samples that were intermediate (score 2) on
immunohistochemistry. Eight patients had tumours that were positive on IHC with a
score of 3+. Table 9 All those who had FISH testing for score 2+ were negative. Of
those that were HER-2 positive, four were ER poor, and all were PR poor or
negative. Table 10 Response by Ki67 was seen in both HER-2 positive and HER-2
negative tumours. Of the 8 HER-2 positive tumours, 7 responded with a reduction in
Ki67 (87.5%), but of 23 HER-2 negative patients, only 11 had a response (47.8%).
This numerical difference in response between HER-2 positive and HER-2 negative
did not reach statistical significance (p=0.10).
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9 14 1 +




14 14 2+ Negative
15 14 3+
16 14 1+
17 14 2+ Negative
18 13 0
19 14 0
20 14 2+ Negative
21 14 3+
22 14 3+
23 14 2+ Negative
24 14 0
25 11 2+ Negative
26 4 1+
28 14 2+ Negative
29 14 0
30 14 1+
31 14 2+ Negative
32 7 1 +
Table 9
HER-2 positivity on immunohistochemistry (FISH on ++): individual values
(responders (highlighted) and non-responders by Ki67).
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Patient number ER (histoscore) PR (histoscore) HER-2 IHC
1 285 70 0
2 170 0 3+
3 285 18 3+
4 200 0 1+
5 260 0 3+
6 285 250 1+
7 160 0 3+
8 170 18 3+
9 295 155 1+
10 210 140 1+; 2+; FISH neg
11 240 90 1+
12 255 180 0
13 210 0 1+
14 210 140 2+; FISH neg
15 155 0 3+
16 240 140 1+
17 230 6 2+; FISH neg
18 300 3 0
19 160 1 0
20 297 200 2+; FISH neg
21 240 100 3+
22 240 120 3+
23 285 5 2+; FISH neg
24 285 180 0
25 270 170 2+; FISH neg
26 275 150 1+
28 240 230 2+; FISH neg
29 225 70 0
30 180 240 1+
31 240 140 2+; FISH neg
32 240 260 1+
Table 10
Combined results for ER, PR and HER-2 for each patient pre-treatment
(responders (highlighted) and non-responders by Ki67).
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phospho-S6 kinase
Cytoplasmic staining for phospho-S6 was seen. Figure 34 For both phosphorylation
sites assessed (ser 235/236 and ser 240/244) there was a significant reduction in
phosphorylation. For p-S6 s235/236 the mean histoscore pre-treatment was 129.4
and this fell to 58.3 post treatment (mean fall 71.2; 95%CI 41.9, 100.4; p<0.001).
Figure 35 and 37; Table 11 For p-S6 s240/244 the mean histoscore pre-treatment
with RAD001 was 142.0 and 31.5 post treatment (mean fall 110.5; 95%CI 82.9-
138.2; p<0.001). Figure 36 and 37; Table 12
There was no evidence for a relationship between pre-treatment scores for either site
of phosphorylation of S6 and Ki67 before or after treatment, nor between the change
in S6 and Ki67 before or after treatment. Reduction in phosphorylation of S6 by the
mTOR inhibitor RAD001 would appear to be independent ofproliferation.
There was a trend toward greater reduction in p-S6 in those tumours that responded
to RAD001 but this did not reach statistical significance for either s235/236
(responders (R) mean fall 89.3; 95%CI 51.7, 127.0; non-responders (NR) mean fall
46.0; 95%CI 1.7, 90.3; p=NS) or s240/244 (R mean fall 124.5, 95%CI 88.5, 160.6;
NR mean fall 91.2; 95%CI 48.8, 133.6; p=NS) sites of phosphorylation.
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Figure 35
Individual results for p-S6 (ser 235/236) before and after treatment with











Change in S6 ser
235/236
1 14 140 0.5 -139.5
2 10 280 85 -195
3 14 180 19.5 -160.5
4 14 30 1.5 -28.5
5 14 152.5 157.5 5
6 14 125 112.5 -12.5
7 14 205 120 -85
8 14 180 12.5 -167.5
9 14 5.5 16 10.5
10 14 55 47.5 -7.5
11 14 195 65 -130
12 14 22 22.5 0.5
13 9 80 25 -55
14 14 40 7.5 -32.5
15 14 270 92.5 -177.5
16 14 210 17.5 -192.5
17 14 75 95 20
18 13 52.5 37.5 -15
19 14 40 42.5 2.5
20 14 187.5 26.5 -161
21 14 100 70 -30
22 14 70 3 -67
23 14 150 22.5 -127.5
24 14 30 75 45
25 11 112.5 150 37.5
26 4 235 82.5 -152.5
28 14 120 85 -35
29 14 105 17 -88
30 14 72.5 127.5 55
31 14 252.5 85 -167.5
32 7 240 85 -155
Table 11
Individual values for phospho-S6 ser (235/236) pre and post treatment













pS6 240/244 pre-treatment pS6 240/244 post-treatment
Figure 36
Individual results for p-S6 (ser 240/244) before and after treatment with











Change in S6 ser
240/244
1 14 105 0 -105
2 10 270 195 -75
3 14 185 0 -185
4 14 110 0.5 -109.5
5 14 185 0.5 -184.5
6 14 122.5 40 -82.5
7 14 105 25 -80
8 14 230 3 -227
9 14 50 1 -49
10 14 57.5 19 -38.5
11 14 175 5 -170
12 14 60 0 -60
13 9 270 5 -265
14 14 50 0 -50
15 14 265 22.5 -242.5
16 14 72.5 1.5 -71
17 14 115 90 -25
18 13 115 57.5 -57.5
19 14 145 27.5 -117.5
20 14 220 37.5 -182.5
21 14 142.5 5.5 -137
22 14 140 0 -140
23 14 197.5 26.5 -171
24 14 2 2.5 0.5
25 11 52.5 35 -17.5
26 4 200 7.5 -192.5
28 14 145 50 -95
29 14 100 62.5 -37.5
30 14 105 85 -20
31 14 252.5 35 -217.5
32 7 157.5 135 -22.5
Table 12
Individual values for phospho-S6 at ser 240/244 pre and post treatment
(responders (highlighted) and non-responders by Ki67).
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pS6 240/244 pre pS6 240/244 post pS6 235/236 pre pS6 235/236 post
Figure 37
Change in phospho-S6 after 2 weeks treatment with RAD001 for all patients




There was no significant change in phospho-mTOR (p-mTOR) in the ITT group.
Figure 38; Table 13 There was no significant difference in change in p-mTOR with
RAD001 treatment between tumours that had high scores for p-mTOR pre-treatment
and those with low p-mTOR. Pre-treatment levels of p-mTOR did not correlate with
either Ki67 at baseline or change in Ki67 with treatment. There was however
evidence for a relationship between the Ki67 pre-treatment and the change in p-
mTOR with treatment (r 0.43, p=0.0168). These data suggest that tumours that were
highly proliferative had a decrease in phosphorylation of mTOR after RAD001
treatment. Figure 39 There was no difference in scores at baseline, nor change in p-
mTOR between responders and non-responders.
Multivariable regression analysis was performed to determine prevariables that may
influence the change in Ki67. From this pre-treatment mTOR as a predictor for
















1 14 127.5 55 -72.5
2 10 135 255 120
3 14 255 212.5 -42.5
4 14 57.5 215 157.5
5 14 170 115 -55
6 14 155 75 -80
7 14 180 130 -50
8 14 140 175 35
9 14 105 115 10
10 14 190 300 110
11 14 200 135 -65
12 14 85 122.5 37.5
13 9 62.5 20 -42.5
14 14 160 245 85
15 14 122.5 35 -87.5
16 14 110 52.5 -57.5
17 14 120 112.5 -7.5
18 13 185 55 -130
19 14 240 75 -165
20 14 145 130 -15
21 14 145 25 -120
22 14 135 120 -15
23 14 140 177.5 37.5
24 14 105 210 105
25 11 135 225 90
26 4 75 245 170
28 14 235 220 -15
29 14 75 52.5 -22.5
30 14 100 230 130
31 14 90 160 70
32 7 170 280 110
Table 13
Individual histoscore values for phospho-mTOR pre and post treatment
(responders (highlighted) and non-responders by Ki67).
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Figure 39
Correlation between p-mTOR change with treatment and pre-treatment Ki67%
showing to the left a reduction in p-mTOR with RAD001 treatment in those
with high pre-treatment Ki67, but to the right an increase in p-mTOR in those
with low pre-treatment Ki67 (r=0.43, p=0.0168).
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phospho-Akt
Staining for p-Akt was both nuclear and cytoplasmic, and separate scores were
calculated for both types of staining. Figure 40 There was a significant reduction in
nuclear phosphorylation of Akt (mean fall 20.9, 95%C1 5.02, 36.79, p=0.012) with
RAD001 treatment. Figure 41 In those that had any nuclear staining before
treatment (n=18), only 5 had residual nuclear staining for p-Akt after treatment with
RAD001. Table 14 Those with high pre-treatment p-Akt nuclear staining had a
significantly greater fall in nuclear p-Akt with RAD001 (p=0.0021). There was no
correlation between pre-treatment p-Akt nuclear staining and Ki67 at baseline or
after treatment. Change in nuclear p-Akt did not correlate with Ki67 at baseline nor
change in Ki67. There was no difference in either baseline or change in nuclear p-
Akt between responders and non-responders to RAD001 treatment.
There was no significant change in levels of phosphorylation of cytoplasmic Akt pre
and post treatment with RAD001. Table 15 Patients with a pre-treatment score above
the median (70) fell by an average of 58.6 (95% CI 25.0, 92.1) with treatment, while
the p-Akt scores of patients with pre-treatment p-Akt below median 70 had no
significant change with treatment (mean rise 12.87, 95% CI fall of 21.7 to rise of
47.5, NS). Thus those with high pre-treatment p-Akt had a significant fall in p-Akt
with treatment, and those with low pre-treatment scores had no change. The change
between the two groups was significant (p=0.0051). There was a correlation between
high pre-treatment Ki67 and high pre-treatment cytoplasmic p-Akt (r=0.45,
p=0.0105), suggesting that highly proliferative tumours have high cytoplasmic
phosphorylation of Akt. Figure 42 There was also a correlation between the change
in Ki67 and change in cytoplasmic p-Akt with treatment (r=0.45, p=0.0106),
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suggesting that these tumours are those that have the greatest reduction in Ki67, with
evidence to suggest a correlation between pre-treatment Ki67 and the change in p-
Akt (r=0.35, p=0.0505). However in the multivariable analysis, pre-treatment
cytoplasmic p-Akt was not identified as a predictor for change in Ki67. There was no
difference between those with high cytoplasmic p-Akt and low cytoplasmic p-Akt
(data split about the median) in terms of the change in Ki67.
There was a significant reduction in cytoplasmic p-Akt in those tumours that were
classified as responding to RAD001 (mean fall 52, 95%CI 19.7, 84.4) compared with
those who did not respond, in which there was no significant change (mean rise 14.8,





Example of staining for p-Akt showing nuclear and cytoplasmic staining pre-
(a) and post- (b) treatment with RAD001.
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Figure 41
Histoscore results for nuclear p-Akt before and after RAD001, showing a
significant reduction in scores after treatment (p=0.012).
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Patient Days of treatment Pre-treatment Post-treatment Change in
number completed nuclear p-Akt nuclear p-Akt nuclear p-Akt
1 14 0 0 0
2 10 230 130 -100
3 14 5 0 -5
4 14 5 0 -5
5 14 1 0 -1
6 14 0 0 0
7 14 0 0 0
8 14 145 0 -145
9 14 0 0 0
10 14 70 0 -70
11 14 0 0 0
12 14 0 10 10
13 9 145 0 -145
14 14 30 0 -30
15 14 10 0 -10
16 14 10 0 -10
17 14 0 30 30
18 13 0 0 0
19 14 0 0 0
20 14 0 0 0
21 14 45 0 -45
22 14 0 0 0
23 14 85 10 -75
24 14 10 0 -10
25 11 0 0 0
26 4 10 45 35
28 14 25 0 -25
29 14 2 0 -2
30 14 15 0 -15
31 14 30 0 -30
32 7 0 0 0
Table 14
Individual histoscores for nuclear phospho-Akt pre and post treatment












1 14 27.5 5 -22.5
2 10 175 100 -75
3 14 215 170 -45
4 14 10 1 -9
5 14 35 70 35
6 14 125 195 70
7 14 45 155 110
8 14 115 20.5 -94.5
9 14 2.5 10 7.5
10 14 57.5 50 -7.5
11 14 29 7.5 -21.5
12 14 60 50 -10
13 9 45 7.5 -37.5
14 14 115 7.5 -107.5
15 14 95 1.5 -93.5
16 14 24.5 25 0.5
17 14 40 122.5 82.5
18 13 172.5 102.5 -70
19 14 205 83 -122
20 14 24 110 86
21 14 235 92.5 -142.5
22 14 137.5 0 -137.5
23 14 145 90 -55
24 14 210 55 -155
25 11 2.5 45 42.5
26 4 112.5 57.5 -55
28 14 98 182.5 84.5
29 14 55 0 -55
30 14 62.5 54.5 -8
31 14 79 50 -29
32 7 70 160 90
Table 15
Individual histoscores for cytoplasmic phospho-Akt pre and post treatment




Correlation between pre-treatment scores for cytoplasmic p-Akt and
proliferation counts, demonstrating that tumours high in p-Akt tended to also











pre c-AKT post c-AKT
Non-Responders
pre c-AKT post c-AKT
Responders
Figure 43
Change in cytoplasmic p-Akt after 2 weeks treatment with RAD001, divided
into non-responders (left) and responders (right), demonstrating a significant
difference between the two groups, with responding tumours to RAD001 having
a significant reduction in score after treatment (p=0.0105), but no change in
those that did not respond to RAD001.
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Apoptosis
There was no significant change in levels of apoptosis measured by active caspase-3
with RAD001 treatment for the ITT population (median pre-treatment 0.6%; 95%CI
0.46, 0.81; median post-treatment 0.22%; 95%CI 0.15, 0.68; p=NS). Figure 44;
Table 16 In those tumours that had high pre-treatment Ki67 there was evidence to
suggest an increase in apoptosis with RAD001 treatment (r=0.37, p=0.04). Figure 45
There was no significant difference between responders and non-responders for pre-










pre apoptosis post apoptosis
Figure 44












1 14 0.70 0.17 -0.53
2 10 0.42 1.69 1.27
3 14 0.60 0.03 -0.57
4 14 1.05 0.16 -0.89
5 14 1.16 0.34 -0.82
6 14 0.09 0.27 0.19
7 14 0.62 3.37 2.75
8 14 1.46 0.98 -0.48
9 14 0.81 0.14 -0.67
10 14 0.34 0.27 -0.07
11 14 0.48 0.06 -0.42
12 14 0.54 0.02 -0.52
13 9 0.26 0.87 0.61
14 14 2.60 2.12 -0.48
15 14 0.73 1.20 0.47
16 14 0.58 0.17 -0.41
17 14 2.04 0.68 -1.36
18 13 0.51 0.22 -0.29
19 14 0.83 0.90 0.07
20 14 0.25 0.16 -0.09
21 14 0.35 0.70 0.35
22 14 0.19 0.03 -0.16
23 14 0.58 0.40 -0.18
24 14 0.81 0.22 -0.59
25 11 0.70 0.46 -0.24
26 4 0.97 0.18 -0.79
28 14 0.13 0.03 -0.10
29 14 0.47 0.06 -0.41
30 14 0.14 0.00 -0.14
31 14 2.10 1.39 -0.71
32 7 0.76 0.08 -0.68
Table 16
Individual values for apoptosis (%) pre and post treatment (responders
(highlighted) and non-responders by Ki67).
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Figure 45
Correlation between pre-treatment proliferation (Ki67%) and change in
apoptosis by caspase-(%) with RAD001 treatment suggesting that those
tumours with higher pre-treatment proliferation had a greater increase in
apoptosis with RAD001 treatment (r= 0.37; p=0.04).
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phospho-PTEN
At the time of completion of this thesis, several attempts had been made to optimise
the immunohistochemical protocol for phospho-PTEN without success. No results
are available for the PTEN status of the tumours in this study. The results of a study
ofPI3KCA mutation status of the tumours from this RAD001 study but not carried
out directly by the candidate will be discussed below.
161
Discussion
The primary outcome measured in this pre-operative study was the change in
proliferation with treatment with RAD001 as measured by Ki67. There was a
significant reduction in proliferation with up to 14 days treatment with RAD001.
Those that had the highest Ki67 pre-treatment had the greatest reduction in
proliferation, which may be expected as those tumours have the greatest potential
fall, but the log transformed data suggest a significant absolute fall in response to
RAD001 treatment in the highly proliferative tumours in this study group. These
highly proliferative tumours were also those that had the greatest increase in
apoptosis with RAD001 treatment, and also tended to be ER negative and of higher
tumour grade. No correlation was found between proliferation and HER-2 positivity.
The measurement ofKi67 has attracted interest recently as a possible predictor of
response to endocrine therapy. 117 Previous pre-operative studies performed in
Edinburgh have used Ki67 as an outcome measure to allow comparison between
agents and the individual efficacy of agents as anti-proliferative agents.56'203 From a
study of letrozole and anastrozole given for 2 weeks pre-operatively there was a
median reduction in Ki67 of 5.8%. 203 The median Ki67 pre-treatment was 6.68%,
which was lower than the pre-treatment median for the patients in this RAD001
study (18.5%), which might in part account for the absolute fall in Ki67 by 8.5%
with RAD001 treatment. In the letrozole and anastrozole study the tumours were all
ER positive and were smaller, mainly screen detected cancers.
Of note from the above results for proliferation, there was one tumour (patient
number 17) that had an unusual change in proliferation, with a rise in Ki67 from 3.60
% to 47.20%. The immunohistochemical staining was repeated on both samples and
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rescored with similar results. It was noted that there was a large proportion of
inflammatory cells in the excision specimen. The pathology of this tumour was
ER+/PR-/HER-2 negative invasive ductal carcinoma (no specific type), grade 3 on
both core and excision specimens, with a whole tumour size 35mm, lymphovascular
invasion and 15 of 21 lymph nodes positive after mastectomy and axillary clearance
(NPI 6.7). Results for the other markers for this patient's tumour in response to
RAD001 reveal a significant reduction in ER score (histoscore pre 230, post 15), no
change in PR, increase in cytoplasmic p-Akt (pre 40, post 122.5), increase in nuclear
p-Akt (pre 0, post 30), no reduction in p-S6 (s240/244 pre 115, post 90; s235/236 pre
75, post 95) and no change in p-mTOR (pre 120, post 112.5). The above combination
of results would represent a tumour that has not had inhibition ofmTOR and that
rather than just maintain its rate of proliferation has dramatically increased its rate of
proliferation. This patient was not noted to have clinical evidence of an inflammatory
cancer but the findings of a significant increase in proliferation in this particular
tumour is concerning as it raises the possibility that there are tumour types that are
resistant to mTOR inhibition, inflammatory tumours in particular. This was the only
tumour noted to have such a lack of response to RAD001. This tumour was HER-2
negative, and it has previously been found with a different mTOR inhibitor, CCI-
779, in metastatic breast cancer that there were no responses seen in HER-2 negative
tumours. 184 In this RAD001 study, there appeared to be a greater response in HER-2
positive tumours (87.5% of HER-2 positive tumours were responders by Ki67%)
than in HER-2 negative tumours (47.8% responders), although responses were seen
in both HER-2 positive and negative tumours, in comparison to the findings with
CCI-779.
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In this RAD001 study those tumours with a high proliferation rate before treatment
were also found to have high levels of cytoplasmic phospho-Akt before treatment.
This would support previous findings that poor prognosis or resistant cancers tend to
have higher proliferation rates, and both greater expression of p-Akt and activity of
mTOR. 147 The above results reinforce previous findings from studies in ovarian
cancer in which RADOO1 reduced proliferation in mice with advanced malignancy
and in combination with cisplatin there was enhanced inhibition of proliferation
particularly in those with high p-Akt and mTOR signalling pre-treatment. 17 ' 04
High pre-treatment levels of Ki67 significantly influenced the change in Ki67 with
treatment, but no other variables were found to predict strongly for response to
treatment with RADOO 1 as assessed by reduction in proliferation. All tumours had a
reduction in S6 phosphorylation independent of levels of proliferation. The
correlation between high proliferation pre-treatment and change in cytoplasmic p-
Akt did not reach significance but there was a significant difference in tumours that
responded to RADOO 1 (as assessed by Ki67) with a reduction in cytoplasmic p-Akt
compared with those that did not have response to RADOO 1.
Previous studies assessing levels of the downstream activity of RADOO 1 on the
mTOR pathway have most commonly used phospho-p70S6 kinase (either one of two
isoforms) antibodies as an outcome measure. It has since been shown that the most
commonly used commercially available antibody for p-p70S6kinase is not phospho-
specific to allow accurate immunohistochemistry assessments, thus making previous
results difficult to interpret. For this study it was decided to assess the cytoplasmic
levels of the ribosomal protein S6 (S6) that is phosphorylated by the p70S6kinase,
which was considered to directly reflect the level of activity. At both sites of
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phosphorylation there was a clear reduction in phosphorylation of S6, this being
more marked at sites 240/244, indicating reduction of activity of the downstream
effects of mTOR with treatment with RAD001. The extent of reduction at either site
did not correlate with either the reduction in Ki67 or with the changes in p-Akt nor p-
mTOR.
While there was no significant change in phosphorylation ofmTOR (s2448) overall,
there was some evidence to suggest that those tumours that had a high Ki67 pre-
treatment were more likely to have an decrease in p-mTOR after RAD001 treatment.
There is debate from published data as to the mechanisms behind phosphorylation of
mTOR at ser2448, but the most recent data would suggest that ser2448 is
predominantly a site for mTORCl and ser 2481 for TORC2, with p-S6 functioning
as the kinase for ser2448. 167 In this case one would expect some correlation between
S6 activity and mTOR activity but no such relationship could be identified from this
data. It appears to be tumours that are highly proliferative that have the greatest
reductions in proliferation, rise in apoptosis and reduction in p-mTOR, implying that
these are the tumours that will best respond to RAD001.
There was a significant reduction in ER scores with RAD001 treatment, with a
significantly greater fall in ER in those tumours that were lower in ER pre-treatment.
This downregulation in ER-poor tumours may be of biological significance in the
study of endocrine resistance. As discussed earlier, current understanding of
resistance to endocrine therapy is of a cross-talk between signal transduction
pathways such as mTOR and an ER signalling shift between nuclear and peri-nuclear
activity. 119'144'205"207 Further discussion of the role ofmTOR inhibitors in
combination with endocrine agents and results from clinical trials will follow. The
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concern regarding the reduction in ER is highlighted by results from the IMPACT
study that had low ER scores after 2 weeks was predictive of poorer recurrence-free
survival at median 37 months follow-up (HR 0.78; 95%CI 0.62, 0.99; p=0.04), but
these results were for absolute ER value at 2 weeks rather than a reduction from
baseline, and may therefore be indicative of the known intrinsic value ofER for
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response to aromatase inhibitors rather than the effect of reducing ER. No such
predictive value was seen in the Edinburgh study of neoadjuvant letrozole for ER and
pathological or clinical response, with no significant change in ER seen with
treatment. 118 What is not clear is the mechanism by which RAD001 reduces ER
expression, and there is thus a possibility that the reduction in ER expression may
render tumours less sensitive to the effects of aromatase inhibition.
Current understanding of the mTOR pathway and the two distinct complexes formed
by mTOR with raptor (mTORCl) and rictor (mTORC2) has been based upon work
with rapamycin, hence the naming of raptor (rapamycin associated companion to
mTOR) and rictor (rapamycin insensitive companion to mTOR). One of the aims of
this study was to determine the action of RAD001 upon mTOR and whether rictor is
indeed insensitive to rapamycin-like mTOR inhibitors in vivo. The result that would
be anticipated from understanding of the current literature is that if one is inhibiting
mTOR raptor only one would expect downregulation of mTOR, p-S6 and
upregulation ofAkt by negative feedback. The negative associations of upregulation
of Akt include resistance to apoptosis, increased cell growth and proliferation,
increased resistance to endocrine treatment and increased risk of metastasis and
reduced survival. I46'l47'l75'176 If however, an mTOR inhibitor inhibits both mTOR
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raptor and mTOR rictor then one would expect downregulation of mTOR and p-S6k,
and also downregulation of p-Akt.
In this study it was found that in all tumours there was a significant reduction in
nuclear p-Akt after treatment with RADOO1, indicating that both raptor and rictor
complexes ofmTOR are inhibited. Similarly, tumours with high cytoplasmic p-Akt
pre-treatment had a reduction in p-Akt in the cytoplasm after treatment with
RADOO 1. However, tumours with a low p-Akt cytoplasmic score treated with
RADOO 1 had no change or an increase in p-Akt cytoplasmic score with RADOO 1
treatment, indicating that tumours without high p-Akt may respond less well to
RADOO 1. In those tumours that responded to RADOO 1 with a reduction in Ki67 there
was a significant decrease in cytoplasmic p-Akt with treatment, indicating that in
tumours where RADOO 1 is effective at inhibiting the mTOR pathway, both
complexes ofmTOR are inhibited.
These results are in keeping with a recent study of RADOO 1 and CCI-779 in acute
myeloid leukaemia (AML), in which blood samples from patients treated with CCI-
779 demonstrated reduction in mTORCl and mTORC2 activity, and levels of p-Akt
(ser 473) were reduced with both CCI-779 and RADOO 1. 208
It was disappointing to be unable to ascertain the PTEN status of these tumours due
to problems with the immunohistochemical staining methodology. This information
would have allowed further interpretation of the influences acting upon the mTOR
pathway. PTEN acts as a brake upon the activity ofAkt and thus mTOR and the
hypothesis is that patients who have PTEN deficient tumours are more likely to
belong to the group who had higher Akt, mTOR and Ki67, and thus be more
responsive to the activity of an mTOR inhibitor. One study assessed the
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antiproliferative activity of RAD001 in tumour cell lines with varying expression of
PTEN and found that while there was a trend towards increased sensitivity to
RAD001 in PTEN null glioblastoma cell lines compared with PTEN expressing cell
lines, no such trend was observed in breast or prostate cell lines.209 In the same study
however, there was evidence to suggest an association between higher p-Akt levels
and the antiproliferative response to RAD001, as found herein.
Further work has been carried out on the paraffin sections available from this study
to characterise the upstream influences of the PTEN pathway upon tumour response
to RAD001. 210 The aim was to assess the PI3KCA mutational status, as described in
a significant proportion of breast cancers. DNA was extracted from the post-
treatment paraffin-embedded tissues and analysed for the 3 most commonly
occurring PIK3CA mutations (H1047R, E542K, E545K) using a multiplex QPCR
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assay using methods previously described. Eight of 31 (25.8%) samples were
found to contain PI3KCA mutations: 5 - E545K; 2 - H1047R; 1 - E542K. Although
cytoplasmic p-Akt scores were higher in pre-treatment tumours containing P13KCA
mutations than in those without mutations (median histoscores - 113.8 and 70,
respectively), the difference was not statistically significant. Five mutations were
found in tumours from 25 patients who completed treatment of which 15 patients
were classified as responders to RAD001 and 10 patients as non-responders
(responders were defined by a fall in % Ki-67 positive cells). 2/15 (13%) responders
and 3/10 (30%) non-responders exhibited PI3KCA mutations. However, no





The aim of this transcriptional profiling study was to characterise the effects of pre¬
operative RAD001 treatment in primary breast cancer, and to determine whether
these effects correlated with those found in the immunohistochemical analysis of
fixed tumour samples from the same patient tumours, and if there is a potential
molecular profile of tumours that respond to RAD001.
Methods
During the clinical phase of this study, fresh frozen tumour biopsies before and after
RAD001 treatment were collected and stored in liquid nitrogen. The results
discussed below have been presented at the San Antonio Breast Cancer Symposium.
212 Frozen sections were removed, sectioned and stained with haematoxylin and
eosin to assess tumour content. Approximately 1 OOmg tissue from pre- and post-
treatment biopsies from 27 patients who completed RAD001 treatment were placed
in RNAlater® ICE (Ambion, Warrington, United Kingdom) overnight at -20°C prior
to RNA extraction.
RNA was extracted using the RNeasy Mini Kit, including RNase-Free DNase
treatment (Qiagen), amplified using Illumina® TotalPrep RNA Amplification Kit
(Ambion), and analysed in duplicate using Illumina Human Ref.8 chip v2. Stratagene
Universal Reference RNA (UHRR) was added to each chip to enable inter-run
variation to be assessed. Gene expression changes were compared before and after
RAD001 treatment between the responders and non-responders using Bioconductor
programmes 213 implemented in the R statistical programming language. 214 Illumina
probe profile expression data were normalised by quartile normalisation within the
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beadarray package 215 and corrected for batch processing effects using the combat
tool.216 Differentially expressed genes and false discovery rate (FDR) were
determined using 'Significance Analysis ofMicroarrays' (SAM) implemented within
the siggenes package. 217 An alternative approach used to look at the effect of
RAD001 was to compare the relative change in gene expression of each probe
calculated between the duplicate pre- and post-treatment samples and find the mean
of the four values. Centred average linkage clustering was performed using the
Cluster218 and TreeView programs. 219
RNA was available from 21 matched biopsies and 23 pre-treatment samples. Patients
were classified as responders to RAD001 by a significant (95% CI) fall in %Ki67 as
discussed previously (n=13 matched; n=14 pre-treatment), or by a significant (95%
CI) fall in cytoplasmic p-Akt positive cells (n=7 matched; n=7 pre-treatment). The
remaining patients were considered as non-responders.
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Results
Effect of RAD001 treatment on gene expression
Duplicate samples were highly consistent although subtle variations were noted.
Viewing the differences in the overall transcriptome before and after RAD001
treatment using multidimensional scaling, the responders tend to group together
suggesting a difference between responders and non-responders. Figure 46
The majority of the post-treatment paired samples (n=21) are to the right of the pre-
treatment samples suggesting some consistency in the response to RADOO1. Of the
top 500 most significantly changed probes following treatment in each set of
replicates, there were 220 probes in common (intersect of top 500, false discovery
rate (FDR) 15%, Figure 47). Of the 13 responders with significant reductions in
proliferation, there were 203 genes which demonstrated a consistent change (FDR
14%), with those genes representing cell cycle (e.g. CDK2, CDC2) significantly
changed with RADOO 1 treatment. In the non-responders, there was a lack of
consistency in change in gene expression (FDR 71%). Similarly, when grouped for
response according to p-Akt change (n=7), there was a consistent change in gene
expression of 121 genes in responders (FDR 17%), but a lack of consistent change in
non-responders (FDR 57%). The functional (KEGG) pathways determined to be
most associated with RADOO 1 treatment when all tumours were analysed together
were the complement and coagulation cascades (p = 0.002; predicted FDR = 1.99),
demonstrating the impact ofmTOR inhibition on the cell cycle and also upon the
immune system. RADOO 1 is currently licensed for use in transplant
immunosuppression. This is also in agreement with the clinical study findings of




Differences in overall transciptome before and after RAD001 showing
consistency of duplicates, and post-treatment samples generally to the right of
the pre-treatment (response defined by Ki67%). Numbers represent sample
number.
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Common differentially expressed genes following RAD001 treatment (intersect
of top 500) in all responding and non-responding tumours (by Ki67%). (FDR =
false discovery rate).
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Effect of RAD001 treatment on mTOR pathway, proliferative genes and
oestrogen dependent gene expression
Many cell cycle genes eg. CDK2 (cyclin-dependent kinase 2) and CDC2 (cell
division cycle 2, G1 to S and G2 to M) were significantly differentially expressed
following RAD001 treatment. Figure 48 CDC2, expression of which appears to be
down-regulated in the responding tumours, has also been reported to be decreased in
220 221B-cell lymphoma cell lines and pancreatic cells after rapamycin treatment.
There was a significant reduction in expression of proliferative genes after RAD001
treatment in those that had responded to RAD001, which may in part be explained by
the definition of response based upon reduction in proliferation, but as with the
immunohistochemical (IHC) finding, there was greater reduction in proliferation
genes in those that were highly proliferative pre-treatment. There was a significant





Change in expression of CDK2 (above) and CDC2 (below) with RAD001
treatment, for responders (red) and non-responders (blue). For both CDK2 and
CDC2 there is a reduction in expression in the responders.
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Of those genes related to oestrogen dependence, two genes were also found to be
down-regulated after RAD001 treatment: KIAA0101 in matched samples for those
that responded to RAD001 by Ki67 and SERPINA3 in those that responded defined
by p-Akt.
Genes involving the mTOR pathway such as mTOR and BAD were not changed
following RAD001 treatment. There was a significant fall in expression ofGSK3B in
all tumours with RAD001 treatment (p=0.003), but no difference between responders
and non-responders. With transcriptional profiling there was a trend toward higher
expression ofmTOR in responders than in non-responders after treatment with
RAD001 (p=O.01). In the immunohistochemical RAD001 study there was a trend
toward those tumours that were highly proliferative pre-treatment having a greater
decrease in p-mTOR. This discordance may reflect different forms of mTOR, in that
the immunohistochemical findings reflect the actions ofmTORCl at ser2448, with
p-S6 functioning as the kinase for ser2448, 167 and the expression of mTOR may
represent mTOR dissociated from either mTORCl or mTORC2.
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Pre-treatment gene expression predicting for response
To determine whether there was a gene expression profile that predicts for response
to RAD001, pre-treatment gene expression of responders (by %Ki67; n=14) and non-
responders (n=9) was compared. No significant difference between the common
differentially expressed genes (intersect of top 500 genes) was found (FDR 50%).
Clustering of 248 significantly differentially expressed genes showed responders
clustered into 2 groups, one group with high expression of proliferative genes by
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both %Ki67 and genomic grade index (GG1), and the other group of responders
less distinct. Figure 49 These results may be attributable to the definition of response
versus non-response calculated upon reduction in %Ki67 as an absolute rather than
relative value, but allow correlation of the immunohistochemical and transcriptional
profiling finding that those with higher pre-treatment proliferation were more likely
to respond to RAD001. Using a 52-gene consensus prognostic classifier for ER-
positive tumours, these highly proliferative tumours would be predicted to have a
poor prognosis. 223
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Response R v NR
52 gene consensus ER+ profile
Extremely poor outcome cell proliferation signature
Subtype I receptor status
GO terms; intracellular transport, protein amino acid
dephosphorylation, biopolymer modification,
peroxisome organization and biogenesis, protein
modification process, dephosphorylation
Genes; DUSP15, DYNLRB2, ERBB4, FNTB, IP04,
ITCH, NBEA, PARP8, PEX1, PEX11G, POFUT1,
PRMT5, PTPN13, RABGEF1, RPGR, ULK2, DUSP16
GO terms; cellular carbohydrate metabolic process,
protein kinase cascade, cell cycle, apoptosis, cell
proliferation, cell death
Genes; ADRA1A, BIRC2, BIRC3, BTG3, CD79A,
CDC20, CDC34, CDC45L, CDKN3, CXCR4, DOK4,
DUSP22, ERN1, GAL, GALK2, GMDS, HK3, IDH3G,
LAMP3, MAPK1, MAPRE2, MCM5, ME2, MT3, PGD,
PIM2, PYGB, SEMA4D, SLC12A6, SLC35A2, SOD2,
STEAP3, SUFU, TNFSF14, TRADD, TRAF3IP2,
TXNL4B, TXNRD1, CDCA8, IFNAR1, ISG20, PHKB
Figure 49
Hierarchical clustering of 248 significantly differentially expressed probes by responders and
non-responders (by %Ki67). Grey and black bars signify which tumours have a good and bad
prognosis based upon the 52-gene consensus classifier for ER-positive tumours 223 and the
extremely poor outcome proliferation signature. 224 Light blue and purple bars signify which
tumours were PR- and HER-2+ respectively. Probes highlighted in red were amongst the 238
differentially expressed probes identified between responding and non responding patients by a
significant reduction in phospho-Akt. The heatmap represents differential expression of genes
(fold changes) in rows and patients in columns. Red is high expression and green is low
expression on a relative (mean-centred) scale.
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There were differences in expression of specific mTOR pathway genes between
responders and non-responders. Expression of BAD was higher in non-responders
than in responders both pre (p=0.05) and post (p=0.003) treatment with RAD001,
and pre-treatment expression of TSC2 was higher in non-responders than responders
(p=0.02). Figures 50 and 51 These findings are suggestive of a gene expression
profile of high expression ofBAD and TSC2 predictive of a lack of response to






Differential expression of BAD with RAD001 treatment in responders (red) and





Differential expression of TSC2 in responders (red) and non-responders (blue)




The findings of homogeneity within the group of responders compared with a
heterogenous group of non-responders are comparable with results from gene
99S
expression profiling of letrozole treated tumours from an Edinburgh series. In this
study it was found that those tumours that had a clinical response to treatment with
letrozole had at 14 days a similar genetic profile as a group that was dissimilar to
non-responding cancers, and that the non-responding cancers were distinctive from
each other.
It has previously been shown that a particular subpopulation of breast cancer patient
groups can be identified by a "proliferation signature" that has an extremely poor
outcome. 224 However, our study suggests that highly proliferating tumours with poor
prognosis are amongst those that respond to RAD001, at least in the short term, with
reductions in expression of oestrogen regulated genes and cell cycle genes.
In the above mentioned letrozole study, genes identified to have been down-
regulated with letrozole treatment could be categorised as those related to oestrogen
99 f,
dependence or proliferation, with tumours grouped into those in which both
oestrogen-dependent and proliferation genes were decreased, those in which markers
were changed only marginally and those in which oestrogen-dependent genes were
decreased but proliferation genes were increased, in keeping with the action of
letrozole as a specific aromatase inhibitor to induce oestrogen deprivation. Similarly,
in a study of gene expression after 14 days treatment with anastrozole or letrozole,




The findings of down-regulation of oestrogen dependence with RAD001 are
particularly interesting given the IHC finding of a significant reduction in ER after 2
weeks treatment with RAD001. Similar findings have been reported from a study of
gene expression correlated to response to combination doxorubicin/
cyclophosphamide (discussed below) in which oestrogen-regulated genes (ESR1,
IRS1) were over-expressed in sensitive tumours compared with resistant tumours
before treatment. 228 In the chemotherapy study, about half the patients were
premenopausal, and some patients had recently stopped hormone replacement
therapy, which may compound these findings.
In the previously mentioned study of gene expression after letrozole treatment no
single gene changed consistently with treatment in all 58 cases, and using the
225criterion of change in at least 50 cases, only 7 genes were identified. This was felt
to be in keeping with the known heterogeneity of breast cancer. By employing the
SAM analysis as employed in the RAD001 study, and considering the incidence and
degree of change, 58 genes were down-regulated and 6 up-regulated after letrozole
treatment. Analysis of the letrozole treated tumours failed to discriminate totally
between responding and non-responding patients, other than to note that responding
tumours displayed a high degree of similarity as a group, in comparison to non-
responding tumours.
Previous studies ofmicroarray expression analysis of pre-treatment biopsies have
had positive findings for predicting response to treatment with combination
228 229doxorubicin/ cyclophosphamide treatment, and for docetaxel therapy. In the
docetaxel study, pre-treatment samples from 24 patients were correlated with clinical
response after 4 cycles, and it was found that, in general, resistant tumours
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overexpressed genes associated with protein translation, cell cycle, and RNA
transcription functions, whereas sensitive tumours overexpressed genes involved in
stressor apoptosis, cytoskeleton, adhesion, protein transport, signal transduction, and
RNA splicing or transport, and apoptosis, similar to our findings with RAD001.
In the 40 patients undergoing combination doxorubicin/ cyclophosphamide gene
expression from pre-treatment biopsies were analysed and correlated with response
99R
after 6 cycles of treatment. Two hundred fifty three differentially expressed genes
were identified, with a 1.5-8.0-fold decreased or 1.5—4.2-fold increased expression in
resistant versus sensitive tumours. Of the 75 genes overexpressed in resistant
tumours, major categories were transcription (GTF3C1, ILF3), differentiation (ST14,
CTNNBIP1), signal transduction (EIF1AX, EIF4EBP1), amino acid metabolism
(SRM, PLOD1, PLOD3), and genes of unknown function. Of the 178 gene
overexpressed in sensitive tumours major categories were cell cycle (BUB3,
CDKN1B), survival (BCL2, BAG1, BIRC1, STK39, WEE1), stress response
(CYP2B6, MAPK14), and oestrogen-regulated genes (ESR1, IRS 1). In general, the
AC-sensitive tumours had increase in expression of genes involved in metabolism,
stress response, survival, and cell cycle relative to tumours resistant to therapy.
For both studies it was recommended that larger validation studies are necessary to
define unique expression patterns for different therapeutic agents. From a pilot
retrospective study in tamoxifen treated patients, a 44-gene expression signature was
found to better predict anti-oestrogen therapy resistance than ER, the currently used
clinical factor used to predict response (77% predictive value versus 50-60% for ER).
9TO
These findings promise regimen-specific gene expression-based predictors for
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The aim of the cell line study was to investigate the effect of RAD001 on breast
cancer cell lines with varying expression of phospho-Akt. From the
immunohistochemical analyses described above it was apparent that nuclear p-Akt
was significantly reduced by RADOO1 treatment, and there was a significant
difference between cytoplasmic phosphorylation of Akt after RADOO 1 in responders
and non-responders. Current understanding of the action ofRADOO 1 and thus
understanding of the mTOR pathway is that the two mTOR complexes act in
different ways upon Akt, but there is newer evidence to suggest that both mTORCl
and mTORC2 are sensitive to mTOR inhibition rather than mTORC2 being
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insensitive, and that this is influenced by treatment duration. By determining the
effect ofRADOO 1 in cells expressing different levels of activity of p-Akt due to
stimulation with heregulin, it was anticipated that it could be determined if both
complexes ofmTOR are inhibited by RADOO 1 with both short and long term
treatment.
Materials and methods
Three breast cancer cell lines were selected for ER and PTEN methylation pairing
from the cell line bank of JMSB group: MDA-MB-453, MDA-MB-361, MCF-7.
Cells were cultured in DMEM (Invitrogen) with 10% foetal calf serum, 50p/ml
penicillin, 50pg/ml streptomycin and 0.29mg/ml L-Glutamine. Prior to introduction
of drug to cells, flasks were incubated for 24 hours in serum-free media with 50p/ml
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penicillin, 50pg/ml streptomycin and 0.29mg/ml L-Glutamine. All experiments were
conducted in duplicate under sterile conditions.
In order to determine the optimum concentration ofRAD001 for use in the time
point experiment IC50s were obtained for each cell line using the following method.
Once cells had reached 50-60% confluence they were incubated overnight in serum-
free media as described above in T-25 flasks. After washing in PBS (Invitrogen),
cells were incubated with RAD001 at four different concentrations with heregulin
(HRG) lOnmol/L, DMSO and serum-free media for 15 minutes. Controls for DMSO
and DMSO-free and for heregulin were also used as shown below.
2x DMSO-free control
2x DMSO control
2xl0nmol/l HRG DMSO control
2xl0nmol/l HRG DMSO + 1 nmol RAD
2xl0nmol/l HRG DMSO + 3 nmol RAD
2xl0nmol/l HRG DMSO + 10 nmol RAD
2xl0nmol/l HRG DMSO+ 30 nmol RAD J
> for each cell line
Cells were then washed with cold PBS, 500pl lysis buffer added and cells scraped
and transferred to eppendorfs and stored on ice. After centrifugation for 10 minutes
at 10,000 rpm at 4°C, the supernatant was transferred to a fresh eppendorf and stored
at -80°C. To quantify the protein extraction, a Bradford Protein Assay was performed
using a Biorad SmartSpec Plus Spectrophotometer, and concentrations for each
sample obtained.
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In order to determine the level of downregulation of the mTOR pathway by
RAD001, Luminex assays were performed for each cell line for p-S6 (ser 235/236)
by the following method. Lysates were diluted to a concentration of 600pg/ml using
the quantification given in the Bradford Protein Asssay with lysis buffer, and further
diluted to 300jug/ml with assay buffer. The lysates were incubated with p-S6
(s235/236) beads in a 96-well plate overnight on a microplate shaker. The lysates
were then incubated with detection antibody for 30 mins, followed by streptavidin
for 10 mins. After washing with resuspension buffer, quantification was performed
by the Biorad Bio-Plex to provide p-S6 concentrations.
In order to determine the effects of RAD001 at its optimum concentration in each
cell line with varying levels ofAkt activation, the IC50 for RAD001 calculated as
above was used for the following experiments. All experiments were conducted in
duplicate under sterile conditions. Cells were cultured in DMEM (Invitrogen) with
10% foetal calf serum, 50p/ml penicillin, 50pg/ml streptomycin and 0.29mg/ml L-
Glutamine. Once cells had reached 50-60% confluence they were incubated for 24
hours in serum-free media with 50p/ml penicillin, 50pg/ml streptomycin and
0.29mg/ml L-Glutamine.
After washing in PBS (Invitrogen), cells were incubated with either RAD001 at IC50
or heregulin at 1 or 10nmol/l or both as shown below for 15, 30, 60 minutes and 24
hours. Controls for DMSO and DMSO-free media were used. Cells incubated with
RAD001 for the required time point, then washed with warm PBS before treatment
with heregulin at the required concentration for 15 minutes. Those that were treated
with heregulin were incubated initially in DMSO media for the same time period as




2x DMSO + IC50 for RAD + lnmol/1 HRG
2x DMSO + IC50 for RAD + 10nmol/l HRG
2x DMSO + IC50 for RAD
2x DMSO + lnmol/1 HRG
2x DMSO + 10nmol/l HRG
>
for each cell line
for each time point
J
Cells were then washed with cold PBS, 500pl lysis buffer added and cells scraped
and transferred to eppendorfs and stored on ice. After centrifugation for 10 minutes
at 10,000 rpm at 4°C, the supernatant was transferred to a fresh eppendorf and stored
at-80°C.
To quantify the protein extraction, a Bradford Protein Assay was performed using a
Biorad SmartSpec Plus Spectrophotometer, and concentrations for each sample
obtained.
In order to determine the downstream effects of RAD001 on the mTOR pathway in
the presence and absence of heregulin stimulation, levels ofp70 S6kinase were
assessed using western blot analysis using the protocol described below. To
determine the effects RAD001 upon p-Akt in the presence and absence of heregulin
stimulation, p-Akt (ser 473) was assessed. To allow normalisation to the test primary
antibody and to control for protein loading reprobing with actin was performed.
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Western blotting method for p-Akt and actin
The protein lysates were thawed and diluted with lysis buffer and gel loading buffer
added. The samples were then heated to 100°C (hot block) for 5 minutes, returned to
ice to cool and spun. The gels were then loaded and run for one hour. The PDVF
Immobilon P Millipore membrane was prepared for transfer in methanol, dH20 then
transfer buffer. Gels were transferred overnight at 30 volts in the cold room.
Membranes were removed and blocked using 5% milk in TBS for one hour at room
temperature. Incubation with primary p-Akt antibody (1:10,000 in 5%milk) was
performed overnight at 4°C on a rocking platform. Membranes were then blocked
using 0.5% blocking agent in TBS for 2x5 mins after washing, followed by
incubation with secondary antibody (biotin 1:2000 in 5% milk) for 1 hour at room
temperature on a rocking platform. Membranes were then incubated with activated
luminal substrate for 1 minute then transferred to developer cassette. The membranes
were exposed several times for different periods until optimal exposure achieved.
Membranes were then reprobed with actin by re-blocking in 5% milk in TBS then
adding the actin primary antibody (1:200,000 in 5% milk in TBS) and incubating
overnight at 4°C. Membranes were then washed and incubated in 5% milk in TBS
2x5mins, then incubated in actin secondary antibody (1:20,000 in 5%milk in TBS)
for 1 hour at room temperature. After washing, membranes were incubated with
luminol and developed as above.
Western blotting method for p70S6k
Gels were loaded and run, then transferred to membrane as described above.
Membranes were removed and blocked using 5% milk in TBS for one hour at room
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temperature. Incubation with primary p70S6k antibody (1:500 in 5%milk) was
performed overnight at 4°C on a rocking platform. Membranes were then blocked
using 0.5% blocking agent in TBS for 5 mins x2 after washing. Incubation with
secondary antibody (biotin 1:2000 in 5% milk) was performed for 1 hour at room
temperature on a rocking platform. Membranes were incubated with activated
luminal substrate for 1 minute then transferred to developer cassette. The membranes
were exposed several times for different periods until optimal exposure achieved.
To quantify the western blot results, a public domain Java image processing program
(Image J) was used. 232'233
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Results
After completing initial studies with MDA-MB-361 cells to obtain an IC50 for
RAD001 in this cell line, it was discovered that there was contamination of this cell
line and it was not possible to use the data for further analysis. Due to time
constraints and lack of a suitable stocked cell line that would pair for ER and PTEN
status, it was decided to proceed with the two cell lines MCF-7 and MDA-MB-453.
For each concentration analysed for both cell lines there were four wells consisting
of two sets of duplicates of cells incubated with RAD001 and further duplication for
the Luminex assay. A mean ratio compared to the standards used (Hela non-
stimulated and PC 12 stimulated cells) was calculated for each concentration
analysed. The results were calculated using the heregulin control as standard, and the
end point of phospho-S6 (ser 235/236) assessed using the Luminex method described
above. The mean ratios for reduction in phospho-S6 are shown below. Figure 52
The optimum concentration was calculated as being the concentration of RAD001 at
which the p-S6 ratio was 50% of that of the heregulin control for each cell line. For
ease of calculations of volumes for the next part of the study, these figures were
rounded to 1.5nM for MCF-7 and lOnM for MDA-MB-453. This calculated
concentration was then used for the following experiment looking at the effect of
RAD001 treatment over time.
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pS6 (s 235/236) after RAD001
♦— MCF7 ■ MDA-MB-453
1.2
0
0 5 10 15 20 25 30
RAD001 nM
Figure 52
Results of experiment to determine IC50 for MCF7 and MDA-MB-453 cell lines
treated with RAD001 at varying concentrations for reduction in p-S6 s235/236
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Results are presented first for p70S6kinase for each cell line (MCF7 and MDA-MB-
453) at the four time points evaluated (15, 30, 60 mins and 24 hours), then as above
for p-Akt. All experiments were run in duplicate, thus results are for MCF7 2a and
2b, MDA-MB-453 2a and 2b etc for each time point. Two isoforms were detected for
p70S6kinase (at 70kDa and 80kDa). Despite repeat experiments, the Western blots
run for the MDA-MB-453 2a for p70S6kinase yielded no bands. The problem was
identified as being during the incubation with p70S6k during the Western blot
process rather than at the time of treatment of cells with RAD001, as reasonable
results were obtained from the Western blots for MDA-MB-453 2a for p-Akt. There
are therefore no results available as a duplicate for the p70S6k in the cell line MDA-
MB-453 treated with RAD001. All blots were quantified as described above using
Image J system to produce the results presented in graphs below.
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Effect of RAD001 on p70S6kinase
MCF7 cell line
MCF-7 p70S6k - 15min (A)
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Western blots and Image J quantification for MCF-7 p70S6k treated for 15min
in duplicate (Expt A & B) with quantification normalised to actin,
demonstrating marked inhibition of p70S6kinase with RAD001 alone, but with
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Figure 54 (B)
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Figure 54
Western blots and Image J quantification for MCF-7 p70S6k treated for 30min
in duplicate (Expt A & B) with quantification normalised to actin,
demonstrating marked inhibition of p70S6kinase with RAD001 alone, and in
one (Expt B) RAD001 inhibition less marked in the presence of heregulin, and
in Expt A RAD001 inhibition even in the presence of heregulin.
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Figure 55 (A)
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70kDa
Figure 55
Western blots and Image J quantification for MCF-7 p70S6k treated for 60mins
in duplicate (Expt A & B) with quantification normalised to actin,
demonstrating marked inhibition of p70S6kinase with RAD001 alone, but not in
the presence of heregulin.
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Figure 56
Western blots and Image J quantification for MCF-7 p70S6k treated for 24
hours in duplicate (Expt A & B) with quantification normalised to actin,
demonstrating marked inhibition of p70S6kinase with RAD001 alone, but not in























































15min 30min 60min 24hr
Figure 57
Effect over time of treatment with RAD001 on p70S6k in cell line MCF-7 for
duplicate experiments (A & B). In (A) there is inhibition of p70S6k over the 24
hour period with RAD001 alone. In the presence of heregulin, RAD001 initially
inhibits p70S6k, but there is evidence of some loss of inhibition of p70S6k at 24
hours. In (B), RAD001 alone inhibits p70S6k up to 24 hours, but not in the
presence of heregulin up to 24 hours.
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MDA-MB-453 cell line
It was not possible to obtain any quantifiable data from Western blots for MDA-MB-
453 for p70S6k at any of the time points examined for the first of the experiments
performed in duplicate. Results shown are for the second run performed as part of the
duplication process (Expt B).
MDA-MB-453 p70S6k - 15min (B)
> S> cP ^ ^ -O .O & O
G° G° <? A OA / / / /N ^ * '///V1 ' « ////^ A % V V' O
Figure 58
Western blots and Image J quantification for MDA-MB-453 p70S6k treated for
15min (Expt B) with quantification normalised to actin, demonstrating marked




MDA-MB-453 p70S6k - 30min (B)
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Figure 59
Western blots and Image J quantification for MDA-MB-453 p70S6k treated for
30mins (Expt B) with quantification normalised to actin, demonstrating marked
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Figure 60
Western blots and Image J quantification for MDA-MB-453 p70S6k treated for
60mins (Expt B) with quantification normalised to actin, demonstrating some
inhibition of p70S6kinase with RAD001 alone compared with heregulin alone,
but less marked inhibition for RAD001 in the presence of heregulin.
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Figure 61
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Figure 61
Western blots and Image J quantification for MDA-MB-453 p70S6k treated for
24 hours (Expt B) with quantification normalised to actin, demonstrating some
inhibition of p70S6kinase with RAD001 alone compared with heregulin alone,










15min 30min 60min 24hr
Figure 62
Effect over time of treatment with RAD001 on p70S6k in cell line MDa-MD-453
for experiments B. There is inhibition of p70S6k over the 24 hour period with
RAD001 alone, and for RAD001 in the presence of heregulin compared with
those treated with heregulin alone.
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Effect ofRAD001 on p-Akt
MCF7 cell line
Figure 63 (A)
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MCF-7 pAkt - 15min (A)
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Figure 63 (B)
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Figure 63
Western blots and Image J quantification for MCF-7 for p-Akt treated for
15min in duplicate (Expt A & B) with quantification normalised to actin,
demonstrating marked inhibition of p-Akt with RAD001 alone, but not in the
presence of heregulin in duplicate experiments.
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Figure 64 (A)
MCF-7 pAkt - 30min (A)
60
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Figure 64 (B) For purposes of analysis the first line (p-Akt) of the top strip and the
second line (actin) of the bottom strip were used.




Western blots and Image J quantification for MCF-7 for p-Akt treated for 30
mins in duplicate (Expt A & B) with quantification normalised to actin,
demonstrating marked inhibition of p-Akt with RAD001 alone, but not in the
presence of heregulin in duplicate experiments.
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Figure 65 (A)
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Figure 65 (B) For purposes of analysis the second line (actin) of the top strip and the
first line (p-Akt) of the bottom strip were used
1 2 3 4 5 6 7 8 9 10 11 12 13 14
MCF-7 pAkt - 60 min (B)
800
Figure 65
Western blots and Image J quantification for MCF-7 for p-Akt treated for 60
mins in duplicate (Expt A & B) with quantification normalised to actin,
demonstrating marked inhibition of p-Akt with RAD001 alone, but not in the




Figure 66 (B) For purposes of analysis the second line (actin) of the top strip and the
first line (p-Akt) of the bottom strip were used.
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Figure 66
Western blots and Image J quantification for MCF-7 for p-Akt treated for 24
hours in duplicate (Expt A & B) with quantification normalised to actin,
demonstrating marked inhibition of p-Akt with RAD001 alone, but not in the































Effect over time of treatment with RAD001 on p-Akt in cell line MCF-7 for
duplicate experiments A & B. There is stimulation of p-Akt with heregulin, and
inhibition of p-Akt throughout the 24 hour period with RAD001 alone, but not
for RAD001 in the presence of heregulin.
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MDA-MB-453 cell line
Figure 68 (A) For the purposes of analysis the first line (p-Akt) of the top strip and
the second line (actin) of the bottom strip were used.
1 2 3 4 5 6 7 8 9 10 11 12 13 14
p-Akt
actin




Figure 68 (B) For purposes of analysis the first line (p-Akt) of the top strip and the
second line (actin) of the bottom strip were used.
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Western blots and Image J quantification for MDA-MB-453 for p-Akt treated
for 15 mins in duplicate (Expt A & B) with quantification normalised to actin,
demonstrating some inhibition of p-Akt with RAD001 alone, but not in the
presence of heregulin in duplicate experiments.
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Figure 69(A) For purposes of analysis the second line (actin) of the top strip and the
first line (p-Akt) of the bottom strip were used.
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MDA-MB-453 pAkt - 30min (A)
/ / p j1 j? j'J'J-•
y y yy y yy v ^ ^y y * *V>VV .<9 to %V-
219
Figure 69 (B)
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Figure 69
Western blots and Image J quantification for MDA-MB-453 for p-Akt treated
for 30 mins in duplicate (Expt A & B) with quantification normalised to actin,
demonstrating marked inhibition of p-Akt with RAD001 alone, but not in the
presence of heregulin in duplicate experiments.
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Figure 70(A) For the purposes of analysis the second line (actin) of the top strip and
the first line (p-Akt) of the bottom strip were used.
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MDA-MB-453 pAkt - 60min (B)
Figure 70
Western blots and Image J quantification for MDA-MB-453 for p-Akt treated
for 60 mins in duplicate (Expt A & B) with quantification normalised to actin,
demonstrating no sustained inhibition of p-Akt with RAD001 alone or in the
presence of heregulin in duplicate experiments.
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Figure 71 (A)
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Figure 71 (B)
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Figure 71
Western blots and Image J quantification for MDA-MB-453 for p-Akt treated
for 24 hours in duplicate (Expt A & B) with quantification normalised to actin,
demonstrating stimulation of p-Akt with heregulin and in (A) some inhibition of
p-Akt with RAD001 alone and in combination with InM heregulin, but in (B) no
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Figure 72
Effect over time of treatment with RAD001 on p-Akt in cell line MDA-MB-453
for duplicate experiments A & B. In (A) there is inhibition of p-Akt sustained
throughout the 24 hour period with RAD001 alone, but not for RAD001 in the
presence of heregulin, with stimulation of p-Akt with lOnM heregulin. In (B)
there is inhibition of p-Akt initially, then less marked for 60 mins and 24 hours,
with stimulation of p-Akt in those treated with lOnM heregulin.
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Discussion
The primary intention of this cell line study was to further investigate the effects of
RAD001 treatment upon p-Akt and the potential significance of p-Akt as a marker of
response to RAD001 treatment. In order to achieve this, it was necessary to assess
the response to treatment of cell lines expressing low and high levels ofp-Akt. To
reduce the possibility of results differing between cell lines, the same cell line was
analysed both with and without heregulin stimulation. Stimulation of breast cancer
cells with heregulin (31 has previously been shown to rapidly phosphorylate Akt with
similar effects to transfecting cells with constitutively active Akt. 234
To determine downregulation of the mTOR pathway p70S6k expression was
assessed, and to determine the effects of p-Akt expression this was directly
measured. As a result of previous findings that incubation with RAD001 over a short
time period downregulates p-Akt, but prolonged treatment (>24 hours) upregulates p-
Akt,231 it was decided to include a 24 hour incubation period for this RAD001 study.
Original pairing of cell lines selected was on the basis of PTEN methylation and ER
positivity. This pairing was lost as the results for the cell line MDA-MB-361 were
rendered invalid due to contamination of all the stock of that cell line with
mycobacteria towards the end of the time of the study. The results from the studies
using MDA-MB-361 cell line stock have therefore not been included here.
The two remaining cell lines are therefore MCF7, ER positive and PTEN
unmethylated and MDA-MB-453, ER negative and methylated for PTEN. As a result
of this lack of pairing, it is difficult to extrapolate from the results any conclusive
evidence over the role of PTEN or ER status on the mTOR pathway. From the
previous discussion of the role ofPTEN in the mTOR pathway it could be expected
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that a cell line that is PTEN methylated will have inactivation of the normal PTEN
suppressor mechanism of inhibiting the PI3K-Akt pathway. This cell line would thus
be expected to display high levels of activation ofAkt and be more likely to be
sensitive to mTOR inhibition by RAD001 treatment. Contrary to this hypothesis
were findings from a study of various tumour cell lines treated with RAD001, which
did not show a higher sensitivity ofPTEN unmethylated cell lines to RAD001 except
for in glioblastoma cell lines. 209 It has however been shown with another mTOR
inhibitor CCI-779 (Wyeth Pharmaceuticals) that in wildtype PTEN breast cancer cell
line MDA-MB-468 and in glioblastoma studies there is an increase in sensitivity to
mTOR inhibition. 182 235 These MDA-MB-468 cells also had elevated Akt and
mTOR signalling.
The results from the MCF7 cell line after treatment with RAD show that there is
consistent downregulation of p70S6k, and thus the mTOR pathway at all time points
with RAD001 treatment only. RAD001 was less effective at downregulating p70S6k
in the presence of heregulin and failed to inhibit p-Akt in the presence of heregulin
stimulation. RAD001 reduced the activity of p70S6k with no suggestion of reduction
of effect over time with increased length of treatment.
A similar but less pronounced reduction in p70S6k was also seen in the MDA-MB-
453 cell line with RAD001 treatment over time. In contrast to the MCF-7 cell line
however, the cells that were treated with RAD001 and heregulin also had a reduction
in p70S6k, in comparison to those treated only with heregulin. While the duplication
of this experiment did not yield results for p70S6k, it could be surmised that the
differences between the two cell lines may be related to the PTEN methylation status
of the MDA-MB-453 cell line. As stated above, a cell line that is PTEN methylated
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will have inactivation of the normal PTEN suppressor mechanism of inhibiting the
PI3K-Akt pathway. This cell line may thus be expected to display high levels of
activation of Akt. However, it can be seen that in the MDA-MB-453 cell line the
expression of p-Akt is less consistent across the samples than that ofMCF-7,
particularly in the presence of heregulin and at longer treatment time points. It has
previously been noted that heregulin (31 failed to induce Akt phosphorylation in an
ER negative variant of MCF-7 cells, while the transient transfection ofERa restored
the Akt phosphorylation by heregulinpi, indicating that the mechanism by which
9T4
heregulin stimulates Akt phosphorylation is mediated by ERa. This would be
consistent with our findings of a lack of activation of Akt in the ER negative cell line
MDA-MB-453, except at the higher heregulin concentration (lOnM). From the same
published study there is evidence to suggest that there is a role of HER-2 in the
mechanism of heregulin stimulation of Akt phosphorylation. Both cell lines used in
the study described herein were HER-2/3 positive.
Treatment with RAD001 in the MCF7 cells produced a significant reduction in p-Akt
in cells that were not stimulated with heregulin for each of the time points in the 24
hour treatment period. In MCF7 cells treated with heregulin there was no change in
p-Akt in either the control cells or those treated with RAD001 and heregulin,
indicating that RAD001 does not reduce p-Akt in the presence of heregulin in this
breast cancer cell line.
The limitations of this study were firstly in relation to the lack of pairing for ER and
PTEN status, which would have given further information primarily into the
heregulin effects upon Akt stimulation but would have given breadth to the study
allowing more robust conclusions. The practical limitations ofWestern blotting and
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the subjective nature of the results achieved from this procedure, even with the
quantification method allowed by the Image J system, limit the application of the
results obtained, and introduce further degree for interpretation bias and error.
It can be concluded from these data that in a PTEN unmethylated and ER positive
cell line (MCF-7), RAD001 is effective for up to 24 hours at downregulating the
mTOR pathway as assessed by p70S6k, and is also effective at downregulating
expression of p-Akt in the absence of heregulin stimulation. In the PTEN methylated
and ER negative cell line MDA-MB-453, there was also downregulation of the
mTOR pathway as assessed by p70S6k over the time period of 24 hours treatment.
However, there was no real pattern of change in expression of p-Akt over the time of
treatment with RAD001, and there was a lack of evidence of stimulation ofp-Akt by
heregulin except at the higher dose (lOnM), in keeping with previous studies. These
results are in contrast to previous findings of resistance to RADOO1 at 24 hours
treatment, and are in keeping with the findings of the immunohistochemical results
of a reduction in nuclear p-Akt in breast tumours treated with RADOO 1 and a
reduction in cytoplasmic p-Akt in tumours that responded with a reduction in
proliferation to RADOO 1 in this thesis.
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Endocrine treated breast tumour study
Aims
In the biological study forming part of this thesis, p-Akt was found to be different
between responders and non-responders (as assessed by Ki67) after RAD001, thus
identifying p-Akt as a potentially significant marker of RAD001 response and
downregulation ofmTOR. The aim was to determine baseline expression and change
with treatment of p-Akt in tumours with known endocrine responsiveness and
endocrine resistance, to further investigate the potential use of RADOO1 in
combination with endocrine agents to prolong or prevent resistance to treatment.
Patients, Materials and Methods
As part of an ongoing prospective audit in Edinburgh 182 patients with large
operable or locally advanced breast cancers that were oestrogen rich (ER 5 or more
on Allred score) were treated with neoadjuvant letrozole. 113 All women were
postmenopausal, defined as amenorrhea for 1 year or luteinising hormone and
follicular stimulating hormone levels in the postmenopausal range. Patients were
followed up initially at 2, 6 and 12 weeks to assess tolerance and to measure
response with assessment based upon measurement with callipers and imaging
(ultrasound at 0, 6 and 12 weeks and mammography at 0 and 12 weeks). Good intra-
and inter-observer variability was shown for all three modalities, with the highest
accuracy with ultrasound. At 3 months all patients were reviewed by a single surgeon
and a treatment decision taken. The decision was either to perform surgery, to
continue letrozole, or to switch to another therapy. Diagnostic core biopsies were
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taken prior to treatment, and at 3 months after treatment, and were core biopsies if
the patient was not proceeding to surgery, or sections from the surgical excision
specimen if the patient underwent surgery.
Clinical and ultrasound volumes were calculated using the formula nD3/6 where 'D'
is the mean diameter of two perpendicular measurements on clinical or
mammographic assessment and the mean of two diameters and the depth
measurement on ultrasound. A patient with no clinical mass palpable after 3 months
was considered as having 100% reduction in clinical volume or a complete clinical
response. The % change in clinical volume was calculated using the formula 100 x
(initial volume - final volume)/ initial volume. The change in volume for 3-6 months
was thus calculated using the following formula: lOOx (volume at 6 months - volume
at 3 months)/ volume at 3 months, and other volumes were calculated similarly.
Modified WHO criteria were used to evaluate tumour response in the neoadjuvant
setting as follows 236:
• Complete response (CR): No measurable tumour.
• Partial response (PR): Reduction in tumour size > 50% from pre-treatment
size.
• Minor response (MR): Reduction in tumour size > 25% and < 50% from pre-
treatment size.
• No change (NC): < 25% decrease or <25% increase in tumour size from pre-
treatment size.
• Progressive disease (PD): 25% or more increase in tumour size from pre-
treatment size.
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There was thus a cohort of patients treated with neoadjuvant letrozole from whom
there is both clinical data on response and biopsy tissue available. Results of
in
response to letrozole over time have been published.
For the purposes of this study and based upon the 3 month ultrasound assessments of
response, sections were taken from the biopsy samples of 30 patients who had both
diagnostic and 3 month tissue available and clear evidence of resistance (no change
(NC) or progressive disease (PD)) or a good response (partial (PR) or minor response
(MR)). Those patients who had a complete response to treatment had no residual
tumour at time of assessment and it was therefore not possible to include this group
in the analysis.
From the study of patients treated with RAD001 it was apparent that p-Akt may be
an important biomarker for response to mTOR inhibitors. It has previously been
shown that patients who develop resistance have high Akt and increased activity of
mTOR. 147 To determine whether patients who had resistance to letrozole had an
increase in p-Akt, immunohistochemical staining was performed on the samples pre
and post letrozole treatment using the same protocols as described earlier (p-Akt, ser
473). Sections were stained in pairs, and double scoring was performed by the same
two scorers as for the RAD001 sections. Staining and counting for Ki67 had
previously been reported using the same method and protocol for staining and
scoring as describer earlier for the RAD001 biological study.
Statistical analysis
Rank correlation was performed to determine correlation between variables in a non-
parametric distribution. Wilcoxon test was carried out for paired samples and Mann-
Witney test for independent samples.
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Results
Sections of tissue were available from 21 patients who had a partial or minor
response to letrozole and from 8 patients who had progressive disease or no change
in tumour size after 3 months treatment with letrozole. Of those who had a minor
response on USS (n=4), one patient had tumour volume reduction of 36%; in another
case this response was confirmed on bidimensional calliper measurement to be a
minor response with 48% reduction in tumour volume, and in three other cases was
found to be greater with callipers with partial response (>50% tumour volume).
Proliferation was measured by Ki67 (%) staining by the same protocol described
earlier. For the 29 tumour pairs examined median Ki67 before letrozole treatment
was 10.3% (95%CI 5.5, 12.1), reduced to median 1.1% (95%CI 0.8, 2.8) after
letrozole treatment. There was a significant reduction in Ki67% for the whole group
after letrozole treatment (p<0.0001), sustained in subgroup analysis by clinical
response. Figure 73 There was no significant difference in pre-treatment
proliferation by Ki67% or change in Ki67% between those that had a clinical
response to letrozole and those that did not respond.
There was no significant change in scores for p-Akt in either cytoplasm or nucleus
with letrozole treatment for the whole group. No significant difference was found in
p-Akt in cytoplasm or nucleus in subgroup analysis for clinical responders or non-
responders, although there were numerical differences between responders and non-
responders. Of those that responded to letrozole clinically (n=21), 71.4% (n=15) had
a reduction or zero histoscore for nuclear p-Akt, and 62.5% of those that did not
respond (n=5) had an increase or no change in histoscore after letrozole. Figure 74
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Figure 73
Proliferation by Ki67 (%) pre and post 3 months of letrozole treatment,
demonstrating significant reduction in proliferation in both responders (as per
clinical assessment, p<0.0001) and non-responders (p=0.0078), but no significant
























Histoscores for nuclear p-Akt (nuc p-Akt) pre and post letrozole treatment for 3
months, showing no significant change in either clinical responders (R) or non-
responders (NR) (R, median histoscore pre 10, 95%CI 0, 31.0; post 0, 95%CI 0,












Responders 7(33.3) 4(19.0) 8 (38.1) 2 (9.5)
Non-
responders
1 (12.5) 4(50) 2 (25.0) 1 (12.5)
Table 17
Summary of changes seen in nuclear p-Akt after letrozole treatment, showing
that 50% of non-responders had an increase in nuclear p-Akt after treatment,



















Histoscores for cytoplasmic p-Akt (cyto p-Akt) pre and post letrozole treatment
for 3 months, showing no significant change in either clinical responders (R) or
non-responders (NR) (R, median histoscore pre 20, 95%CI 0, 51.7; post 10,
95%CI 0, 40.9; p=0.8536; NR, median histoscore pre 15, 95%CI 0, 68.8; post 10,











Responders 4(19.0) 7(33.3) 9 (42.9) 1 (4.8)
Non-
responders
2 (25.0) 2 (25.0) 3 (37.5) 1(12.5)
Table 18
Summary of changes seen in cytoplasmic p-Akt after letrozole treatment,
showing no difference in cytoplasmic p-Akt between responders and non-
responders.
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No correlation was found between pre-treatment levels of p-Akt (either nuclear or
cytoplasmic) expression and pre-treatment Ki67. There was a significant positive
correlation between Ki67 % pre-letrozole and the change in Ki67 with treatment
(Spearmans (rho) 0.916, p<0.0001) for the whole group and for subgroup analysis of
clinical responders (rho 0.947, p<0.0001) and non-responders (rho 0.905, p=
0.0167). There was no correlation between pre-letrozole scores for (either nuclear or
cytoplasmic) p-Akt and change in Ki67 with treatment (nuclear staining p=0.98;




As can be seen from the above data, the nuclear and cytoplasmic scores for p-Akt
prior to treatment are similar in tumours that respond and those that do not respond to
letrozole. It is not possible from these data to determine any predictive value of
initial levels ofp-Akt for response to endocrine treatment. There was a trend toward
an increase in nuclear p-Akt in those tumours that are unresponsive to letrozole over
3 months treatment (median histoscore 30 after treatment) compared with no change
or a decrease in those tumours that responded (median histoscore 0 after treatment),
but this did not reach statistical significance. Despite the small sample size, 50% of
those that were resistant to letrozole had an increase in nuclear p-Akt. There was no
difference in nuclear or cytoplasmic scores for p-Akt with 3 months treatment, nor
between the group who responded to treatment and those who were resistance to
treatment. One other study has reported results of a retrospective analysis of tumours
237from patients treated with endocrine therapy for expression of p-Akt (ser 473).
Clinical efficacy data was available for 36 patients with metastatic breast cancer who
had received endocrine therapy (median follow-up period not stated). 12 (33%)
tumours were positive for p-Akt (defined as >10% cytoplasmic staining), with a
positive correlation between HER-2 positivity and p-Akt staining (p<0.01). Clinical
response rate was poorer in those with HER-2 positive tumours (p<0.05) and those
with Akt phosphorylation (p<0.01), with the smallest clinical benefit in patients with
both HER-2 and p-Akt positivity (p<0.01), although this subgroup was of small size
(n=3). In this study there were a number of flaws including no description of the
method of assessment of clinical response, no follow-up time period stated and
multiple endocrine therapies used (anastrozole or exemestane n=23, tamoxifen or
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tremifen n=15, LHRH agonist +- tamoxifen n=7, medroxyprogesterone acetate n=l).
The authors attempted to assess the response rates according to therapy used, but the
small numbers make any conclusions drawn questionable. The results are promising
in view of the results of the biological study suggestive of a greater response to
RAD001 in tumours that are HER-2 positive and high in p-Akt, thus the potential
value of RAD001 in tumours that respond less well to endocrine agents.
One of the drawbacks of the pilot study described in this thesis was that tissue
samples were utilised retrospectively and there were limitations with the volume of
tissue available in what is a valuable tumour series. The other main flaw in design of
this study that reflects the difficulty with pre-operative trials is that those patients
who had the best sensitivity to letrozole reflected in a complete response were
automatically self-selected out of analysis as no tumour was available after treatment
due to complete pathological response. This highlights the importance of studies
assessing the predictive value of 2 week biopsy for response, as suggested for Ki67
in previous letrozole studies. 117
One other study has reported results analysing the mTOR pathway in patients treated
with letrozole. The original design of the study was a comparative study of
letrozole alone versus letrozole with metronomic oral cyclophosphamide in patients
aged over 70 years with T2-4, N0-1, ER positive and/or PR positive breast cancer
randomised to treatment for 6 months. From the biological samples from 114 patients
collected at the time of entry into the study and at surgery after 6 months treatment
tissue microarrays were constructed and a retrospective analysis of the mTOR
pathway was performed using immunohistochemistry to assess PI3k, p-Akt (ser
473), p-mTOR (ser2448), ERa (ser 118), Ki67, HER-2, p53 and bcl-2. Scoring of
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immunohistochemistry was performed by one observer scoring on intensity of
staining only: (0) no staining, (1) weak staining, (2) moderate staining, (3) strong
staining. A high baseline positive expression of p-Akt (91%), PI3k (97%) and p-
mTOR (88%) was noted. Baseline expression of p-Akt had no correlation with
tumour variables such as grade, stage, histology, ER, PR or HER-2 status. There was
a positive correlation between baseline p-Akt expression and baseline Ki67, but
without an increasing trend of Ki67 making the significance doubtful. With both
treatment arms of the study combined there was a significant reduction in expression
of PI3k (p=0.002), p-Akt (p<0.05) and p-mTOR (p=0.00001) with treatment over 6
months. In the letrozole alone arm of the study the reduction in p-Akt expression did
not reach significance (p=0.84). Disease response was obtained in 41 of 57 patients
in the letrozole arm, and in 50 of 57 in the letrozole and cyclophosphamide arm. For
all patients, a reduction in p-Akt was associated with better disease response
(p=0.05), with no significant relationship to response for PI3k and p-mTOR. Ki67
also decreased after treatment in both arms, and this reduction significantly
correlated with p-Akt reduction (p<0.05), but not with PI3k or p-mTOR. Baseline
expression of PI3k, p-mTOR and p-Akt did not show a predictive role for disease-
free survival at median follow-up of 46 months. These findings of an association
between reduction in p-Akt and better disease response support the growing body of
evidence for the use ofmTOR inhibition, and for combined use with endocrine
agents for greater response.
Studies are underway using letrozole and RAD001 to trial the evidence of the
combination approach to prevent resistance to letrozole through the mTOR pathway.
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In a Phase I study ofRAD001 18 patients who had metastatic or locally recurrent
advanced breast cancer who had received letrozole for >4months without objective
response (stable or progressive disease) were entered sequentially to continue on
letrozole and to receive 5mg RAD001 (first 6 patients) or lOmg RAD001 (next 12
patients). 239 Primary outcomes were for safety, pharmacokinetics and efficacy by
tumour response. The most commonly observed adverse events (AEs) were mouth
ulcers (n=3/6 with 5mg RAD001, n=6/12 with lOmg RAD001), anorexia (n=0/6 with
5mg, n=8/12 with lOmg) and fatigue (2/6 with 5mg, 6/12 with lOmg). The
combination of letrozole and RAD001 did not appear to alter the pharmacokinetics
of RAD001. One complete response was seen in the lOmg RAD001 arm in a patient
with skin lesions who had a sustained response for 22 months who had progressive
disease on letrozole alone. One patient had a volume reduction in liver metastases by
28% and had stable disease for 13 months, having been on letrozole therapy for 2
years prior to the study.
There has been one randomised study of letrozole alone or in combination with
RAD001.240 In this study 270 patients with newly diagnosed ER positive breast
cancer >2cm were randomised to receive either letrozole 2.5mg and RAD001 lOmg
once daily or letrozole 2.5mg and placebo for 16 weeks prior to surgery. The primary
outcome was response rate by palpation at 4 months, with response rate by
mammography and ultrasound, rate of breast conservation and rate of pathological
complete response as secondary outcomes. Tumour biopsies were taken at 0 and 15
days. The two randomised groups had similar baseline age, tumour stage, proposed
breast conservation or mastectomy. There was a trend toward a higher response rate
in the group who received letrozole and RAD001 with an overall response rate of
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68.1% versus 59.1% in the letrozole and placebo group (p=0.062). This trend
reached significance when the response was assessed by ultrasound scan (58% with
RAD001 and letrozole and 47% with letrozole alone, p=0.035) and on clinical
examination (66.7% RAD001 and letrozole vs 54.5% letrozole alone, p=0.021).
There were significantly more adverse events in the RAD001 and letrozole group
(89.8%) compared with letrozole alone (63.6%), with the rate of grade 3/4 adverse
events (AE) 22.6% in the RAD001 + letrozole arm versus 3.8% in the placebo +
letrozole arm. The most frequently occurring AEs were mouth ulcers (36.5% with
RAD001 and letrozole versus 6.1% with letrozole alone), rash (20.4% versus 7.6%)
and fatigue (17.5% versus 9.8%). The most frequent grade 3/4 AEs with RAD001 +
letrozole were hyperglycaemia (n=7), mouth ulcers (3), interstitial lung disease/
pneumonitis (3) and infections (3). In the RAD001 and letrozole group 46.4%
discontinued treatment before 112 days, compared to 18.9% discontinuing letrozole
alone. This rate of discontinuation is higher than results for the single agent study
performed as part of this thesis and this may be due to the higher 1 Omg dose of
RAD001 used within the combination study, as well as a longer study time period.
This combination study was designed to also incorporate testing a number of
candidate predictive response markers with the aim of determining potential
biomarkers of response.241 Those biomarkers analysed by immunohistochemistry
were ER, PR, Ki67, S6 total and p-S6 (235/236 and 240/244), total Akt and p-Akt
(s473), PTEN, cyclin D, A1B1; HER-2 by FISH; PI3kinase and p53 were analysed
by mutational analysis. PTEN and cyclin D in this study were analysed using a
prototype assay developed in collaboration with Dako. Biomarker evaluation was
possible on 181 patients who had sufficient treatment duration. Of the 181 biomarker
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evaluable cases there were 79 in the combination arm and 102 in the letrozole alone
arm. Marked downregulation in progesterone receptor and cyclin D1 were seen in
response to letrozole. Phospho-S6 levels showed dramatic down-regulation only in
response to RAD001. Cell cycle response, as defined by either % reduction in Ki67
at day 15 or by proportion of patients with Ki67<2 at day 15, was also significantly
higher in the RAD001 + letrozole arm (57% vs 30% for Ki67<2 at day 15, p<0.01).
The increased cell cycle response rate in the RAD001 arm was found in all subsets of
tumours, including PTEN-positive, PIK3CA wild-type tumours.
Of the 79 cases in the letrozole and RAD001 arm, 44 had high pre-treatment
expression ofp-S6 (240/244) with a response rate in this subgroup of 81.8%,
compared with a response rate of 60% in those with low pre-treatment expression of
p-S6 (p=0.216). This only reached significance when those patients who did not have
sufficient treatment duration were included (n=26, 25 of which were from the
RAD001 and letrozole treatment arm) which improved the significance to p=0.028.
For the letrozole alone arm, the expression of p-S6 was high in 53/101 cases, with
response rate of 67.9% in the high p-S6 pre-treatment subgroup versus 58.3% in the
low p-S6 pre-treatment subgroup (p=NS). In our biological study of RAD001 5mg as
a single agent there was a trend toward a greater reduction in p-S6 scores in those
tumours that responded to treatment (as measured by Ki67) compared with those that
did not respond. No other biomarkers analysed in this study were identified as
potential predictors of response to RAD001. There were only small numbers of
patients with HER-2 positive tumours in the study, and no data is available for the
response rates in the HER-2 positive versus negative groups. In the RAD001 and
letrozole arm 50/79 (63.3%) had high p-Akt expression, with response rates of 74%
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versus 69% for high and low pre-treatment p-Akt (p=0.999). The rates were similar
for the letrozole alone arm. High Ki67 was not found to predict for response to RAD
and letrozole or letrozole alone, but a significantly higher proportion of patients in
the RAD001 arm had an antiproliferative response defined as logarithm of
percentage positive Ki67 of less than 1 at day 15. These improved response rates
with combination of letrozole and RAD001 are suggestive of an increased response
to letrozole in the neoadjuvant setting. There is a need to assess the lower dose of
RAD001 as used in this thesis in order to determine if the high rate of
discontinuation due to side effects can be reduced with lowering the dose. If this is
the case then longer follow-up studies would be required to assess the potential
benefits of RAD001 in combination with endocrine agents to prevent or delay the
development of resistance to these agents.
While the scope of this study is of the potential role of RAD001 in the prevention or
delay of endocrine resistance, there are now emerging studies investigating RAD001
in combination with signal transduction agents, thus far only in cell lines. RAD001 in
combination with the epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitor gefinitib was found in non-small cell lung cancer cells to suppress both S6
activation and MAPK signaling, and had an increased growth inhibitory effect
compared with either agent alone.242 In another study in renal cell cancer cell lines,
RAD001 in combination with a duel EGFR and vascular endothelial growth factor
(VEGF) receptor inhibitor, AEE778, inhibited cell proliferation.243 These
combinations ofmTOR inhibition with other therapeutic agents targeted at specific




Breast cancer is a common cancer in the UK, with 100 new cases diagnosed every
day. 1 Management of breast cancer has traditionally been local treatment with
surgery followed by systemic treatment with chemotherapy or hormonal agents.
Neoadjuvant treatment has been employed for inoperable or large tumours, and more
recently has been recognised as useful for determining response to agents in the
longer term, rather than awaiting recurrence. This in turn has led to the concept of
tumour profiling to determine response to treatment. The best example of this is ER
status which has been shown to be important in determining response to aromatase
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inhibitors and tamoxifen. ' ' " Despite ER positivity, however, a significant
problem with the use of these hormonal agents is the development of resistance,
either de novo or acquired over time with treatment. Signal transduction pathways
have been implicated in this resistance mechanism, such as the PI3K/ Akt/ mTOR
pathway. 11 ''124 Breast tumours with high levels of p-Akt and mTOR expression
are associated with resistance to treatment, increased local recurrence and poorer
overall survival. 147 Preclinical studies of mTOR inhibitors have shown restoration of
response to tamoxifen and that the combination of tamoxifen and mTOR inhibitors
has synergistic antitumoural effect. 149
This is the first clinical study to report results of RAD001 5mg daily in early breast
cancer, a dose that was tolerated by most patients in the study, with the exception of
the most commonly reported symptom of mouth ulcers. Of the eight patients who
experienced this side effect, four withdrew from the study with Grade I or II (mild or
moderate) level symptoms. Patients were aware that the drug was on a trial basis and
not for treatment purposes, and this may have influenced the tolerability of
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symptoms for patients. It is reasonable to expect that the level of tolerability of a
drug in the early stage of treatment in a pre-operative setting will be different than
that in an adjuvant or advanced study due to different levels of expectation and
previous experience of patients. The significant reductions in white cells and
neutrophils with RAD001 treatment are of concern, particularly in the pre-operative
setting. There was no increase in infective complications in the patients participating
in this study, and in particular among those who had reduction in neutrophils counts,
and all those who had reduced neutrophils had an appropriate response to surgery
with a raise in neutrophil counts post-operatively. Had information regarding the
nadir of 14 days in these blood parameters been available prior to commencement of
the study, it may have been necessary to reconsider the duration of treatment to avoid
coinciding with this nadir. Similarly, the reduction in platelets could have resulted in
significant peri-operative bleeding. There were 4 patients in the group who
developed haematoma, but in only one of these patients was the platelet count
reduced. The timing of this study coincided with the introduction of the use of low
molecular weight heparin different to that used previously in the Edinburgh Breast
Unit, and it was noted that there was an increase in bleeding complications during
that time period, resulting in a subsequent switch back to the original prophylactic
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therapy, with resolution of this problem.
The primary outcome measured in this pre-operative study was the baseline and
change in proliferation with treatment with RAD001 as measured by Ki67. The
significant reduction in proliferation with 5mg RAD001 confirms the antitumoural
activity ofRAD001 at this dose. Given the problems of tolerability of RAD001 at
lOmg experienced in the letrozole-RADOOl combination trial, 240 it is encouraging to
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see mTOR inhibition confirmed by reduction in p-S6 and proliferation at a dose of
5mg daily. These data would suggest this dose will be effective and tolerable in
patients with early breast cancer.
Tumours that had the greatest reduction in proliferation were those that had high
levels of proliferation and were of higher tumour grade before treatment. These
highly proliferative tumours had high levels of p-Akt before treatment. Neither p-
Akt, p-mTOR nor p-S6 were shown to be predictive for response to RAD001 as
measured by reduction in proliferation.
The significant reduction in nuclear phosphorylation ofAkt with RAD001 treatment
indicates inhibition of both mTOR raptor and mTOR rictor in the clinical setting. It
was originally thought that the mTOR rictor complex was rapamycin insensitive, but
recent cell line work has suggested that prolonged treatment with rapamycin results
231in inhibition of rictor. The clinical study described herein shows that with
RAD001 nuclear p-Akt was reduced in almost all cases, and cytoplasmic p-Akt
reduced in those tumours with high scores pre-treatment, suggesting tumours with
high p-Akt are more sensitive to RAD001. Further investigation of this in a clinical
setting by selecting tumours on the basis of p-Akt score is recommended to further
assess this.
We were unable to confirm in cell line studies the influence of varying p-Akt
expression on the activity ofRAD001. In the PTEN unmethylated, ER positive
MCF7 cell line there was reduction ofmTOR activity as assessed by p70S6k with
RAD001 in the absence of heregulin stimulation. The heregulin treated cells had
increased p-Akt compared with controls but RAD001 treatment did not have a
demonstrable effect upon p70S6k in the presence of heregulin. In the MDA-MB-453
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cells the results are more difficult to interpret due to the mechanism by which
heregulin upregulates Akt and a lack of p-Akt stimulation in response to heregulin,
particularly over time. It can be concluded that in a PTEN unmethylated, ER positive
cell line RAD001 is effective up to 24 hours at downregulating the mTOR pathway
as assessed by p70S6k in the absence of heregulin stimulation, but due to incomplete
cell line pairing the conclusivity of these results is limited to this interpretation.
The clinical significance of this potential use of p-Akt as a predictive marker lies in
previous findings of elevated p-Akt and mTOR activity in tumours resistant to
endocrine therapy, suggesting a promising role for the combination ofmTOR
inhibitor and endocrine inhibition. From our study of tumours before and after
treatment with letrozole there was a trend towards a reduction in nuclear
phosphorylation of Akt in those who responded to letrozole, and an increase in those
that were resistant, but with no difference in baseline values between responders and
non-responders to suggest a predictive value. This may be due to small sample size
but similar lack of predictive value of p-Akt was found in the combination study of
RAD001 and letrozole. 241
Tumours were not selected for this study on the basis of tumour type, ER, PR or
HER-2 status, although all tumours had some level of ER positivity. There appeared
to be a greater response in tumours that were E1ER-2 positive. Combining this broad
range of baseline tumour characteristics may have affected the results of this study,
as these represent biologically different tumours with potentially different
219mechanisms and drivers for proliferation, and different clinical outcomes. Further
studies should focus on more defined populations to avoid this potential dilution of
248
results, in addition to investigation more specifically on tumours with high
proliferation, high p-Akt and HER-2 positivity.
The findings of the biological study demonstrate the effectiveness ofRAD001 at a
dose of 5mg daily at reducing proliferation in early breast cancer. Further study is
warranted to investigate the potential role of p-Akt as a predictive tool for RAD001
response, and to investigate combination therapy at a dose of 5mg to reduce the rate
of adverse events and thus completion of treatment. This would allow analysis of the
role ofmTOR inhibition in preventing or delaying endocrine resistance.
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Please Reply To: Edinburgh Breast Unit, Western General Hospital,
Edinburgh EH4 2XU.
Tel: 0131 537 2907 Fax: 0131 537 2653 email: jmd@ed.ac.uk
A STUDY TO EVALUATE THE BIOLOGICAL EFFECTS OF RAD 001 ON
INVASIVE BREAST CANCER
Patient Information Leaflet
You are being invited to take part in a research study. Before deciding, it is important
that you understand why the research is being done and what it will involve. Please take
time to read the following information carefully and discuss it with others if you wish.
Ask us if there is anything that is not clear, or if you would like more information. Take
time to decide whether or not you wish to take part.
What is the purpose of the study?
The Edinburgh Breast Unit is involved in a range of studies trying to identify new and
effective drugs for breast cancer. RAD001 is a drug that is already used in patients who
have had a kidney or liver transplant. There is some evidence that is may be an effective
treatment for breast cancer.
RAD 001 is a drug which works against growth factors produced by tumours.
Normal cells are under strict control. One of the mechanisms by which growth is
controlled is through agents called growth factors. If you cut your finger growth factors
are produced and this stimulates the skin to produce more cells to heal the cut. As soon
as the cut has healed, the flow of growth factors is reduced to stop the skin overgrowing.
As part of the cancer forming process, abnormal cells including cancer cells produce
increased amounts of growth factors and this causes the cancer cells to grow in an
uncontrolled manner. Increased amounts of growth factors continue to be produced
even though the cancer cells are growing faster than normal cells.
RAD 001 is a growth factor inhibitor, and studies in cell lines and in animal models have
shown that RAD 001 is effective at reducing the rate at which breast tumours grow. The
aim of this study is to investigate whether RAD001 is effective at slowing down or
stopping the growth of breast cancers by looking at the number of cells growing.
Specimens of the cancer taken before and after the treatment will be stained to see the
growing cells so that they can be counted under the microscope. We will also look at
which parts of the cancer cells are switched off by the drug by further staining of the
cancer and by looking at the levels of activity of genes in the cancer cells themselves.
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Why Have I Been Chosen?
You have been invited to take part in this study because we know from your core biopsy
that you have an early breast cancer, and it has been decided that the best treatment for
you will be surgery. If you agree to take part in this study you will receive RAD001 for
14 days before your operation. This is long enough for the drug to have the effects on
the cancer. There is no evidence to suggest that this will be of long term benefit to you,
but the information we get from this study may help us to better treat future patients with
breast cancer.
Initially 30 patients will be invited to take part in this study.
WhatWill Be Involved?
Your participation in this study is entirely voluntary and if you decide not to take part it
will not affect your medical care in any way. If you decide to take part you will take one
tablet a day for 14 days before your operation. The day before surgery you will have
blood removed to check that the RAD 001 has not had any effects on your body. When
you have surgery and your cancer is removed, a portion of the cancer will be taken to
investigate whether there has been any changes between the initial biopsy you had
performed at diagnosis and the sample removed at the time of surgery.
It will involve one extra visit to the clinic and two extra blood tests if you take part in
this study. You will be reimbursed for any extra expenses related to this study including
travel expenses.
You should continue to take all your usual medications. There are no dietary or lifestyle
restrictions when taking this drug.
What Are The Benefits of This Study?
The benefit of the new drug RAD 001 is not known at this time. It is hoped that this
new drug will prove useful in the treatment ofwomen with breast cancer. There is
evidence that RAD 001 should reduce the number of cancer cells growing in the tumour
so and the aim of performing the study is to investigate whether RAD 001 is a drug that
is likely to be useful in the treatment of breast cancer.
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Are There Any Risks?
All medicines may cause side effects and some patients may have unforeseen risks. In
studies with RAD001, there have been no major toxicities noted at the dose of 5mg - the
dose which will be used in this trial. The most common side effects reported at the 5mg
dose have been skin rash (acne type or red non-specific rash), fatigue and mouth ulcers.
One patient had a lowering of the platelet blood count (platelets are important for blood
clotting) after 15 days of treatment, but this lowering was not to serious levels and
resolved without any treatment. More serious side effects have been reported at higher
doses of RAD001, but few patients have had to stop treatment. The serious side effects
reported at higher doses have included tiredness, mouth ulcers, nausea and
breathlessness. Other side effects noted to mild or moderate degree at higher doses
included lowering of platelet count, raised cholesterol in the blood, diarrhoea,
constipation, vomiting, headache, cough and skin rashes - either acne or reddening of
the skin on the neck, face, body, or arms and legs.
It is possible that you may develop some of the side effects listed above, although it is a
low dose of RAD001 being used for a short period of time. Please report all side effects
to us. You will be carefully monitored and we will take a sample of blood the day before
your operation to check that there have been no major changes as a result of the drug.
If you do develop problems, report these immediately to our research team at the
Edinburgh Breast Unit by contacting Lorna Renshaw the study nurse, or Jane Macaskill
the study research fellow (contact numbers on next page).
If you do become ill or injured as a result of participation in this clinical trial, medical
treatment will be provided by the hospital. Novartis, the company who produce this
drug, will abide by the code of practice recommended by the Association of British
Pharmaceutical Industry.
Suppose I Refuse to Participate or Change My Mind?
Your doctor's main concern is your medical care and either you or he/she may stop your
study treatment at any time if it is not suitable for you. You may withdraw from the
study at any time, without giving a reason, and it will not affect your future treatment in
any way. If you stop taking the drug you will not receive any other treatment before
surgery - this being the current standard of care. Should you decide to withdraw from
the study, any tissue taken specifically for the study will be destroyed.
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Will My Identity Remain Confidential?
Yes. With your permission, your GP will be informed that you are taking part in the
study. Your doctor may allow a "responsible person" from the authorized medicines
regulatory body to check the results relating to your treatment. Your name will not be
disclosed and you will only be identified by your initials and your study number. All
results will be coded and cannot be identified as your own except by the research team
here at Edinburgh Breast Unit. All research documentation will be retained for 15 years
here at the Western General Hospital.
Who Can I Contact if I Have Any Problems or Questions?
If you have any concerns or questions about this study at any time, please contact:
Mr J Michael Dixon (Consultant Surgeon), Edinburgh Breast Unit, Western General
Hospital, Edinburgh Tel: 0131 537 2907
You can also contact the research nurse for the study:
Lorna Renshaw, Research Nurse, Edinburgh Breast Unit, Western General Hospital,
Edinburgh Tel: 0131 537 1615 or 0131 537 1000 + ask for bleep 5559
If you want independent advice on this study, please contact
Dr Ian H Kunkler, Consultant in Clinical Oncology, Department of Clinical Oncology,
Western General Hospital, Edinburgh Tel: 0131 537 2214
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A STUDY TO EVALUATE THE BIOLOGICAL EFFECTS OF RAD 001 ON
INVASIVE BREAST CANCER
Informed Consent




1. I confirm that I have read and understand the information sheet
for the above study and have had the opportunity to ask questions.
2. I understand that my participation is voluntary and that I am free to
withdraw at any time, without giving any reason, without my
medical care or legal rights being affected.
3. I agree to my General Practitioner being informed ofmy participation
in this study.
Name of Patient Date
Name of Person Taking Consent





Copies: 1 for patient, 1 for researcher, 1 to be kept with hospital notes
RAD001 Consent Form General Practitioner December 2004, version 1
DearPatient, Wewouldbgratefulify ldr corh n takeyourt bletsforhcou seftreatm nt.Ifou missanytablets,pleasewouldy urecortha on why. Alsoifyouhavenyside fectsduringthru treatment,pleaserecordhd tailsofsy ptom(s) nexttohedaysasymptom(s)occur. Thankyouforyourco- pe ation. DayDatetablets takenReasonforny missedtablets
Sideeffects (ifany)
1




Reason forany missed tablets
Side effects (ifany)
6 7 8 9 10 11 12 13 14
Please Reply To: Edinburgh Breast Unit, Western General Hospital,
Edinburgh EH4 2XU.
Tel: 0131 537 2907 Fax: 0131 537 2653 email: monicakmcgill@hotmail.com
A STUDY TO EVALUATE THE BIOLOGICAL EFFECTS OF RAD 001 ON
INVASIVE BREAST CANCER
Letter to General Practitioner
Dear Doctor
Your patient has agreed to take part in the above trial and to take RAD 001 which is a
new drug which is being developed by Novartis Pharmaceuticals. It is a growth factor
inhibitor to be taken for 14 days before surgery. Although it has not been used in many
patients with cancer, it has been widely used in patients having renal transplants. The
only problems experienced in these studies have been a reduced platelet count, although
no patient as yet developed bleeding problems. A reduction in neutrophil count with
some increase in non-specific infections has also occasionally been reported.
The aim of this study is to determine whether RAD 001 is a potent growth factor
inhibitor and produces a reduction in proliferation in the cancer and an increase in
cancer cell death.
We do not anticipate any problems with such a short term period of treatment but if your
patient develops any side effects which could be related to the drug treatment, then they
have been informed that they should stop the treatment immediately and let us know.
Your patient has also been informed that she may withdraw from the study at any time
without giving a reason and that this would not affect her treatment in anyway.
Yours sincerely,
Mr J Michael Dixon,
Consultant Surgeon and Senior Lecturer
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Thank you for your letter of 26 January 2005, responding to the Committee's request for
further information on the above research and submitting revised documentation.
The further information has been considered on behalf of the Committee by the Chair
Confirmation of ethical opinion
On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for the
above research on the basis described in the application form, protocol and supporting
documentation as revised.
Conditions of approval
The favourable opinion is given provided that you compiy with the conditions set out in the
attached document. You are advised to study the conditions carefully.
Approved documents
The final list of documents reviewed and approved by the Committee is as follows:
Document Type: Version: Dated: Date Received:




Protocol 1 01/11/2004 19/11/2004






























The study should not commence at any NHS site until the local Principal Investigator has
obtained final management approval from the R&D Department for the relevant NHS care
organisation.
Notification of other bodies
The Committee Administrator wiii notify the research sponsor and the Medicines and Health'
Care Products Regulatory Agency that the study has a favourable ethical opinion.
Statement of compliance
This Committee is recognised by the United Kingdom Ethics Committee Authority under the
Medicines for Human Use (Clinical Trials) Regulations 2004, and is authorised to carry out
the ethical review of clinical trials of investigational medicinal products.
The Committee is fully compliant with the Regulations as they relate to etnics committees
and the conditions arid principles of good clinical practice.
The Committee is constituted in accordance with the Governance Arrangements for
Research Ethics Committees (July 2001) and complies fully with the Standard Operating
Procedures for Research Ethics Committees in the UK.
04/MRE03/39 Piease quote this number on ail correspondence
Wifh the Committee's best wishes for the success of this project,
Or Siri't^h Thomas
Chair \
Enclosures Standard approval conditions
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R&D Project ID: 2004/W/BU/01
REC Ref: MREC: 04/MP.E01/89
Title: A study to evaluate the biological effects of RAD001 on invasive
breast cancer
The above project has undergone a review of resource and financial implications by the
R&D Office and I am satisfied that all the necessary arrangements have been set in place.
On behalf of the Chief Executive and Medical Director, I am happy to give Divisional
management approval to allow the project to commence, subject to the approval of the
appropriate Research Ethics Sub-Committee having also been obtained.
We would ask you to note that under Section A, question 35 of the COREC application
form, NHS Lothian provides indemnity for negligence for NHS and honorary ciinica! staff
wherever research involves patients attending the hospitals. It is not empowered to
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Lothian University Hospitals NHS Trust
R&D Department








THE MEDICINES FOR HUMAN USE (CLINICAL TRIALS) REGULATION'S
2004 S.I. 1031
Product Type: Medicinal Product with Special Characteristics
Product: RADOOl
Protocol number: 2004/W/BU/01, August 2004
NOTICE OF ACCEPTANCE
I am writing to confirm that the Licensing Authority, acting ur/der regulation 18(2)(b( or
(c), or 19(2)(a) or (8), or 20(2)(a) or (5), of the Regulations and according to the type of
medicinal product involved1, accepts your request to carry out a clinical trial in
accordance with your application received on 06 October 2004 which we acknowledged in
our letter dated i 1 November 2004 subject to you receiving a favourable opinion from the
relevant ethics committee in accordance with regulation 15(1). You may therefore carry
out the trial as notified, but I must remind you of the Authority's powers under regulation
31 to suspend or terminate a clinical trial if the conditions set out in regulation 31(l)(a)
and (b) are satisfied.
Remarks:
* Cerfican tablets are licensed in an EU Member State (MA nos 18690-3). No further
information on the marketed product is required. The applicant should confirm whether the
product to be used is the marketed product or not. The marketed product is available in
strengths of 0.25. 0.5, 0.75 and lmg. The application form makes reference to a 5mg
strength being used. The applicant should also confirm, the maximum daily dose since this
is given in the application form as 30mg but as 5mg in the protocol. If the product being
used is Certican tablets then the application form should be revised to show the use of a
product which has a MA in another EU Member Stare. The relavant Member Statae and
the MA number should be provided.
' The Licensing Authority*-, authorisation powers for clinical trials are regulation 18 for those involving
general medicinal products, regulation 19 for those involving medicinal products for gene therapy etc., and
regulation 29 for those involving medicinal products with special characteristics.
* A sample of the labelling should be provided.
The authorisation is effective from the date of this letter and may continue under this
authorisation. In accordance with regulation 27, you must notify the Licensing Authority
within 90 days of the conclusion of the trial, that it has ended.
Yours sincerely
Mrs Salma Syed
Clinical Trial Unit
